WO2012058125A1 - Inhibitors of hepatitis c virus - Google Patents

Inhibitors of hepatitis c virus Download PDF

Info

Publication number
WO2012058125A1
WO2012058125A1 PCT/US2011/057398 US2011057398W WO2012058125A1 WO 2012058125 A1 WO2012058125 A1 WO 2012058125A1 US 2011057398 W US2011057398 W US 2011057398W WO 2012058125 A1 WO2012058125 A1 WO 2012058125A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
esi
added
cyclopropyl
Prior art date
Application number
PCT/US2011/057398
Other languages
French (fr)
Inventor
Min Zhong
Leping Li
Original Assignee
Presidio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012058125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2013031141A priority Critical patent/SG189985A1/en
Priority to UAA201306405A priority patent/UA108671C2/en
Priority to EP11836903.2A priority patent/EP2632261B1/en
Priority to AU2011320696A priority patent/AU2011320696B2/en
Priority to CN201180061899.2A priority patent/CN103269586B/en
Priority to US13/882,138 priority patent/US20130302282A1/en
Priority to KR1020137013396A priority patent/KR101594166B1/en
Priority to CA2815537A priority patent/CA2815537A1/en
Priority to BR112013009789A priority patent/BR112013009789A2/en
Application filed by Presidio Pharmaceuticals, Inc. filed Critical Presidio Pharmaceuticals, Inc.
Priority to NZ609564A priority patent/NZ609564A/en
Priority to MX2013004655A priority patent/MX2013004655A/en
Priority to EA201390433A priority patent/EA025151B1/en
Priority to JP2013536688A priority patent/JP5731004B2/en
Priority to US13/456,181 priority patent/US9085587B2/en
Publication of WO2012058125A1 publication Critical patent/WO2012058125A1/en
Priority to US13/544,261 priority patent/US8614207B2/en
Priority to IL225853A priority patent/IL225853A0/en
Priority to ZA2013/03752A priority patent/ZA201303752B/en
Priority to US14/083,429 priority patent/US9309260B2/en
Priority to HK13113396.8A priority patent/HK1185763A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the invention relates to compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non- structural 5B (“NS5B”) protein of HCV.
  • HCV hepatitis C virus
  • HCV is a single-stranded RNA virus that is a member of the Flaviviridae family.
  • the virus shows extensive genetic heterogeneity as there are currently seven identified genotypes and more than 50 identified subtypes.
  • viral RNA is translated into a polyprotein that is cleaved into ten individual proteins.
  • the core (C) protein and the envelope glycoproteins El and E2.
  • p7 an integral membrane protein, follows El and E2.
  • NS5B is the RNA polymerase or replicase of the virus and is responsible for replication of both positive and negative-strand genomic RNA during the viral replicative cycle. NS5B plays an essential and critical role in viral replication, and a functional NS5B replicase is required for HCV replication and infection. Thus, inhibition of NS5B RNA-dependent polymerase activity is believed to be an effective way of treating HCV infection.
  • HCV infection is a serious health issue. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is thus a major worldwide cause of liver-related premature mortality.
  • the present disclosure describes a class of compounds targeting the NS5B protein and methods of their use to treat HCV infection in humans.
  • the present disclosure describes a class of heterocyclic compounds targeting HCV NS5B polymerase and methods of their use to treat HCV infection in humans.
  • L 1 , L 2 and L 3 together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L 1 , L2 , or L 3 is independently selected from a group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • U or V is independently CH, N, CF, CC1, or CCN;
  • W, X, or Z is independently C or N;
  • Y is NR N , N, O, S, Se, or -CR a R b ;
  • R N is hydrogen, C 1-4 alkyl, C 3 - & cycloalkyl, C 4- 5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
  • R a , R b is independently hydrogen, methyl, or together form a C3.6 cycloalkyl bearing 0-1 heteroatom of O or NR 1 ;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, C 1-4 alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, C]_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R s , R 9 , R 10 , or R n is independently hydrogen, C 1-4 alkyls, cyclopropyl, C 1- alkoxys, or cyclopropoxy; and R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, d-4 alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S.
  • the compounds may have an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half-maximal inhibition of HCVlb replication (EC 50 ) in a 1 b_Huh-Luc/Neo- line in culture, of 1 mM or less.
  • the compounds may have the structure w ere n , together w ith the attached carbons of the aromatic ring, is a seven- or eight-member
  • the compounds may have the structure wherein ? together with the attached carbons of the aromatic ring, form a 5-9 member ring, L 1 is -C(R 15 R 16 )-, and L 3 is - N(S0 2 Me)- or -0-, where R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C 2 -4 alkynyl, C 1-4 alkyl, cyclopropyl, C1 -4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3- 6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S.
  • L , L and L together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L , L , or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, C 1-4 alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, Ci_ 4 alkyl, cyclopropyl, C alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R u is independently hydrogen, Ci_ 4 alkyls, cyclopropyl, Ci_ 4 alkoxys, or cyclopropoxy;
  • R 15 , R 16 is independently hydrogen, hydroxy], azide, C 2 - 4 alkenyl, C 2-4 alkynyl, C 1-4 alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Q_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S.
  • R 15 , R 16 is independently hydrogen, hydroxy], azide, C 2 - 4 alkenyl, C 2-4 alkynyl, C 1-4 alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Q_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S.
  • L 1 , L 2 and L 3 together with the attached carbons of the aromatic ring form a 5-9 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L ! , L 2 , or L 3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) admir-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R is a substituted or unsubstituteed aryl or heteroaryl
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 5 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, CM alkyl, cyclopropyl, Ci_4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, C alkyls, cyclopropyl, CM alkoxys, or cyclopropoxy;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 -4 alkynyl, C alkyl, cyclopropyl, CM alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or CM alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member rings optionally containing 0-3 heteroatoms of O, NR and/or S.
  • R 6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, ⁇ alkyl, cyclopropyl, Q_ 4 aikoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, Cj -4 alkyls, cyclopropyl, C alkoxys, or cyclopropoxy.
  • R 1 is -C(0)NHMe or .
  • R 2 is selected from the group consisting of
  • Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
  • R 12 is selected from the group of hydrogen, halide, -CN, -OCHF 2 , -OCF 3 , alkyl, cycloalkyl, aikoxy, cycloalkoxy, aiylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
  • n 0, 1, 2, 3, or 4;
  • G is O, NR N , S, or CR a R b ;
  • A is N, O, S, or or CR a R b ;
  • D, E is independently C or N.
  • R 2 is selected from the roup consisting of
  • each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
  • R 12 is selected from the group of hydrogen, haiide, -CN, -OCHF 2 , -OCF3, alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
  • n 0, 1, 2, 3, or 4;
  • G is O, NR N , S, or CR a R b ;
  • A is N, O, S, or CR a R b ;
  • D, E is independently C or N.
  • R is selected from the group consisting of
  • R is 3 ⁇ 4— - / or F .
  • L , L , or L is independently selected from the group consisting of a bond, -0-, -C(R R ), -NR 3 -, -S(0) n -, -P(0) n -, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, Ci -4 alkyl, cyclopropyl, C 1- alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, C]_ 4 alkyls, cyclopropyl, Ci_ alkoxys, or cyclopropoxy;
  • R 12 is independently C]_ 3 alkyl, cyclorpopyl, -OMe, or -NHMe;
  • R is independently hydrogen, -Ac, or -S(0) 2 Me
  • R 14 is independently hydrogen or Me
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C alkenyl, C 2 _ 4 alkynyl, C]_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C1 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • a 1 or A 2 is independently -CR a R b -, -N(R N )-, or -0-.
  • embodiment of the fist aspect is selected from the group
  • L , L , or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(0)-, -Si(R 4 R 5 )-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, ally], alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, CM alkyl, cyclopropyl, C 1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl ;
  • R 8 , R 9 , R 10 , or R 1 1 is independently hydrogen, C 1-4 alkyls, cyclopropyl, C t _ 4 alkoxys, or cyclopropoxy;
  • R i2 is independently C 1-3 alkyl, cyclorpopyl, -OMe, or -NHMe;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2-4 alkenyl, C 2-4 alkynyl, C ⁇ alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • a 2 is independently -CR a R -, -N(R N )-, or -0-.
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-,-C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 1 is selected from hydrogen, halide, -CF 3 , -CN, -C(0)H, -C(0)OR 6 -, -C(0)NHR 7 , -
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 3 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C 2 - 4 alkynyl, CM alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1 -4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S.
  • L L 2 is independently selected from the group consisting of a bond, -0-, -C(R 15 R 16 )-, -
  • R 2 is an aryl or heteroaryl having one or more R 17 substituents
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R is independently Ci -3 alkyl, cyclopropyl, -OMe, or -NHMe;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C 2 - 4 alkynyl, CM alkyl, cyclopropyl, C]_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Q_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is F, CI or CN.
  • the compound of this embodiment may have an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half-maximal inhibition of HCVlb replication (EC5 0 ) in a lb_Huh-Luc/Neo-ET cell line in culture, of 100 nM or less.
  • the compound of this embodiment may have the structure in which is
  • the compound in this embodiment may be selected from the group consisting of compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, B240, B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71, B84, B93, B100, B101, B106
  • the above compounds include compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240.
  • a 7 or 8 member ring having an internal oxygen atom as exemplified by compounds B45, B118, B148, B197, B168, B187, B190; B192, B196, B207, B214, B191, B212, B218, B221, B222, B226, B232, B233, B236, B237, B238, B239, and B240;
  • the structure , together with the attached carbons of the aromatic ring in this embodiment may be a seven- or eight-member ring.
  • R 2 in this embodiment may be a phenyl substituted with one or more R 17 substituents.
  • R 2 in this embodiment may be a 4-phenoxyphenyl and the phenoxy group is substituted with one or more R 17 substituents.
  • R in this embodiment may be selected from ⁇ — " and
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5- 12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
  • L'or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -,
  • -S(0) favor-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R is an aryl or heteroaryl and may be substituted with one or more R substituents, R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R ] 6 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C 2 - 4 alkynyl, C]_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • a fourth aspect of the invention is a compound that has the structure:
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -,-S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycioalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl ;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 alkenyl, C 2 _ 4 alkyny], C 1-4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F,
  • R 1 is selected from the group consisting of H , H , and and R 2 is selected from the group consisting of
  • Exemplary compounds in this embodiment include those identified by ID NOS: B89, B96, B97, B 125, B126, and B129.
  • R in this embodiment may be .
  • R in this embodiment may be a phenyl substituted with one or more R substituents.
  • R 2 in this embodiment may be a 4-phenoxyphenyl and the phenoxy group is substituted with one or more R 17 substituents. [0044] R 2 in this embodiment may be selected from 5 and
  • a fifth aspect of the invention is a compound of formula IV.
  • L 1 , L 2 and -N(S ( 3 ⁇ 4Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C 2 -4 alkynyl, CM alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L ! or L 2 is independently selected from the group consisting of a bond, -0-, -C(R 15 R 16 )-, - NR 3 -, -S(0) admir-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alky], alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R N is hydrogen, Ci -4 alkyl, C 3 ⁇ cycloalkyl, C 4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
  • R 2 is an ary] or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 A alkenyl, C 2 alkynyl, CM alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C]_ 4 alkenylidene or R J 5 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L J or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) favor-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl;
  • R , R is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 -4 alkynyl, C 1 -4 alkyl, cyclopropyl, C]_ 4 alkoxy, or cyclopropoxy or
  • R 15 and R 16 together are a carbonyl or C]_4 alkenylidene or R !5 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) N -, -P(0)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 13 , R 16 is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 -4 alkynyl, C].
  • 4 alkyl, cyclopropyl, CM alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L , L " and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(0)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C 2 - 4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L , L and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl; and R , R is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5- 12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) admir-, -P(O)-, -Si(R 4 R 5 )-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C2-4 alkynyl, C alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 1 5 and R ! 6 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L , L and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) admir-, -P(0)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R l3 , R 16 is independently hydrogen, hydroxyl, azide, C 2 _ 4 alkenyl, C 2-4 alkynyl, C 1-4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R ) 5 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • a thirteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention, including the exemplary compounds identified by the above ID NOS.
  • the composition may be formulated for oral delivery, and may include a second and/or third anti-HCV agents.
  • the compound administered may be one or more of the exemplary compounds identified by the above ID NOS.
  • the method may include administering to the subject, either in a single or separate administrations, a second anti-HCV agent selected from the group consisting of interferon-alpha, ribavirin, or both.
  • the administering may be by oral route.
  • the above compound for use in the treatment of HCV infection in an infected subject.
  • the compound may be one of those identified by ID NOS above.
  • Some of the compounds of the invention possess chiral carbons.
  • the invention included all stereoisomeric forms, including enantiomers and diastereomers as well as mixtures of stereomers such as racemates.
  • the stereoisomers or their precursors can be either asymmetrically synthesized or obtained by separations of the racemates according to methods commonly known in the art.
  • the invention is intended to include all isotopically labeled analogs of the compounds of the invention.
  • Isotopes include those atoms having the same atomic number but different mass.
  • isotopes of hydrogen include 2 H(D) and 3 H(T) and isotopes of carbon include lj C and 14 C.
  • Isotopically labeled compounds of the invention can be prepared according to methods commonly known in the art. Such compounds may have various potential uses as, but not limited to, standards and reagents in determining biological/pharmacological activities. For those stable isotopically labeled compounds of the invention, they may have the potential to favorably modulate biological, pharmacological, or pharmacokinetic properties.
  • alkanoyl as used herein contemplates a carbonyl group with a lower alkyl group as a substituent.
  • alkenyl as used herein contemplates substituted or unsubstituted, straight and branched chain alkene radicals, including both the E- and Z-forms, containing from two to eight carbon atoms.
  • the alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, -N0 2 , C0 2 R, C(0)R, -O-R, - N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2 , -OC(0)R,
  • alkoxy contemplates an oxygen with a lower alkyl group as a substituent and includes methoxy, ethoxy, butoxy, trifluromethoxy and the like. It also includes divalent substituents linked to two separated oxygen atoms such as, without limitation, -0-CF 2 -0-, -0-(CH 2 )i_ 4 -0-(CH 2 CH 2 -0)i -4 - and -(0-CH 2 CH 2 -0) M -.
  • alkoxycarbonyl as used herein contemplates a carbonyl group with an alkoxy group as a substituent.
  • alkyl as used herein contemplates substituted or unsubstituted, straight and branched chain alkyl radicals containing from one to fifteen carbon atoms.
  • lower alkyl as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ten- butyl and the like.
  • the alkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -N0 2 , -C(0) 2 R, -C(0)R, -O-R, -N(R N ) 2 , - N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, - S0 3 R, -S(0) 2 N(R N ) 2 , phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halogen, -CN, -N0 2 , -C(0) 2 R, -C(0)R, -O-R, -N(R N ) 2 , - N(R N )C(0)R
  • alkylene alkenylene and alkynylene as used herein refers to the groups “alkyl,” “alkenyl” and “alkynyl” respectively, when they are divalent, ie, attached to two atoms.
  • alkylsulfonyl as used herein contemplates a sulfonyl group which has a lower alkyl group as a substituent.
  • alkynyl as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to eight carbon atoms and having at least one carbon-carbon triple bond.
  • alkynyl includes, for example ethynyl,
  • alkynyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N0 2 , - C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, -SO 3 R, -S(0) 2 N(R N ) 2 , phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • amino as used herein contemplates a group of the structure -NR N 2 .
  • amino acid as used herein contemplates a group of the structure
  • the present invention also includes, without limitation, D-configuration amino acids, beta-amino acids, amino acids having side chains as well as all non-natural amino acids known to one skilled in the art.
  • aralkyl as used herein contemplates a lower alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted or unsubstituted.
  • the aralkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2) -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, -SO3R, -S(0) 2 N(R N ) 2 , phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • aryl as used herein contemplates substituted or unsubstituted single-ring and multiple aromatic groups (for example, phenyl, pyridy] and pyrazole, etc.) and polycyclic ring systems (naphthyl and quinolinyl, etc.).
  • the polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyl s, aryl, heterocycles and/or heteroaryls.
  • the aryl group may be optionally substituted with one or more substituents selected from halogen, alkyl, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, - C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, -S0 3 R, -S(0) 2 N(R N ) 2 , -SiR 3 , -P(0)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halogen, alkyl, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R,
  • arylsulfonyl as used herein contemplates a sulfonyl group which has as a substituent an aryl group.
  • the term is meant to include, without limitation, monovalent as well as multiply valent aryls (eg, divalent aryls).
  • cycloalkyl as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing from three to twelve carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl and the like.
  • cycloalkyl also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused").
  • the cycloalkyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, - N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, -S(0) 2 N(R N ) 2 , phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from halo, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, - N(R N
  • cycloalkenyl as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing from four to twelve carbon atoms in which there is at least one double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl and the like.
  • cycloalkenyl also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused").
  • the cycloalkenyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, - C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, -S(0) 2 N(R N ) 2 , phosphate,
  • halo or halogen as used herein includes fluorine, chlorine, bromine and iodine.
  • heteroalkyl as used herein contemplates an alkyl with one or more heteroatoms.
  • heteroatom particularly within a ring system, refers to N, O and S.
  • heterocyclic group contemplates substituted or unsubstituted aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member.
  • Preferred heterocyclic groups are those containing five or six ring atoms which includes at least one hetero atom and includes cyclic amines such as morpholino, piperidino, pyrrolidino and the like and cyclic ethers, such as tetrahydrofuran, tetrahydropyran and the like.
  • Aromatic heterocyclic groups also termed "heteroaryl” groups, contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, oxodiazole, thiadiazole, pyridine, pyrazine, pyridazine, pyrimidine and the like.
  • heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two or more atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • polycyclic heteroaromatic systems examples include quinoline, isoquinoline, cinnoline, tetrahydroisoquinoline, quinoxaline, quinazoline, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, indazole, purine, benzotriazole, pyrrolepyridine, pyrrazolopyridine and the like.
  • the heterocyclic group may be optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CN, -N0 2 , -C0 2 R, -C(0)R, -O-R, -N(R N ) 2 , -N(R N )C(0)R, -N(R N )S(0) 2 R, -SR, -C(0)N(R N ) 2 , -OC(0)R, -OC(0)N(R N ) 2 , -SOR, -S0 2 R, - S0 3 R, -S(0) 2 N(R ) 2 , -S1R 3 , -P(0)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
  • substituents selected from the group consisting of halo, alkyl, -CN, -N0 2 , -C0 2 R, -C
  • oxo as used herein contemplates an oxygen attached with a double bond.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention which is made with counterions understood in the art to be generally acceptable for pharmaceutical uses and which possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,
  • salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like (see, e.g. , Berge et al, 1977, /. Pharm. Set 66: 1-19).
  • phosphate and phosphonate refer to the moieties having the following structures, respectively:
  • salts and “hydrates” refers to the hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion.
  • Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity, flowability and manufacturability of the resulting bulk drug.
  • sulfonamide as used herein contemplates a group having the structure
  • R s is selected from the group consisting of hydrogen, -Qo alkyl,
  • Substituted sulfonyl as used herein contemplates a group having the structure O S R
  • alkylsulfonyl and arylsulfonyl including, but not limited to alkylsulfonyl and arylsulfonyl.
  • thiocarbonyl means a carbonyl wherein an oxygen atom has been replaced with a sulfur.
  • Each R is independently selected from hydrogen, -OH, -CN, -N0 2 , halogen, to C12 alkyl, Q to Q2 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino, and oxo.
  • Each R N is independently selected from the group consisting of hydrogen, -OH, Q to C12 alkyl, Ci to C 12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.
  • Two R N may be taken together with C, O, N or S to which they are attached to form a five to seven membered ring which may optionally contain a further heteroatom.
  • the compounds of the present invention may be used to inhibit or reduce the activity of HCV, particularly HCV's NS5B protein.
  • inhibition and reduction of activity of the NS5B protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound.
  • the inhibition or reduction in the measured activity is at least a 10% reduction or inhibition.
  • reduction or inhibition of the measured activity of at least 20%, 50%, 75%, 90% or 100%, or any number in between, may be preferred for particular applications.
  • L 1 , L 2 and L 3 together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L 2 , or L 3 is independently selected from a group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) favor-, -P(0)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • U or V is independently CH, N, CF, CC1, or CCN;
  • W, X, or Z is independently C or N;
  • Y is NR N , N, O, S, Se, or -CR a R b ;
  • R N is hydrogen, C 1-4 alkyl, C 3 _6 cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
  • R a , R b is independently hydrogen, methyl, or together form a C3.6 cycloalkyl bearing 0- 1 heteroatom of O or NR ;
  • R is a substituted or unsubstituted aryl or heteroaryl
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl;
  • R is hydrogen, allyl, C]_4 alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, Ci_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, C 1-4 alkyls, cyclopropyl, d_4 alkoxys, or cyclopropoxy;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2-4 alkenyl, C 2-4 alkynyl, C1-4 alkyl, cyclopropyl, d-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or d-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • L , L and L together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L 1 , L 2 , or L 3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, Q_4 alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, Ci_ 4 alkyl, cyclopropyl, CM alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, C 1-4 alkyls, cyclopropyl, Ci -4 alkoxys, or cyclopropoxy;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C 2-4 alkynyl, Ci_ 4 alkyl, cyclopropyl, Ci -4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci- 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring
  • L 1 , L 2 and L 3 together with the attached carbons of the aromatic ring form a 5-9 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
  • L 1 , L 2 , or L 3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide; n is 0, 1 , or 2;
  • R 2 is a substituted or unsubstituteed aryl or heteroaryl
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, C 1 -4 alkyl, cyclopropyl, C alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 11 is independently hydrogen, CM alkyls, cyclopropyl, C1.4 alkoxys, or cyclopropoxy;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C 2- 4 alkynyl, C 1-4 alkyl, cyclopropyl, C alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 6 is hydrogen, allyl, C alkyl, cyclopropyl, or benzyl;
  • R is hydrogen, C alkyl, cyclopropyl, CM alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R H is independently hydrogen, C alkyls, cyclopropyl, C alkoxys, or cyclopropoxy.
  • R is -C(0)NHMe or [0101]
  • R 2 is selected from the rou consisting
  • Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
  • R 12 is selected from the group of hydrogen, halide, -CN, -OCHF 2 , -OCF 3 , alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
  • n 0, 1 , 2, 3, or 4;
  • G is O, NR N , S, or CR a R b ;
  • A is N, O, S, or or CR a R b ;
  • D, E is independently C or N.
  • R 2 is selected from the group consisting of
  • Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
  • R is selected from the group of hydrogen, halide, -CN, -OCHF2, -OCF3, alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
  • n 0, 1, 2, 3, or 4;
  • G is O, NR N , S, or CR a R b ;
  • A is N, O, S, or CR a R b ;
  • R 2 is selected from the group consisting of
  • each phenyl moiety is optionally substituted with 0-2 nitrogen atoms.
  • L 1 , L 2 , or L 3 is independently selected from the group consisting of a bond, -0-, -C(R 15 R 16 ), -NR 3 -, -S(0) n -, -P(0) admir-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alky], alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl; R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R is hydrogen, Q_ 4 alkyl, cyclopropyl, Ci -4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 1 ! is independently hydrogen, Cj. 4 alkyls, cyclopropyl, C 1-4 alkoxys, or cyclopropoxy;
  • R 12 is independently C ]-3 alkyl, cyclorpopyl, -OMe, or -NHMe;
  • R 13 is independently hydrogen, -Ac, or -S(0)2Me
  • R 14 is independently hydrogen or Me
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C2- 4 alkynyl, C ⁇ alkyl, cyclopropyl, Q_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • a 1 or A 2 is independently -CR a R b -, -N(R N )-, or -0-.
  • L 1 , L 2 , or L 3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) favor-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl;
  • R 6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
  • R 7 is hydrogen, Q_ 4 alkyl, cyclopropyl, Ci_ 4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
  • R 8 , R 9 , R 10 , or R 1 1 is independently hydrogen, C 1-4 alkyls, cyclopropyl, C 1-4 alkoxys, or cyclopropoxy;
  • R 12 is independently Q_ 3 alkyl, cyclorpopyl, -OMe, or -NHMe;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2- 4 alkynyl, Ci_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci- alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S ; and
  • a 2 is independently -CR a R b -, -N(R N )-, or -0-.
  • L ] or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-,-C(R I5 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is a substituted or unsubstituted aryl or heteroaryl ;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 and R 16 are independently hydrogen, hydroxyl, azide, C 2 - 4 alkyenes, C 2 _ alkynes, C 1-4 alkyls, , cyclopropyl, C 1- alkoxys, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci-4 alkenyls.
  • R 1 may be .
  • One Group of exemplary high-activity compounds are identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240 in Appendix A, and a second group of high-activity compounds are identified by ID NOS: B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71
  • a 7 or 8 member ring having an internal oxygen atom as exemplified by compounds B45, B118, B148, B197, B168, B187, B190; B192, B196, B207, B214, B191, B212, B218, B221, B222, B226, B232, B233, B236, B237, B238, B239, and B240;
  • L 1 , L 2 and -NCSOaMe)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L*or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) favor-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 - 4 alkenyl, C 2 - 4 alkynyl, Ci ⁇ alkyl, cyclopropyl, C 1 - 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • a fourth aspect of the invention is a compound that has the structure:
  • L , L and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R ] 5 R 16 )-, -NR 3 -,-S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyi, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R is an aryl or heteroaryl and may be substituted with one or more R substituents
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 and R 16 are independently hydrogen, hydroxyl, azide, C 2 - 4 alkyenes, C 2 ⁇ 4 alkynes, Ci_ 4 alkyls, , cyclopropyl, C 1-4 alkoxys, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C]_4 alkenyls; and
  • R 17 is H, F, CI, or CN.
  • a fifth aspect of the invention is a compound of formula IV.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L'or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyi, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl ;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 - alkynyl, alkyl, cyclopropyl, Ci_ 4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5- 1 2 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L'or L 2 is independently selected from the group consisting of a bond, -0-, -C(R 15 R 16 )-, - NR 3 -, -S(0) sanction-, -P(O)-, -Si(R 4 R 5 )-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R N is hydrogen, C alkyl, C 3 _6 cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 . 4 alkenyl, C 2-4 alkynyl, C ] alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L*or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) favor-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 . 4 alkynyl, C 1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L , L and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) admir-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl;
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2- alkynyl, C1-4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C].
  • 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L'or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 1 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2- 4 alkynyl, Cj_4 alky], cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or Ci_ 4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L 1 , L 2 and -N(S0 2 Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) admir-, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 3 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 -4 alkenyl, C 2 -4 alkynyl, C1.4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • L 1 , L 2 and -N(SC>2Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L'or L 2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1 , or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R 3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 13 , R 16 is independently hydrogen, hydroxyl, azide, C 2 . 4 alkenyl, C 2 . 4 alkynyl, Ci_ 4 alkyl, cyclopropyl, C 1-4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C]_ 4 alkenylidene or R and R joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S;
  • R 17 is H, F, CI or CN
  • V is CH, N, CF, CC1, or CCN.
  • L 1 , L 2 and -N(SC>2Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
  • L or L ⁇ is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R 15 R 16 )-, -NR 3 -, -S(0) n -, -P(O)-, -Si(R 4 R 5 )-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
  • n 0, 1, or 2;
  • R 2 is an aryl or heteroaryl and may be substituted with one or more R 17 substituents;
  • R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
  • alkoxylcarbonyl cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
  • R 4 and R 5 are independently methyl, ethyl, or cyclopropyl
  • R 15 , R 16 is independently hydrogen, hydroxyl, azide, C 2 _4 alkenyl, C 2 - 4 alkynyl, Ci_ 4 alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R 15 and R 16 together are a carbonyl or C 1-4 alkenylidene or R 15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR N and/or S; and
  • R 17 is H, F, CI or CN.
  • a thirteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention.
  • a fourteenth aspect of the invention provides use of the compounds of the invention in the manufacture of a medicament.
  • the medicament is for the treatment of hepatitis C.
  • a fifteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention.
  • the compounds of the invention may be prepared by a variety of synthetic routes, samples of them are illustrated in the synthetic schemes outlined below.
  • the synthesis starts with constructing the central scaffolds such as benzofuran, benzothiophene, imidazopyridine or pyrazolopyridine by employing various synthetic techniquesknown to those skilled in the art. (e.g. in Heterocyclic Chemistry, J.A. Joule and K. Mills, J Wiley and Sons, 2010.) .
  • further functional group manipulations including but not limited to chain elongation, amidation, esterification, cyclization are performed as necessary to lead to the target molecules.
  • the central cores may be preferred to be introduced toward the end of the synthesis.
  • protection-deprotection and, in some cases, orthogonal protection-deprotection strategies are required to accomplish the desired transformation. More comprehensive descriptions of these synthetic methodologies, techniques can be in found in these and other references: Comprehensive Organic Transformations, R.C. Larock Ed., Wiley-RCH, 1999. Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3 rd ed. J Willey and Sons, 1999. .
  • IC 50 The concentration of an inhibitor that causes a 50 % reduction in a measured activity
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). H NMR spectra were recorded on a Bruker 400 MHz or 500 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons.
  • Electrospray spray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HP1 100 HPLC for sample delivery.
  • Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses) or a single m/z value for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 5 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using an acetonitrile/water gradient (10%-90%) acetonitrile in water with 0.1% formic acid as delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH 4 OAc in acetonitrile/water as delivery solvent.
  • Enantiomeric purity was determined using a Hewlett-Packard Series 1050 system equipped with a chiral HLPC column (ChiralPak AD, 4.6 mm x 150 mm) and isocratic elution using 5:95 isopropanol-hexane as mobile phase.
  • Scheme A describes a general approach to building fused rings with different sizes that are attached to benzazole moieties and some chemical transformations on these fused rings.
  • Reduction of N0 2 substituted benzazole A-l, followed by sulfonylation gives A-3, which is installed a substituted terminal alkyne to afford A-5.
  • a [Pd]-mediated ring cyclization forms A-6.
  • A-6 can be prepared using A-7 as a starting material for the Heck reaction.
  • Hydrogenation of A-6 generates A-8, which can also be obtained from A-10 by hydrogenation.
  • A-10 can be converted from A-6 through an isomerization.
  • Cleavage of the double bond of A-6 using conditions such as onzonolysis gives A-9, which can be readily converted into A-11 to A-21 following typical reduction, a- alkylation, ⁇ -alkylation, elimination, and/or hydrogenation conditions.
  • Scheme B describes a general approach to B-3 bearing two substituents at the benzylic carbon. N-alkylation of A-3 with B-1 gives B-2, which is readily converted to B-3 through an intra-molecular Heck reaction when X 1 is a halide.
  • B-3 can be prepared using B-4 as a precursor.
  • Scheme C describes a general approach to cyclopropyl-substituted analogs C-1, C 2, C-3 and C-4 from A-6, A-10, A-13 and A-18, respectively.
  • Scheme D describes a general approach to cyclopropyl-substituted analogs C-1, C 2, C-3 and C-4 from A-6, A-10, A-13 and A-18, respectively.
  • Scheme D describes a general approach to analog D-2 from A-6. Hydroboration of A-6 gives D-1, in which the -OH can be readily converted into its mesylate, toyslate, or halide. Subsequent nucleophilic substitution with a nucleophile generates D-2.
  • Scheme E describes an alternative approach to build fused rings with different sizes that are attached to benzazole moieties. Sonogashira reaction of either A-1 or E-3 and E-1 gives E-2, which is hydrogenated to afford E-4. Selective sulfonylation of E-4, followed by ring closure forms A-14. Conversion the the triple bond of E-2 into a carbonyl group, followed by reduction of the -N0 2 , sulfonylation and ring closure generates A-9.
  • Scheme F describes an alternative approach to build fused rings with different sizes that are attached to benzazole moieties. Sonogashira reaction of either A-1 or E-3 and E-1 gives E-2, which is hydrogenated to afford E-4. Selective sulfonylation of E-4, followed by ring closure forms A-14. Conversion the the triple bond of E-2 into a carbonyl group, followed by reduction of the -N0 2 , sulfonylation and ring closure generates A-9.
  • Scheme F describes a general approach to analogs F-4 and F-7 from A-2. Sulfonylation of F-1 with F-2 gives F-3, which undergoes cyclization to afford F-4, Similaily, F-7 can be prepared using F-6 instead of F-2 to react with F-1.
  • Scheme G describes a general approach to fused analogs G-6, G-7, G-8, G-12 and G-14. Heck reaction of A-1 with G-1 gives G-2, which can also be prepared from E-2. Reduction of G-2, followed by sulfonylation affords G-3, which is the key precursor to the following transformations that give various fused analogs G-6, G-7, G-8, G-12 and G-14.
  • Scheme H describes a general approach to fused analogs G-6, G-7, G-8, G-12 and G-14.
  • Scheme H describes a general way to prepare H-5, H-6 and H-7. Suzuki coupling of A-1 and H-1 gives H-2, which is converted to H-4 following the same strategy depicted in Scheme E. Further transformations of H-4 may readily afford H-5, H-6 and H-7. Similarly, H-9 can be synthesized by replacing A-1 with suitable starting materials.
  • Scheme I describes general ways to build a functionalized benzofuran moiety.
  • O- protection of 1-1, followed by Sonogashira reaction with a substituted alkyne gives 1-3, which is de-protected in the presence of an acid to afford 1-4.
  • This compound undergoes a [Pd]- mediated ring cyclization to form 1-5, which can be readily converted to 1-7 by following a two-step sequence of saponification and amide formation.
  • 1-4 can be converted to 1-5 through a two-step transformation of NIS or NBS-promoted cyclization and [Pd] mediated carbonylation.
  • Scheme J describes a general way to build a functionalized pyrazole-pyridine moiety. N-amination of J-l gives pyridium salt J-2, which undergoes a ring cyclization with alkynecarboxylate J-3 to form substituted pyrazole-pyridine J-4. Saponification of J-4, followed by amide formation affords J-5.
  • Scheme K describes a general way to build a functionalized pyrazole-pyridine moiety. N-amination of J-l gives pyridium salt J-2, which undergoes a ring cyclization with alkynecarboxylate J-3 to form substituted pyrazole-pyridine J-4. Saponification of J-4, followed by amide formation affords J-5.
  • Scheme K describes a general way to build a functionalized imidazole-pyridine moiety. Cyclization of substituted aminopyridine K-1 with bromo-ketoester K-2 gives the cyclized product K-3, which can be readily converted to K-4 by following a two-step sequence of saponification and amide coupling.
  • Scheme L describes a general way to build a functionalized benzothiophene moiety.
  • Sonogashira reaction of L-1 with a substituted alkyne gives L-2, which is converted to thio- ether L-3.
  • An 12-promoted ring cyclization of L-3 affords benzothiophene L-4.
  • the iodo group can be readily transformed into a carboxylate to form functionalized L-5, which undergoes saponification and amide formation to give L-6.
  • Scheme M describes general ways to build a functionalized 2H-indazole moiety.
  • Cu-mediated N-arylation gives a mixture of IH-inzaole M-2 and the desired 2H-indazole M- 3.
  • the latter can be readily converted to M-4 following a two-step sequence of saponification and amide formation.
  • 2H-indazole M-5 can be brominated at the C-3 position to give M-6, which undergoes a [Pd] -mediated carbonylation to afford M-3.
  • Scheme N describes a general way to build a functionalized indole moiety.
  • a condensation of N-l and keto-ester N-2 gives N-3.
  • Reduction of N-3, followed by a ring formation affords substituted indole N-4, which can be readily converted to N-5 by following a two-step sequence of saponification and amide formation.
  • Step 1 Refer to Scheme 1. To a solution of compound 1-1 (40.0 g, 325 mmol) in water (40 mL) were sequentially added compound 1-2 (12 g, 162 mmol), Cu(OAc) 2 (0.6 g, 3.25 mmol) and Cul (0.6 g, 3.25 mmol). After stirring at 100 °C for 48 hrs, the reaction mixture was cooled to rt and added 30% (w/w) aq. NaOH (20 mL). The resulting mixture was extracted with EtOAc (60 mL x 3) and aq. phase was adjusted to pH 7 to 8 by adding coned, aq. HC1.
  • Step 2 A mixture of compound 1-3 (40.0 g, 20.5 mmol) in polyphosphoric acid (PPA) (100 mL) was mechanically stirred at 90 °C for 3 hrs. The mixture was cooled to 60 °C and ice water (50 mL) was added with stirring for 30 min. Subsequently, the mixture was extracted with EtOAc (120 mL x 3). The organic extracts were combined, washed with water (40 mL) and brine (40 mL), and dried over anhydrous Na 2 S0 4 .
  • PPA polyphosphoric acid
  • Step 3 A solution of compound 1-4 (4.00 g, 22.6 mmol) and Et 3 N (9.40 mL, 67.8 mmol) in DCM (200 mL) was added MsCl (6.46 g, 56.4 mmol) at 0 °C. After stirring at rt for 3 hrs, the reaction was quenched by adding ice water (250 mL) and the aq. phase was extracted with DCM (100 mL x 2). The organic extracts were combined, washed with water and brine, and dried over anhydrous Na 2 S04.
  • Step 4 To a suspension of Ph 3 PCH 3 Br (14.0 g, 39.2 mmol) in 130 mL of THF was added n-BuLi (2.5 M in hexane, 15.7 mL, 39.2 mmol) at 0 °C. After stirring at 0 °C for 2 hr, a solution of compound 1-5 (4.00 g, 15.7 mmol) in anhydrous THF (30 mL) was added. After stirring at rt overnight, the reaction mixture was quenched by adding aq. NH4CI (sat., 20 mL).
  • Step 5 To a solution of compound 1-6 (2.70 g, 10.7 mmol) in dry toluene (200 mL) was added ZnEt 2 (1 M in hexane, 85.4 mL, 85.4 mmol), followed by CH2I2 (46 g, 171mmol) at 0 °C. After stirring at rt overnight, the reaction mixture was partitioned between EtOAc (100 mL) and 5% HC1 (100 mL). The organic layer was dried with anhydrous Na 2 S04 and concentrated and the residue was purified by silica gel column chromatography (DCM) to give compound 1-7 (2.1 g, 72% yield).
  • DCM silica gel column chromatography
  • Step 7 To a solution of compound 1-8 (200 mg, 0.58 mmol) in CH 2 CI 2 (6 mL) was added BBr 3 (4 N in DCM, 0.6 mL, 2.4 mmol) at -20 °C. After stirring at 0 °C for 1 hr, the reaction was quenched by adding ice-water (50 mL). The mixture was extracted with DCM (50 mL x 2) and the combined extracts were washed with water and brine, and dried with anhydrous Na 2 S0 4 .
  • Step 8 To a solution of compound 1-9 (1 .60 g, 4.82 mmol) in 30 mL THF was added DMAP (30 mg) and TEA (1.46 g, 14.46 mmol). The resulting mixture was cooled to 0 °C and SEMC1 (1.60 g, 9.64 mmol) was added. After stirring at rt for 10 hrs, the reaction mixture was poured into water (50 mL) and extracted with EtOAc (60 mL x 3). The combined organic extracts were washed brine (30 mL) and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 1-10 (2.2 g, 99% yield) as a yellow oil. LC-MS (ESI): mlz 485 [M+Na] + .
  • Step 9 To a solution of compound 1-10 (1.60 g, 3.47 mmol) in 20 mL of DMF were added 1-11 (0.50 g, 4.16 mmol), Cul (33 mg, 0.17 mmol), Pd(PPh 3 ) 2 Cl 2 (244 mg, 0.35 mmol), P(r-Bu) 3 (140 mg, 0.69 mmol) and piperidine (1.18 g, 13.9 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. Subsequently, the reaction mixture was cooled to rt, poured into water (60 mL), and extracted with EtOAc (100 mL x 2).
  • Step 10 To a solution of compound 1-12 (750 mg, 1.50 mmol) in dioxane (10 mL) was added 4 N HCl/dioxane (2 mL). After stirring at rt for 2 hrs, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 1-13 (600 mg, quantitative yield) as a yellow oil.
  • Step 11 To a solution of compound 1-13 (600 mg, 1.62 mmol) in MeOH (20 mL) was added NaOAc (265 mg, 3.24 mmol), K 2 C0 3 (448 mg, 3.24 mmol), PdCl 2 (28 mg, 0.16 mmol), and CuCl 2 (653 mg, 4.86 mmol). The resulting mixture was flushed with CO and stirred at rt overnight under an atmosphere of CO. The mixture was diluted with EtOAc (80 mL) and filtered through Celite ® 545. The filtrate was washed with water (30 mL) and brine (30 mL), and dried with anhydrous Na 2 S0 4 .
  • Step 12 To a solution of compound 1-14 (70 mg, 0.16 mmol) in MeOH/THF (1 mL/2 mL) was added LiOH (0.65 mmol). After stirring at 70 °C for 2 hr, the reaction mixture was cooled to rt and acidified by adding IN aq. HC1 (7 mL). The resulting mixture was filtered and the solid was dried in vacuo to give compound 1-15 (60 mg, 91% yield) as a white solid.
  • DCM/MeOH 600/1 (v/v)
  • Step 1 Refer to Scheme 2. A suspension of NaH (16.1 g, 402 mmol) in anhydrous
  • Step 3 To a solution of compound 2-3 (9.0 g, 55 mmol) and TEA (13.6 g, 135 mmol) in DCM (200 mL) at 0 °C was added MsCl (9.1 g, 80 mmol). After stirring at rt for 30 min, the reaction mixture was added ice water (250 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na 2 S04.
  • Step 5 A solution of BBr 3 (13.6 mL/4.0M, 54.4 mmol) in DCM was added to a solution of compound 2-5 (5.04 g, 13.6 mmol) in CH 2 C1 2 (100 mL) at -20 °C. After stirring at -20 °C for 1 hr, the reaction mixture was added ice water (200 mL). The resulting mixture was extracted with DCM (lOOmL x 2) and the combined organic extracts were washed water and brine and dried with anhydrous Na 2 SC>4.
  • Step 7 To a solution of 2-7 (1.60 g, 3.31 mmol) in 20 mL DMF were added 2-8 (0.48 g, 4.0 mmol), Cul (32 mg, 0.17 mmol), Pd(PPh 3 ) 2 Cl 2 (232 mg, 0.330 mmol), P(i-Bu) 3 (133 mg, 0.660 mmol) and piperidine (1.13 g, 13.2 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. The resulting mixture was poured in to ice water (60 mL) and extracted with EtOAc (100 mL x 2).
  • Step 8 To a solution of compound 2-9 (1.2 g, 2.52 mmol) in 16 mL dioxane was added 4 N HC1 in dioxane (7.6 mL) at rt. After stirring at rt for 30 min, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 2-10 (870 mg, quantitative yield) as a yellow oil, which was used directly for the next step without purification.
  • Step 9 To a solution of compound 2-10 (600 mg, 1.74 mmol) in MeOH (17 mL) were added NaOAc (285 mg, 3.48 mmol), K 2 C0 3 (481 mg, 3.48 mmol), PdCl 2 (31.0 mg, 0.17 mmol) and CuCl 2 (702 mg, 5.22 mmol) and the resulting mixture was flushed with CO. After stirring at rt overnight, the mixture was concentrated and the residue was diluted with EtOAc (100 mL) and filtered. The filtrate was washed with water (30 mL) and brine (30 mL) and dried with anhydrous Na 2 S0 4 .
  • Step 10 To a solution of compound 2-11 (140 mg, 0.35 mmol) in MeOH/THF (2 mL/4 mL) was added LiOHH 2 0 (58 mg, 1.4 mmol) at rt. After stirring at 70 °C for 1 hr, the reaction mixture was cooled to 0 °C and acidified with IN aqueous HC1 (3 mL). The suspension was filtered and the solid was dried in vacuo to give compound 2-12 (136 mg, quantitative yield) as a white solid, which was used directly for the next step without further purification. LC-MS (ESI): mlz 390 [M+H] + . [0173] Step 11.
  • Step 1 Refer to Scheme 3. A mixture of compound 3-1 (2.00 g, 5.16 mmol) (prepared by following the procedures described in WO200759421 with some modifications) and 10% Pd/C (1.0 g) in EtOAc (40 mL) was stirred at rt for 2 hr under an atmosphere of H 2 . The reaction mixture was filtered and the filtrate was concentrated to give compound 3-2 (1.7 g, 92% yield). LC-MS (ESI): mlz 358 [M+H] + .
  • Step 2 To a solution of compound 2 (1.70 g, 4.76 mmol) and TEA (1.32 mL, 9.52 mmol) in DCM (50 mL) was added MsCl (0.660 g, 5.71 mmol) at 0 ° C . After stirring at rt for 30 min, the reaction mixture was added ice water (250 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na 2 S0 4 .
  • Step 3 To a solution of compound 3-3 (4.00 g, 9.5 mmol) in DMF (50 mL) was added K 2 C0 3 (5.25 g, 38.0 mmol) and compound 3-4 (1.54 g, 1 1.4 mmol) at rt. After stirring at 80 °C overnight, the reaction mixture was poured into ice water (60 mL). The resulting mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 3-5 (4.2 g, 92% yield) as a yellow solid.
  • Step 4 To a solution of compound 3-5 (2.1 g, 4.3 mmol) in CH 2 C1 2 (100 mL) was added BC1 3 (1 N in DCM, 12.9 mL) at -78 °C, the solution was allowed to stirred at -30 °C for 1 hr and then quenched with ice-water (200 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine, and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 3-6 (1.7 g, 86% yield) as a yellow solid. LC-MS (ESI): mlz 448 [M+H] + .
  • Step 5 To a solution of compound 3-6 (3.30 g, 7.37 mmol) in CH 2 C1 2 (160 mL) were sequentially added DMAP (45 mg, 0.37 mmol), DIEA (2.58 mL, 14.8 mmol) and Tf 2 0 (1.5 mL, 8.9 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction mixture was added ice-water (100 mL). The organic layer was washed with water and brine and dried with anhydrous Na 2 S04.
  • Step 6 To a solution of compound 3-7 (3.00 g, 5.18 mmol) in 20 mL DMF was added Pd(OAc) 2 (116 mg, 0.520 mmol), PPh 3 (136 mg, 0.520 mmol), LiCl (242 mg, 5.70 mmol) and Et 3 N (1.44 mL, 10.4 mmol) at rt. The resulting mixture was flushed with Ar and stirred at 120 °C overnight. The mixture was cooled to rt and poured into 60 mL water. The resulting mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water (50 mL x 3) and dried with anhydrous Na 2 S0 4 .
  • Step 7 To a solution of compounds 3-8 and 3-8' (1.00 g, 2.33 mmol) in
  • Step 8 To a solution of compounds 3-9 and 3-9' (950 mg, 2.37 mmol) in DMF (5 mL) was added HATU (1.35 g, 3.55 mmol). The resulting mixture was stirred at rt for 30 min and added DIEA (3.30 mL, 19.0 mmol) and MeNH 2 HCl (639 mg, 9.47 mmol). After stirring at rt for 20 min, the reaction mixture was poured into ice water (50 mL). The suspention was filtered and the solid was purified by silica gel column chromatography to give a mixture of compounds 3-10 and 3-10' (580 mg, 59% yield).
  • Step 1 Refer to Scheme 4. To a solution of compound 3-1 (4.00 g, 10.3 mmol) in CH 2 C1 2 (30 mL) was added BC1 3 (1 N in CH 2 C1 2 , 20.6 mmol) at 0 °C. After stirring at rt for 1 hr, the reaction mixture was added ice water (100 mL). The mixture was extracted with
  • Step 2 To a solution of compound 4-1 (3.4 g, 9.8 mmol) in CH 2 C1 2 (100 mL) were added DMAP (120 mg, 0.980 mmol) and DIEA (1.52 g, 1 1.8 mmol), followed Tf 2 0 (3.20 g, 11.3 mmol) at 0 °C. After stirring at 0 °C for 2 hrs, the reaction mixture was added ice water (100 mL). The organic layer was separated, washed with water and brine, and dried with anhydrous Na2S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 4-2 (4.6 g, quantitative yield) as a yellow solid. LC-MS (ESI): mlz 478 [M+H] + .
  • Step 3 To a solution of 4-2 (2.0 g, 4.2 mmol) in 20 mL DMF was added 4-3 (0.44 g, 6.3 mmol), Cul (0.16 g, 0.84 mmol), Pd(PPh 3 ) 2 Cl 2 (0.29 g, 0.42 mmol) and Et 3 N (20 mL). The resulting mixture was flushed with Ar, stirred at rt for 1 hr and poured into ice water (100 mL). The mixture was extracted with EtOAc (50 mL x 5) and the combined organic extracts were washed with water and dried with anhydrous Na2S0 4 .
  • Step 5 To a solution of compound 4-5 (1.80 g, 4.85 mmol) in CH 2 C1 2 (50 mL) was added DMAP (6 mg) and anhydrous pyridine (3.07 g, 38.8 mmol), followed by MsCl (1.60 g, 14.5 mmol) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added ice water (50 mL). The organic layer was separated, washed with water and brine and dried with anhydrous Na 2 S0 4 .
  • Step 6 To a suspension of NaH (0.21 g, 60% in mineral oil, 5.31 mmol) in anhydrous THF (160 mL) was added a solution of compound 4-6 (1.40 g, 2.65 mmol) in anhydrous THF (40 mL) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added sat. aq. NH 4 CI (10 mL). The resulting mixture was concentrated and the residue was diluted with EtOAc (100 mL). The mixture was washed with water and brine and dried with anhydrous Na 2 S0 4 .
  • Step 7 To a solution of compound 4-7 (50 mg, 0.12 mmol) in MeOH/THF (2 mL/4 mL) was added LiOH (2,0 N, 0.46 mmol). The resulting mixture was stirred at 70 °C for 2 hrs, cooled to rt and acidified with 1 N aq. HC1 (5 mL). Subsequently, the suspension was filtered and the solid was washed with waster and dried in vacuo to give crude compound 4-8 (46 mg, 95% yield) as a white solid, which was used directly for the next step without further purification.
  • Step 1 Refer to Scheme 5. To a suspension of Zn (3.92 g, 60.3 mmol) in EtOH (80 mL) was added HOAc (3 mL), followed by solution of compound 5-1 (2.0 g, 8.6 mmol) in EtOH (20 mL) at rt. After stirring at rt overnight, the reaction mixture was filtered. The filtrate was concentrated and the residue was diluted with EtOAc (150 mL). The mixture was washed with water (200 mL) and brine (100 mL) and dried with anhydrous Na 2 S0 4 .
  • Step 2 A solution of compound 5-2 (10.0 g, 49.8 mmol) in anhydrous pyridine (50 mL) was added MsCl (4.04 mL, 52.2 mmol) at 0 °C. After stirring at rt for 30 min, the reaction mixture was diluted with EtOAc (200 mL). The mixture was washed with 1 N aq.
  • Step 3 To a solution of compound 5-3 (800 mg, 2.86 mmol) in DMF (10 mL) were added compound 5-4 (51 1 mg, 3.43 mmol) and K 2 CO 3 (1.58 g, 1 1.4 mmol). After stirring at 80 °C for 4 hrs, the reaction mixture was added ice-water (50 mL) and EtOAc (50 mL). The organic layer was washed with water (50 mL x 5) and brine (50 mL) and dried with anhydrous Na 2 S0 4 .
  • Step 4 To a solution of compound 5-5 (980 mg, 2.83 mmol) in DMF (5 mL) were added Pd(OAc) 2 (64 mg, 0.28 mmol), PPh 3 (297 mg, 1.13 mmol), LiCl (132 mg, 3.1 1 mmol) and Et 3 N (572 mg, 5.66 mmol) and the resulting mixture was flushed with Ar and stirred at 120 °C for 1.5 hrs. Subsequently, the reaction mixture was cooled to rt and poured into water (60 mL).
  • Step 5 To a solution of compound 5-6 (3.60 g, 13.5 mmol) in toluene (60 mL) were added ZnEt 2 (1 M in hexane, 108 mmol) and CH 2 I 2 (57.6 g, 216 mmol) at 0 °C. After stirring at rt overnight, the reaction mixture was diluted with EtOAc (100 mL) and the resulting mixture was washed with 5% (w/w) aq. HC1 (100 mL) and brine and dried with anhydrous Na 2 S0 4 .
  • Step 6 To a solution of compound 5-7 (1.80 g, 6.43 mmol) in DCM (65 mL) was added NBS (2.28 g, 12.9 mmol) at 0 °C. After stirring at rt for 24 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography
  • Step 7 To a solution of compound 5-8 (800 mg, 2.23 mmol) in CH 2 C1 2 (30 mL) was added BBr 3 (4 N in DCM, 8.91 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction ixture was poured into ice-water (150 mL). The resulding mixture was extracted with DCM (50 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 5-9 (670 mg, 87% yield) as a white solid. LC-MS (ESI): m/z 346
  • Step 8 To a solution of compound 5-9 (670 mg, 1.94 mmol) in THF (30 mL) were added DMAP (20 mg) and TEA (588 mg, 5.82 mmol). The resulting mixture was cooled to 0 °C and SEMC1 (643 mg, 3.87 mmol) was added. After stirring at rt for 1.5 hrs, the reaction mixture was poured into water (50 mL). The mixture was extracted with EtOAc (60 mL x 3) and the combined organic extracts were washed with brine (30 mL) and dried anhydrous Na 2 SC .
  • Step 9 To a solution of compound 5-10 (460 mg, 0.970 mmol) in DMF (6 mL) were added compound 1-11 (139 mg, 1 .16 mmol), Cul (9.3 mg, 0.050 mmol), Pd(PPh 3 ) 2 Cl 2 (68 mg, 0.097 mmol), P(f-Bu) 3 (39 mg, 0.19 mmol) and piperidine (330 mg, 3.88 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. Subsequently, the reaction mixture was added into water (60 mL) and extracted with EtOAc (50 mL x 2).
  • Step 11 To a solution of compound 5-12 (80 mg, 0.21 mmol) in TFA (0.5 mL) and
  • Step 12 To a solution of compound 5-13 (80 mg, 0.16 mmol) in DMF (3 mL) and MeOH (3 mL) were added Pd(PPh 3 ) 4 (91 mg, 0.080 mmol) and Et 3 N (64 mg, 0.64 mmol). The resulting mixture was flushed with CO and stirred at 60 °C for 4 hrs under an atmosphere of CO. Subsequently, the mixture was water (20 mL) and extracted with EtOAc (60 mL x 2). The combined organic extracts were washed with water (60 mL x 5) and dried with anhydrous Na 2 S0 4 .
  • Step 13 To a solution of compound 5-14 (70 mg, 0.16 mmol) in MeOH/THF (1 mL/2 mL) was added LiOH (0.63 mmol). After stirring at 70 °C overnight, the reaction mixture was cooled to 0 °C and acidified with 1 N aq. HC1 (7 mL). The suspention was filtered and the solid was washed with water and dried in vacuo to give crude compound 5-15 (60 mg, quantitative yield) as a white solid, which was used for the next step without further purification.
  • Step 1 Refer to Scheme 6. To a solution of compound 3-3 (4.35 g, 10.0 mmol) in DMF (40 mL) was added K 2 C0 3 (5.52 g, 40.0 mmol) and compound 6-1(1.79 g, 12.0 mmol). After stirring at 80 °C overnight, the reaction mixture was cooled to rt and poured into water (60 mL). The mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water and dried with anhydrous Na 2 S04.
  • Step 2 To a solution of compound 6-2 (2.0 g, 4.0 mmol) in CH 2 C1 2 (80 mL) was added BC1 3 (1 N in DCM, 8.0 mmol) at -30 °C. After stirring at -30 to -20 °C for 30 rain, the reaction mixture was poured into ice-water (100 mL). The mixture was extracted with DCM (80 mL x 2) and combined organic extracts were washed with water and brine and dried with anhydrous Na 2 S0 4 .
  • Step 3 To a solution of compound 6-3 (1.40 g, 3.04 mmol) in CH 2 C1 2 (40 mL) were added DMAP (19 mg, 0.15 mmol) and DIEA (0.590 g, 4.56 mmol), followed by Tf 2 0 (1.03 g, 3.64 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction mixture was added into ice water (50 mL). The organic layer was washed with water and brine and dried with anhydrous Na 2 S0 4 .
  • Step 5 To a solution of compound 6-4 (1.00 g, 1.69 mmol) in 20 mL DMF was added Pd(OAc) 2 (38 mg, 0.17 mmol), PPh 3 (177 mg, 0.680 mmol), LiCl (79.0 mg, 1.86 mmol) and Et 3 N (1.00 mL, 6.75 mmol). The resulting mixture was flushed with Ar and stirred at 120 °C overnight. Subsequently, the mixture was cooled to rt and poured into 60 mL water. The resulting mixture was extracted with EtOAc (80 mL x 2) and the combined organic extracts was washed with water and dried with anhydrous Na 2 S0 4 .
  • Step 6 To a solution of compound 6-5 (300 mg, 0.680 mmol) in MeOH/THF (4 mL/8 mL) was added 2.0 N aq. LiOH (2.72 mL, 1.36 mmol). After stirring at 75 °C for 2 hrs, the reaction mixture was colled to rt and acidified with 2 N aq. HC1 to pH 5 - 6. The suspension was filtered and the solid was washed with water and dried in vacuo to give compound 6-6 (260 mg, 92% yield) as a white solid, which was used directiy for the next step without further purification. LC-MS (ESI): mlz 416 [M+H] + .
  • Step 7 To a solution of Et 2 Zn (1.1 M in toluene, 10 mL, 11 mmol) in 1 , 2- dichloroethane (10 mL) was added a solution of CH 2 I 2 (5.87 g, 22 mmol) in 1, 2- dichloroethane (10 mL) at -78 °C under an atmosphere of N 2 . After stirring at -15 °C for 30 min, the mixture was cooled to -78 °C. Subsequently, a solution of compound 6-6 (200 mg, 0.481 mmol) in 1, 2-dichloroethane (15 mL) was added. The reaction mixture was then stirred at room temperature for 40 hrs and added 1 M aq.
  • Step 1 Refer to Scheme 8. To a stirred solution of compound 4-2 (9.00 g, 18.9 mmol) in DMF (100 mL) were added Et 3 N (7.84 mL, 56.6 mmol), Pd(OAc) 2 (212 mg, 0.94 mmol), dppp (469 mg, 1.13 mmol) and butyl vinyl ether (12.1 mL, 94.4 mmol) under an atmosphere of Ar. After stirring at 100 °C for 2 hrs, the reaction mixture was concentrated. The residue was diluted with EtOAc (250 mL) and the resulting mixture was washed with water (100 mL x 3) and dried with anhydrous Na 2 S0 4 .
  • Step 2 A solution of compound 8-1 (3.90 g, 9.13 mmol) in THF (60 mL) was added 1 N aq. HC1 (10 mL) at rt. After stirring at rt for 15 min, the reaction mixture was concentrated and the residue was diluted with DCM (100 mL). The resulting mixture was washed with brine and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 8-2 (3.27 g, 96% yield) as a yellow solid, which was used for the next step without further purification.
  • Step 3 To a stirred solution of compound 8-2 (2.00 g, 5.38 mmol) in EtOAc (50 mL) was added SnCl 2 2H 2 0 (3.47 g, 16.2 mmol). After stirring at 80 °C for 1 hr, the reaction mixture was added sat. aq. NaHC0 3 (50 mL) and the resulting mixture was stirred at rt for 30 min. Subsequently, the mixture was filtered through Celite ® 545 and the the filtered cake was washed with EtOAc (50 mL x 3). The organic layer of the filtrate was washed with brine and dried with anhydrous Na 2 S0 4 .
  • Step 4 To a stirred solution of compound 8-3 (900 mg, 2.64 mmol) in anhydrous pyridine (15 mL) was added MsCl (0.25 mL, 3.17 mmol) at 0 °C. After stirring at rt for 1 hr, the reaction mixture was diluted with EtOAc (100 mL) and the resulting mixture was washed with 2 N aq. HC1 (20 mL x 2) and H 2 0 (50 mL x 3) and dried with anhydrous Na 2 S0 4 .
  • Step 5 To a solution of compound 8-4 (380 mg, 0.91 mmol) in MeOH (10 mL) and THF (10 mL) was added NaBH 4 (172 mg, 4.54 mmol) in several portions at 0 °C. After stirring at 0 °C for 15 min, the reaction was quenched by adding acetone (1 mL). The mixture was concentrated and the residue was diluted with EtOAc (100 mL). The resulting mixture was washed with 2 N aq. HC1 (20 mL) and H 2 0 (50 mL x 3) and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 8-5 (240 mg, 63% yield), which was used for the next step without further purification.
  • Step 6 To a stirring solution of compound 8-5 (50 mg, 0.12 mmol) in THF (15 mL) was added NaH (24 mg, 0.6 mmol) at 0 °C under an atmosphere of Ar. After stirring at rt for 15 min, the mixture was added compound 8-6 (106 mg, 0.24 mmol) (prepared following the procedure described in Angew. Chem. Intl. Ed. 2008, 47, 3784) at 0 °C and the resulting mixture was stirred at 0 °C for 3 hrs and rt overnight. Subsequently, saturated aq. NH 4 C1 (10 mL) was added to quench the reaction and the mixture was concentrated.
  • Step 8 To a solution of compound 8-8 (40 mg, 0.10 mmol) in DMF (3 mL) was added HATU (43 mg, 0.12 mmol). The resulting mixture was stirred at rt for 60 min and DIEA (0.16 mL, 0.95 mmol) and MeNH 2 HCl (20 mg, 0.29 mmol) were added. After stirring at rt for 15 min, the reaction mixture was added into water (30 mL). The suspension was filtered and the solid was washed with water and dried in vacuo. The residue was dissolved in DCM (1.5 mL) and the solution was added into hexane (40 mL).
  • Step 1 Refer to Scheme 9. To a solution of compound 4-2 (2.37 g, 5.00 mmol) in anhydrous THF (70 mL) were added commercially available 2-ally-4,4,5,5-tetramethyl-l,3,2- dioxaborolane (1.09 g, 6.50 mmol), Pd(PPh 3 ) 4 (0.58 g, 0.50 mmol) and CsF (3.0 g, 19.87 mmol) under an atmosphere of Ar. The resulting mixture stirred at 80 °C 3 hrs and concentrated. The residue was diluted with water (100 mL) and extracted with EtOAc (50 mL x 3).
  • Step 3 To a solution of compound 9-2 (420 mg, 1.13 mmol) in MeOH (11 mL) and THF (1 1 mL) was added NaBH 4 (172 mg, 4.53 mmol) at 0 °C. After stirring at 0 °C for 30 min, several drops of acetone was added to quench the reaction. The mixture was concentrated and the residue was diluted with water (50 mL) and EtOAc (50 mL). The aq. phase was extracted with EtOAc (50 mL x 2) and the combined organic extracts were washed with brine and dried with anhydrous Na9S0 4 . The solvent was removed and the residue was dried in vacuo to give crude compound 9-3 (422 mg, quantitative yield), which was used for the next step without further purification. LC-MS (ESI): m/z 374 [M+H] + .
  • Step 4 To a solution of compound 9-3 (410 mg, 1.10 mmol) in EtOAc (150 mL) was added 10% Pd/C (400 mg). The resulting mixture was flushed with H 2 and stirred at rt overnight under an atmosphere of H 2 . Subsequently, the reaction mixture was filtered through Celite ® 545 and the filtered cake was washed with EtOAc (50 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 9-4 (372 mg, 99% yield). LC-MS (ESI): m/z 344 [M+H] + .
  • Step 5 To a solution of compound 9-4 (372 mg, 1.08 mmol) in CH 2 C1 2 (10 mL) were added DMAP (20 mg), Et 3 N (654 mg, 6.48 mmol) and MsCl (500 mg, 4.33 mmol) at 0 °C. After stirring at 0 °C for 30 min and rt for 1.5 hrs, the reaction mixture was added saturated aq. NaHC0 3 (5 mL). The mixture was diluted with DCM (50 mL) and the organic layer was washed with brine and dried with anhydrous Na 2 SC>4.
  • Step 6 To a solution of compound 9-5 (200 mg, 0.500 mmol) in MeOH/THF (6 niL/12 mL) was added LiOH (2.0 N aq. solution, 2.0 mmol). The resulting mixture was stirred at 70 °C for overnight and then acidified with IN aq. HC1 (aq, 4 mL) at 0 °C. The suspension was filtered and the solid was washed with water and dried in vacuo to give crude compound 9-6 (170 mg, 90% yield) as a white solid, which was used for the next step without further purification. LC-MS (ESI): m/z 376 [M+H] + .
  • Step 7 To a solution of compound 9-6 (70 mg, 0.18 mmol) in DMF (4 mL) was added HATU (85 mg, 0.22 mmol). The resulting mixture was stirred at rt for 30 min, followed by adding DIEA (0.33 mL, 1.8 mmol) and MeNH 2 HCl (76.0 mg, 1.12 mmol). After stirring at rt for 20 min, the reaction mixture was added into water (50 mL). The resulting suspension was filtered and the solid was washed with water and dried in vacuo.
  • Step 1 Refer to Scheme 10. To a mixture of ;Pr 2 NH (27 mL, 190.7 mmol) in THF (140 mL) was dropwisely added nBuLi (2.5M in Hexanes, 73 mL, 181.6 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 min, then warmed up to rt with stirring for another 20 min. Subsequently, to a mixture of compound 10-1 (10 g, 45.4 mmol) (prepared by following the procedure described in WO2009051306) and I 2 (28.5g, 114 mmol) in THF (70 mL) was dropwisely added LDA solution freshly prepared at -78 °C.
  • nBuLi 2.5M in Hexanes, 73 mL, 181.6 mmol
  • Step 2 A mixture of compound 10-1 (3.34 g, 10 mmol), 10-2 (1.40 g, 10 mmol) and Pd(PPh 3 ) 4 (0.58 g, 0.5 mmol) in 2 M aq. Na 2 C0 3 (15 mL) and dioxane (75 mL) was degassed and refilled with nitrogen. The process was repeated 3 times. The mixture was then stirred at 90 °C in a sealed flask for 24 hrs. After being cooled down, the reaction mixture was concentrated. The residue was partitioned between DCM and water. The aqueous layer was extracted with DCM several times. The combined organic extracts were dried with anhydrous Na 2 S04.
  • Step 4 To a solution of compound 10-4 (1.98 g, 5.91 mmol) in dichloromethane at - 45 °C was slowly added a solution of BBr 3 (0.68 mL, 7.1 mmol) in dichloromethane (6 mL). The resulting mixture was stirred at the temperature for 30 min, and then in an ice-water bath for 30 min. Subsequently, the cold reaction mixture was diluted with dichloromethane (100 mL), and ice water (10 mL) was slowly added into the solution to destroy the excess amount of BBr 3 . The organic layer was washed with water and dried over anhydrous Na 2 S0 4 .
  • Step 1 Refer to Scheme 12. A solution of Br 2 (1 M in AcOH, 10 mL, 10 mmol) was slowly added into a solution commercially available compound 12-1 (1.24 g, 10 mmol) in AcOH (35 mL) at rt. After stirring at rt for 1 hr, the reaction mixture was filtered and the solid was dried in vacuo to give compound 12-2 (1.41 g, 69% yield).
  • ⁇ NMR 300 MHz, CD 3 OD
  • Step 2 A mixture of compound 12-2 (1.41 g, 6.9 mmol) and 2-bromo-3-(4-fluoro- phenyl)-3-oxo-propionic acid ethyl ester (12-3) (1.01 g, 3.5 mmol) in ethanol (100 mL) was stirred at 70 °C for 22 hrs. The solvent was removed and the residue was partitioned between DCM (50 mL) and water (25 mL). The organic layer was washed with sat. aq. Na 2 C0 3 solution and water and dried with anhydrous Na 2 S0 4 .
  • Step 3 A solution of Li OH (0.25 g, 6.0 mmol) in water (4.5 mL) was added into a solution of compound 12-4 (0.90 g, 2.3 mmol) in THF (9 mL). After stirring at 50 °C for 24 hrs, the reaction mixture was acidified to pH ⁇ 3.0 by adding 1 N aq. HC1. The solvent was removed and the residue was dried in vacuo to give crude compound 12-5, which was used for the next step without further purification.
  • Step 4 A mixture of compound 12-5 (0.83 g, 2.28 mmol), CH 3 NH 2 HC1 (0.31 g, 4.56 mmol), EDC HCl (0.66 g, 3.42 mmol), HOBt H 2 0 (0.52 g, 3.4 mmol) and DIPEA (1.88 mL, 1 1.4 mmol) in DMF (22 mL) was stirred at 50 °C for 18 hrs. The reaction mixture was added into ice water (250 L) and filtered. The solid was washed with water and dried in vacuo to give crude compound 12-6.
  • Step 5 BBr 3 (1.73 mL, 19 mmol) was slowly added into a solution of compound 12-6 (0.68 g, 1.8 mmol) in DCM (4 mL) at 0 °C. The resulting reaction mixture was stirred at rt for 16 hrs under an atmosphere of N 2 and treated with ice water (25 mL). After adjusting the pH of the mixture to basic using 5 N aq. NaOH, the mixture was extracted with DCM (25 mL x 3). The combined organic extracts dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was purified by silica gel column chromatography to give compound 12-7 (0.36 g, 55% yield). LC-MS: m/z 366 [M+H] + .
  • Step 7 A mixture of compound 12-8 (200 mg, 0.46 mmol), Pd(OAc) 2 (10.3 mg, 0.046 mmol), PPh 3 (48.5 mg, 0.19 mmol), LiCl (21.5 mg, 0.51 mmol) and Et 3 N (0.26 mL, 1.8 mmol) in DMF (6.0 mL) was degassed and refilled with N 2 . The process was repeated for 3 times. After stirring at 120 °C for 18 hrs, the mixture was added into ice water (100 mL).
  • Step 1 Refer to Scheme 13, to a solution of compound 13-1 (10.0 g, 64.9 mmol) in EtOH (400 mL) was added 10% Pd/C (w/w) (4.60 g). The reaction mixture was allowed to stir at rt under an atmosphere of 3 ⁇ 4 for 24 hrs. Subsequently, the reaction mixture was filtered through Celite ® 545 and the filtered cake was washed with EtOAc (100 mL x 3). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 13-2 (8.0 g, 99% yield) as a dark red oil, which was used for the next step without further purification. LC-MS (ESI): m/z 125 [M+H] + .
  • Step 3 To a solution of 0-(mesitylsulfonyl)hydroxy amine (MSH) (17.8 mmol) in DCM (100 mL) was added compound 13-3 (5.00 g, 17.8 mmol). After stirring at rt overnight, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 13-4, which was used for the next step without further purification.
  • Step 5 To a solution of compound 13-5 (1.00 g, 2.45 mmol) in DMF (25 mL) were added K 2 C0 3 (1.02 g, 7.36 mmol) and 5-bromopent-l-ene (732 mg, 4.91 mmol) at rt. After stirring at 80 °C for 2 hrs, the reaction mixture was poured into ice water (100 mL). The resulting solution was extracted with EtOAc (100 mL x 3) and the organic extracts were combined, washed with water (50 mL x 3) and dried with anhydrous Na 2 S0 4 .
  • Step 6 A mixture of 2-(diethylamino)ethanefhiol-HCl (535 mg, 3.15 mmol) and t- BuONa (637 g, 6.62 mmol) in anhydrous DMF (25 mL) was stirred at rt for 15 min under an atmosphere of N 2 . Subsequently, a solution of compound 13-6 (1.0 g, 2.1 mmol) in anhydrous DMF (5 mL) was added and the resulting mixture was refluxed for 30 min, poured into ice water (50 mL) and kept at 0 °C. The pH value of the reaction mixture was adjusted to 3 to 4 by adding 1 N aq.
  • Step 9 To a solution of compound 13-9 (95 mg, 0.21 mmol) in EtOH (40 niL) and THF (10 mL) was added 10% Pd/C (40 mg). The resulting mixture was stirred at rt for 16 hrs under an atmosphere of 3 ⁇ 4. The resulting mixture was filtered and the filtrate was concentrated and dried in vacuo to give crude compound 13-10, which was used for the next step without further purification.
  • Step 10 A mixture of compound 13-10 (95 mg, 0.213 mmol) and LiOH (2.0 M, 0.852 mmol) in MeOH (4 mL) and THF (8 mL) was stirred at 75 °C for 48 hrs. The mixture was cooled to rt and concentrated. The residue was diluted with water (30 mL) and adjusted its pH value to 5-6 by adding 2 N aq. HC1. The resulting mixture was extracted EtOAc (50 mL x 3) and the organic extracts were combined, washed with brine and dried with anhydrous Na 2 S04.
  • Step 11 To a solution of compound 13-11 (85.0 mg, 0.20 mmol) in DMF (2 mL) was added HATU (93.0 mg, 0.24 mmol). After stirring at rt for 30 min, the reaction mixture was added DIPEA (53 mg, 0.41 mmol) and MeNH 2 ' HCl (17 mg, 0.24 mmol) and the resulting mixture was stirred at rt for 30 min. Subsequently, the reaction mixture was poured into ice water and the suspension was filtered. The solid was collected and dried in vacuo to give crude compound 13-12.
  • DIPEA 53 mg, 0.41 mmol
  • MeNH 2 ' HCl 17 mg, 0.24 mmol
  • Step 1 Refer to Scheme 14. A mixture of compound 14-1 (10.0 g, 43.28 mmol) and LiOH (5.46 g, 129.8 mmol) in THF (400 mL), MeOH (200 mL) and water (100 mL) was stirred at 70 °C for 2 hrs under an atmosphere of N 2 . Subsequently, the reaction mixture was cooled to 0 °C and adjusted its pH value to 6 by adding coned, aq. HC1. The resulting suspension was filtered and the solid was dried in vacuo to give compound 14-2 (7.8 g, 83% yield). LC-MS (ESI): m/z 211 [M+H] + .
  • Step 3 A mixture of compound 14-3 (5.10 g, 17.7 mmol) and methyl 2-bromo-3-(4- fluorophenyl)-3-oxopropanoate (5.84 g, 21.2 mmol) in DMF (80 mL) was stirred at 80 °C for 42 hrs under an atmosphere of N 2 . Subsequently, the reaction mixture was cooled to 0 °C, followed by adding a solution of NaHC0 3 (1.9 g) in water (20 mL). After stirring at 0 °C for 15 min, the mixture was diluted with water (100 mL) and the resulting suspension was extracted with EtOAc (100 mL x 3).
  • Step 5 To a stirred solution of compound 14-5 (1.4 g, 3.86 mmol) in pyridine (30 ml) was added MsCl (1.33 g, 1 1.6 mmol) at 0 °C. After stirring at rt for 1.5 hrs, the reaction mixture was concentrated and the residue was diluted with water (50 mL). Subsequently, the mixture was adjusted its pH value to 5-6 by adding 2N aq. HCl. The resulting suspension was filtered and the solid was dried in vacuo to give compound 14-6, which was used for the next step without further purification.
  • Step 7 To a solution of compound 14-7 (970 mg, 2.19 mmol) in DMF (30 mL) was added K 2 CO 3 (1.21 g, 8.76 mmol) and 5-bromopent-l-ene (784 mg, 5.26 mmol) at rt. After stirring at 80 °C for 16 hrs and at 90 °C for 24 hrs, the reaction mixture was concentrated and the residue was diluted with water (50 mL). The mixture was extracted with EtOAc (50 mL x 2). The organic extracts were combined, washed with water (50 mL x 2) and dried with anhydrous Na 2 S04.
  • Step 8 Following the procedure described for the synthesis of compound 13-11 and replacing compound 13-8 with 14-8, compound 14-12 was obtained.
  • Scheme 15 Scheme 15
  • Step 1 Refer to Scheme 15. To a solution of NaH (80 g, 60% mineral oil dispersion, 2 mol) in toluene (1.2 L) was added diethyl carbonate (295 g, 2.50 mol) at 0 °C. After stirring at rt for 2 hrs, the mixture was added drop wise to a solution of compound 15-1 (99 g, 0.50 mol) in toluene (400 mL) at reflux. After refluxing overnight, the reaction mixture was cooled to rt and sequentially treated with HOAc (140 mL) and aq. HC1 (2 M, 864 mL).
  • Step 2 To a solution of compound 15-2 (100 g, 369 mmol) in DMF (70 mL) was added p-benzoquinone (40 g, 369 mmol), followed by ZnCl 2 (50 g, 369 mmol) in portions at rt. After stirring at 105 °C for 3.5 hrs, the reaction mixture was partitioned between water (800 mL) and EtOAc (800 mL) and filtered. The aqueous phase was extracted with EtOAc (500 mL x 2). The combined organic extracts were washed with water (1000 mL x 2) and dried with anhydrous Na 2 S0 4 .
  • Step 3 To a solution of compound 15-3 (26 g, 72 mmol) in NMP (200 mL) was added CS 2 CO 3 (47.0 g, 144 mmol). After stirring at rt for 20 min, 2-bromopropane (20.0 ml, 216 mmol) was added. The resulting mixture was stirred at 80 °C for 4 hrs, then diluted with ammonia and agitated for 30 min. The mixture was diluted with water (200 mL) and the aqueous phase was extracted with EtOAc (150 mL x 3). The combined organic extracts were washed with water (200 mL x 3) and dried with anhydrous Na 2 S0 4 . The solvent was removed and the residue was dried in vacuo to give compound 15-4 (27.5 g, 95% yield) as a colorless oil.
  • Step 4 To a solution of HNO 3 (cone. 66 mL, 0.89 mol) and CH 2 C1 2 (300 mL) a solution of compound 15-4 was added drop wise (27.5 g, 68.2 mmol) in CH 2 C1 2 (120 mL) at
  • Step 5 A mixture of compound 15-5 (5.0 g, 1 1.2 mmol), 4-fluorophenol (1.7 g, 14.5 mmol), Pd(OAc) 2 (250 mg, 1.12 mmol), f-BuXphose (380 mg, 0.9 mmol) and K 3 PO 4 (4.8 g,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

Description

INHIBITORS OF HEPATITIS C VIRUS
Field of the Invention
[0001] The invention relates to compounds useful for inhibiting hepatitis C virus ("HCV") replication, particularly functions of the non- structural 5B ("NS5B") protein of HCV.
Background of the Invention
[0002] HCV is a single-stranded RNA virus that is a member of the Flaviviridae family. The virus shows extensive genetic heterogeneity as there are currently seven identified genotypes and more than 50 identified subtypes. In HCV infected cells, viral RNA is translated into a polyprotein that is cleaved into ten individual proteins. At the amino terminus are structural proteins: the core (C) protein and the envelope glycoproteins, El and E2. p7, an integral membrane protein, follows El and E2. Additionally, there are six nonstructural proteins, NS2, NS3, NS4A, NS4B, NS5A and NS5B, which play a functional role in the HCV life cycle, {see, for example, B.D. Lindenbach and CM. Rice, Nature. 436:933- 938, 2005). NS5B is the RNA polymerase or replicase of the virus and is responsible for replication of both positive and negative-strand genomic RNA during the viral replicative cycle. NS5B plays an essential and critical role in viral replication, and a functional NS5B replicase is required for HCV replication and infection. Thus, inhibition of NS5B RNA- dependent polymerase activity is believed to be an effective way of treating HCV infection.
[0003] Infection by HCV is a serious health issue. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is thus a major worldwide cause of liver-related premature mortality.
[0004] The current standard of care treatment regimen for HCV infection involves interferon-alpha, alone, or in combination with ribavirin and a protease inhibtor. The treatment is cumbersome and sometimes has debilitating and severe side effects and many patients do not durably respond to treatment. New and effective methods of treating HCV infection are urgently needed.
Summary of the Invention
[0005] Essential functions of the NS5B protein in HCV replication make it an attractive intervention target for treating HCV infection. The present disclosure describes a class of compounds targeting the NS5B protein and methods of their use to treat HCV infection in humans. [0006] The present disclosure describes a class of heterocyclic compounds targeting HCV NS5B polymerase and methods of their use to treat HCV infection in humans.
[0007] In a first aspect of the inve la I are provided:
Figure imgf000003_0001
wherein,
L1, L2 and L3 together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
L 1 , L2 , or L 3 is independently selected from a group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
U or V is independently CH, N, CF, CC1, or CCN;
W, X, or Z is independently C or N;
Y is NRN, N, O, S, Se, or -CRaRb;
RN is hydrogen, C1-4 alkyl, C3-& cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
Ra, Rb is independently hydrogen, methyl, or together form a C3.6 cycloalkyl bearing 0-1 heteroatom of O or NR1;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NR7)OM -C(=NOMe)NH 7, C(=NOH)NHR7, -CH(CF3)NHR8, -
CH(CN)NHR9, -S(0)2NHR10,
Figure imgf000003_0002
R2 is a substituted or unsubstituted aryl or heteroaryl;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxy lcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, C1-4 alkyl, cyclopropyl, or benzyl;
R 7 is hydrogen, C]_4 alkyl, cyclopropyl, C1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
Rs, R9, R10, or Rn is independently hydrogen, C1-4 alkyls, cyclopropyl, C1- alkoxys, or cyclopropoxy; and R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, d-4 alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S.
[0008] The compounds may have an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half-maximal inhibition of HCVlb replication (EC50) in a 1 b_Huh-Luc/Neo- line in culture, of 1 mM or less.
Figure imgf000004_0001
[0009] The compounds may have the structure w ere n , together w ith the attached carbons of the aromatic ring, is a seven- or eight-member
[0010] The compounds may have the structure wherein
Figure imgf000004_0002
? together with the attached carbons of the aromatic ring, form a 5-9 member ring, L1 is -C(R15R16)-, and L3 is - N(S02Me)- or -0-, where R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, C1 -4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3- 6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S.
Figure imgf000004_0003
Figure imgf000005_0001
1 2 3
L , L and L together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
1 3
L , L , or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - 7, -C(=NR7)OMe, -C (=NOMe)NHR7 , C(=NOH)NHR7, -CH(CF3)NHR8, -
Figure imgf000005_0002
R2 is a substituted or unsubstituted aryl or heteroaryl;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxy lcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, C1-4 alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Ci_4 alkyl, cyclopropyl, C alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or Ru is independently hydrogen, Ci_4 alkyls, cyclopropyl, Ci_4 alkoxys, or cyclopropoxy; and
R15, R16 is independently hydrogen, hydroxy], azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Q_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S. [0012] In a second embodiment of the first aspect,
Figure imgf000006_0001
Figure imgf000006_0002
L1, L2 and L3 together with the attached carbons of the aromatic ring form a 5-9 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
L! , L2, or L3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NR7)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
N-
CH(CN)NHR9, -S(0)2NHR10, -C(=NCN)NHRn, -κ -K) - l or H
R is a substituted or unsubstituteed aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R5 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, CM alkyl, cyclopropyl, Ci_4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R11 is independently hydrogen, C alkyls, cyclopropyl, CM alkoxys, or cyclopropoxy; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C alkyl, cyclopropyl, CM alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or CM alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member rings optionally containing 0-3 heteroatoms of O, NR and/or S.
[0013] In a third embodiment of the first aspect, R1 is hydrogen, halide, -C(0)OR6-, - 7, -C( 7)OMe, -C(0)N(OH)R7, -C(=NOMe)NHR7, C(=NOH)NHR7, -
Figure imgf000007_0001
R6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Ο alkyl, cyclopropyl, Q_4 aikoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl; and
R8, R9, R10, or R11 is independently hydrogen, Cj-4 alkyls, cyclopropyl, C alkoxys, or cyclopropoxy.
[0014] In a fourth embodiment of the first aspect, R1 is hydrogen, Br, I, -COOH, - C(0)OMe, -C(O) OEt, -C(0)0 rBu, -C(0)NHMe, -C(0)NHOMe, -C(=NOMe)NHMe, - -C(=NMe)OMe, -C(0)N(OH)Me, -C(0)NHS(0 Me, -CH(CF3)NHMe, -
Figure imgf000007_0002
In a fifth embodiment of the first aspect, R1 is -C(0)NHMe or .
[0016] In a sixth embodiment of the first aspect, R2 is selected from the group consisting of
Figure imgf000007_0003
Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
R12 is selected from the group of hydrogen, halide, -CN, -OCHF2, -OCF3, alkyl, cycloalkyl, aikoxy, cycloalkoxy, aiylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
m is 0, 1, 2, 3, or 4;
G is O, NRN, S, or CRaRb; A is N, O, S, or or CRaRb; and
D, E is independently C or N.
[0017] In a seventh embodiment of the first as ect, R2 is selected from the roup consisting
Figure imgf000008_0001
each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
R12 is selected from the group of hydrogen, haiide, -CN, -OCHF2, -OCF3, alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
m is 0, 1, 2, 3, or 4;
G is O, NRN, S, or CRaRb;
A is N, O, S, or CRaRb; and
D, E is independently C or N.
2
[0018] In an eighth embodiment of the first aspect, R is selected from the group consisting
Figure imgf000008_0002
substituted with 0-2 nitrogen atoms.
[0019] In a ninth embodiment of the first aspect, R is ¾— -/ or F .
Figure imgf000009_0001
L , L , or L is independently selected from the group consisting of a bond, -0-, -C(R R ), -NR3-, -S(0)n-, -P(0)n-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NMe)O -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF NHR8, -
CH(CN)NHR , -S(0)2NHR1U,
Figure imgf000009_0002
R2 is a substituted or unsubstituted aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Ci-4 alkyl, cyclopropyl, C1- alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R11 is independently hydrogen, C]_4 alkyls, cyclopropyl, Ci_ alkoxys, or cyclopropoxy;
R12 is independently C]_3 alkyl, cyclorpopyl, -OMe, or -NHMe;
R is independently hydrogen, -Ac, or -S(0)2Me;
R14 is independently hydrogen or Me;
R15, R16 is independently hydrogen, hydroxyl, azide, C alkenyl, C2_4 alkynyl, C]_4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
A1 or A2 is independently -CRaRb-, -N(RN)-, or -0-.
[0021] embodiment of the fist aspect, is selected from the group
consisti
Figure imgf000010_0001
, a R ,
L , L , or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(0)-, -Si(R4R5)-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NMe)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
Q ,n N N N' N N-N
CH(CN)NHR , -S(0)2NHR , -C(=NCN)NHR , H , H , H , or H ;
R2 is a substituted or unsubstituted aryl or heteroaryl;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, ally], alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, CM alkyl, cyclopropyl, C1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl ;
R8, R9, R10, or R1 1 is independently hydrogen, C1-4 alkyls, cyclopropyl, Ct_4 alkoxys, or cyclopropoxy;
Ri2 is independently C1-3 alkyl, cyclorpopyl, -OMe, or -NHMe;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C^ alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
A2 is independently -CRaR -, -N(RN)-, or -0-. [0022] In a twelfth embodiment of the fist aspect,
Figure imgf000011_0001
wherein,
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-,-C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, -
C(0)N(OH)R7, -C(=NMe)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
CH(CN)NHR9, -S(0)2NHR10,
Figure imgf000011_0002
R2 is a substituted or unsubstituted aryl or heteroaryl;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R3 are independently methyl, ethyl, or cyclopropyl; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, CM alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1 -4 alkenylidene or R15 and R 16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S.
[0023] In a second aspect of the invention is a compound that has the structure:
Figure imgf000011_0003
wherein
L1 , L2 and-N(S02R12)- together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, -
NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2; and R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - 7, -C(=NOMe)NHR7, C(=NOH)NHR7, -C(CF3)NHR8, -C(CN)NHR9, -
Figure imgf000012_0001
R2 is an aryl or heteroaryl having one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R is independently Ci-3 alkyl, cyclopropyl, -OMe, or -NHMe;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, CM alkyl, cyclopropyl, C]_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Q_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is F, CI or CN.
[0024] The compound of this embodiment may have an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half-maximal inhibition of HCVlb replication (EC50) in a lb_Huh-Luc/Neo-ET cell line in culture, of 100 nM or less.
[0025] The compound of this embodiment may have the structure in which
Figure imgf000012_0002
is
Figure imgf000012_0003
Figure imgf000013_0001
Figure imgf000014_0001

Figure imgf000015_0001
[0027] The compound in this embodiment may be selected from the group consisting of compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, B240, B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71, B84, B93, B100, B101, B106, B108, B109, Bill, B112, B113, B115, B116, B119, B123, B124, B134, B136, B137, B142, B144, B146, BUT, B150, B151, B153, B154, B155, B156, B157, B159, B160, B161, B162, B164, B165, B166, B167, B170, B172, B173, B174, B175, B176, B178, B179, B180, B181, B183, B184, B186, B188, B189, B193, B195, B199, B200, B202, B203, B204, B205, B210, B215, B216, B217, B219, B220, B222, B223, B224, B225, B227, B228, B229, B230, B231, B234, B235, and B241.
Figure imgf000016_0001

Figure imgf000017_0001
[0029] The above compounds include compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240.
[0030] As can , the compounds in this embodiment may be subdivided into
subsets wherein
Figure imgf000017_0002
(i) a 7 or 8 member aliphatic ring, as exemplified by compounds B5, B15, B35, B67, B85, B92, B120, B130, B198, B94, and B130;
(ii) a 7 or 8 member ring having an internal oxygen atom, as exemplified by compounds B45, B118, B148, B197, B168, B187, B190; B192, B196, B207, B214, B191, B212, B218, B221, B222, B226, B232, B233, B236, B237, B238, B239, and B240;
(iii) a 7 or 8 member ring having a second internal nitrogen atom, as exemplified by compounds B107, B139, B145, B171, and B208; and
(iv) a fused 7 or 8 member ring, as exemplified by compounds B127, B128, B131, B132, B138, B158, B163, B169, B189, and B201.
[0031] R in this emb
[0032] The structure
Figure imgf000017_0003
, together with the attached carbons of the aromatic ring in this embodiment may be a seven- or eight-member ring.
[0033] R2 in this embodiment may be a phenyl substituted with one or more R17 substituents. [0034] R2 in this embodiment may be a 4-phenoxyphenyl and the phenoxy group is substituted with one or more R17 substituents.
[0035] R
Figure imgf000018_0001
in this embodiment may be selected from ^— " and
[0036] In a third aspect of the invention is a compound of formula II.
Figure imgf000018_0002
Wherein,
L1 , L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5- 12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
L'or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-,
-S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
2. 17
R is an aryl or heteroaryl and may be substituted with one or more R substituents, R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R] 6 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C]_4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0037] In a fourth aspect of the invention is a compound that has the structure:
Figure imgf000018_0003
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-,-S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycioalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
R' is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - 7, -C(=NR7)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
Figure imgf000019_0001
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl ;
R15, R16 is independently hydrogen, hydroxyl, azide, C2 alkenyl, C2_4 alkyny], C1-4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F,
p
Figure imgf000019_0002
[
Figure imgf000020_0001
0039] R1 is selected from the group consisting of H , H , and and R2 is selected from the group consisting of
Figure imgf000020_0002
[0040] Exemplary compounds in this embodiment include those identified by ID NOS: B89, B96, B97, B 125, B126, and B129.
[0041] R in this embodiment may be
Figure imgf000020_0003
.
[0042] R in this embodiment may be a phenyl substituted with one or more R substituents.
[0043] R2 in this embodiment may be a 4-phenoxyphenyl and the phenoxy group is substituted with one or more R17 substituents. [0044] R2 in this embodiment may be selected from 5 and
Figure imgf000021_0001
[0045] In a fifth aspect of the invention is a compound of formula IV.
Figure imgf000021_0002
Wherein,
L1, L2 and -N(S(¾Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, CM alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0046] In a sixth aspect of the invention is a compound of formula V.
Figure imgf000021_0003
Wherein,
L1 , L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si; L!or L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, - NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alky], alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
RN is hydrogen, Ci-4 alkyl, C3^ cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
R2 is an ary] or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2A alkenyl, C2 alkynyl, CM alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C]_4 alkenylidene or RJ 5 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0047] In a seventh aspect of the d of formula VI.
Figure imgf000022_0001
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
LJor L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; R , R is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, C]_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C]_4 alkenylidene or R!5 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0048] In an eighth aspect of the invention is a compound of formula VII.
Figure imgf000023_0001
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)N-, -P(0)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R13, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C].4 alkyl, cyclopropyl, CM alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0049] In a ninth aspect of the invention is a compound of formula VIII.
Figure imgf000023_0002
Wherein, L , L" and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(0)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents, R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0050] In a tenth aspect of the invention is a compound of formula X.
Figure imgf000024_0001
Wherein,
1 2
L , L and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; and R , R is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0051] In an eleventh aspect of the invention is a compound of formula XI.
Figure imgf000025_0001
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5- 12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
aikoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R1 5 and R! 6 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0052] In a twelfth aspect of the invention is a compound of formula XII.
Figure imgf000025_0002
Wherein, 1 2
L , L and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(0)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
Rl3, R16 is independently hydrogen, hydroxyl, azide, C2_4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R) 5 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0053] A thirteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention, including the exemplary compounds identified by the above ID NOS. The composition may be formulated for oral delivery, and may include a second and/or third anti-HCV agents.
[0054] Also disclosed is a method of treating HCV infection in a subject by the steps of administering to the subject, a pharmaceutically acceptable dose of the above compound, and continuing the administering until a selected reduction of in the subject's HCV titer is achieved.
[0055] The compound administered may be one or more of the exemplary compounds identified by the above ID NOS. The method may include administering to the subject, either in a single or separate administrations, a second anti-HCV agent selected from the group consisting of interferon-alpha, ribavirin, or both. The administering may be by oral route.
[0056] Also disclosed is the above compound, for use in the treatment of HCV infection in an infected subject. The compound may be one of those identified by ID NOS above.
[0057] Further disclosed is the use of the above compound, such as one of the ones identified by ID NOS, in the preparation of a medicament for the treatment of HCV in an HCV-infected subject.
[0058] Some of the compounds of the invention possess chiral carbons. The invention included all stereoisomeric forms, including enantiomers and diastereomers as well as mixtures of stereomers such as racemates. The stereoisomers or their precursors can be either asymmetrically synthesized or obtained by separations of the racemates according to methods commonly known in the art.
[0059] The invention is intended to include all isotopically labeled analogs of the compounds of the invention. Isotopes include those atoms having the same atomic number but different mass. For example, isotopes of hydrogen include 2H(D) and 3H(T) and isotopes of carbon include ljC and 14C. Isotopically labeled compounds of the invention can be prepared according to methods commonly known in the art. Such compounds may have various potential uses as, but not limited to, standards and reagents in determining biological/pharmacological activities. For those stable isotopically labeled compounds of the invention, they may have the potential to favorably modulate biological, pharmacological, or pharmacokinetic properties.
Detailed Description
[0060] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Definition of standard chemistry terms may be found in reference works, including Carey and Sundberg (2007) "Advanced Organic Chemistry 5th Ed." Vols. A and B, Springer Science+Business Media LLC, New York. The practice of the present invention will employ, unless otherwise indicated, conventional methods of synthetic organic chemistry, mass spectroscopy, preparative and analytical methods of chromatography, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology.
[0061] The term "alkanoyl" as used herein contemplates a carbonyl group with a lower alkyl group as a substituent.
[0062] The term "alkenyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkene radicals, including both the E- and Z-forms, containing from two to eight carbon atoms. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, -N02, C02R, C(0)R, -O-R, - N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, -C(0)N(RN)2, -OC(0)R,
-OC(0)N(RN)2, S(0)R, S02R, -S03R, -S(0)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0063] The term "alkoxy" as used herein contemplates an oxygen with a lower alkyl group as a substituent and includes methoxy, ethoxy, butoxy, trifluromethoxy and the like. It also includes divalent substituents linked to two separated oxygen atoms such as, without limitation, -0-CF2-0-, -0-(CH2)i_4-0-(CH2CH2-0)i-4- and -(0-CH2CH2-0)M-. [0064] The term "alkoxycarbonyl" as used herein contemplates a carbonyl group with an alkoxy group as a substituent.
[0065] The term "alkyl" as used herein contemplates substituted or unsubstituted, straight and branched chain alkyl radicals containing from one to fifteen carbon atoms. The term "lower alkyl" as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ten- butyl and the like. The alkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -N02, -C(0)2R, -C(0)R, -O-R, -N(RN)2, - N(RN)C(0)R, -N(RN)S(0)2R, -SR, -C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, - S03R, -S(0)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0066] The term "alkylene," "alkenylene" and "alkynylene" as used herein refers to the groups "alkyl," "alkenyl" and "alkynyl" respectively, when they are divalent, ie, attached to two atoms.
[0067] The term "alkylsulfonyl" as used herein contemplates a sulfonyl group which has a lower alkyl group as a substituent.
[0068] The term "alkynyl" as used herein contemplates substituted or unsubstituted, straight and branched carbon chain containing from two to eight carbon atoms and having at least one carbon-carbon triple bond. The term alkynyl includes, for example ethynyl,
1 -propynyl, 2- propynyl, 1-butynyl, 3-methyl-l -butynyl and the like. The alkynyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N02, - C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, -C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, -SO3R, -S(0)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0069] The term "amino" as used herein contemplates a group of the structure -NRN 2.
[0070] The term "amino acid" as used herein contemplates a group of the structure
Figure imgf000028_0001
in either the D or the L
configuration and includes but is not limited to the twenty "standard" amino acids: isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine and histidine. The present invention also includes, without limitation, D-configuration amino acids, beta-amino acids, amino acids having side chains as well as all non-natural amino acids known to one skilled in the art. [0071] The term "aralkyl" as used herein contemplates a lower alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted or unsubstituted. The aralkyl group may be optionally substituted with one or more substituents selected from halogen, -CN, -N02, -C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, -C(0)N(RN)2) -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, -SO3R, -S(0)2N(RN)2, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0072] The terms "aryl," "aromatic group" or "aromatic ring" as used herein contemplates substituted or unsubstituted single-ring and multiple aromatic groups (for example, phenyl, pyridy] and pyrazole, etc.) and polycyclic ring systems (naphthyl and quinolinyl, etc.). The polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyl s, aryl, heterocycles and/or heteroaryls. The aryl group may be optionally substituted with one or more substituents selected from halogen, alkyl, -CN, -N02, -C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, - C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, -S03R, -S(0)2N(RN)2, -SiR3, -P(0)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0073] The term "arylsulfonyl" as used herein contemplates a sulfonyl group which has as a substituent an aryl group. The term is meant to include, without limitation, monovalent as well as multiply valent aryls (eg, divalent aryls).
[0074] The term "carbamoyl" as used herein contemplates a group of the structure
O C NRN2
[0075] The term "carbonyl" as used herein contemplates a group of the structure
O C .
[0076] The term "carboxyl" as used herein contemplates a group of the structure
O C O .
[0077] The term "cycloalkyl" as used herein contemplates substituted or unsubstituted cyclic alkyl radicals containing from three to twelve carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl and the like. The term "cycloalkyl" also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused"). The cycloalkyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N02, -C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, - N(RN)S(0)2R, -SR, -C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, -S(0)2N(RN)2, phosphate, phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
[0078] The term "cycloalkenyl" as used herein contemplates substituted or unsubstituted cyclic alkenyl radicals containing from four to twelve carbon atoms in which there is at least one double bond between two of the ring carbons and includes cyclopentenyl, cyclohexenyl and the like. The term "cycloalkenyl" also includes polycyclic systems having two rings in which two or more atoms are common to two adjoining rings (the rings are "fused"). The cycloalkenyl group may be optionally substituted with one or more substituents selected from halo, -CN, -N02, -C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, - C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, -S(0)2N(RN)2, phosphate,
phosphonate, alkyl, cycloalkenyl, aryl and heteroaryl.
[0079] The term "halo" or "halogen" as used herein includes fluorine, chlorine, bromine and iodine.
[0080] The term "heteroalkyl" as used herein contemplates an alkyl with one or more heteroatoms.
[0081] The term "heteroatom", particularly within a ring system, refers to N, O and S.
[0082] The term "heterocyclic group," "heterocycle" or "heterocyclic ring" as used herein contemplates substituted or unsubstituted aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member. Preferred heterocyclic groups are those containing five or six ring atoms which includes at least one hetero atom and includes cyclic amines such as morpholino, piperidino, pyrrolidino and the like and cyclic ethers, such as tetrahydrofuran, tetrahydropyran and the like. Aromatic heterocyclic groups, also termed "heteroaryl" groups, contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, oxodiazole, thiadiazole, pyridine, pyrazine, pyridazine, pyrimidine and the like. The term heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two or more atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls. Examples of polycyclic heteroaromatic systems include quinoline, isoquinoline, cinnoline, tetrahydroisoquinoline, quinoxaline, quinazoline, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, indazole, purine, benzotriazole, pyrrolepyridine, pyrrazolopyridine and the like. The heterocyclic group may be optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CN, -N02, -C02R, -C(0)R, -O-R, -N(RN)2, -N(RN)C(0)R, -N(RN)S(0)2R, -SR, -C(0)N(RN)2, -OC(0)R, -OC(0)N(RN)2, -SOR, -S02R, - S03R, -S(0)2N(R )2, -S1R3, -P(0)R, phosphate, phosphonate, cycloalkyl, cycloalkenyl, aryl and heteroaryl.
[0083] The term "oxo" as used herein contemplates an oxygen attached with a double bond.
[0084] By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
"Pharmaceutically acceptable salt" refers to a salt of a compound of the invention which is made with counterions understood in the art to be generally acceptable for pharmaceutical uses and which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,
1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid,
4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, piperidine, dimethylamine, diethylamine and the like. Also included are salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like (see, e.g. , Berge et al, 1977, /. Pharm. Set 66: 1-19).
[0085] The terms "phosphate" and "phosphonate" as used herein refer to the moieties having the following structures, respectively:
O 0 I I
-p- P-OR
OR OR
[0086] The terms "salts" and "hydrates" refers to the hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity, flowability and manufacturability of the resulting bulk drug.
[0087] The term sulfonamide as used herein contemplates a group having the structure
Figure imgf000032_0001
[0088] The term "sulfonate" as used herein contemplates a group having the structure O
I 0 Rs
O wherein Rs is selected from the group consisting of hydrogen, -Qo alkyl,
C2-C10 alkenyl, C2-Q0 alkynyl, C1-C10 alkanoyl, or Q-Qo alkoxycarbonyl.
[0089] The term "sulfonyl" as used herein contemplates a group having the structure
Figure imgf000032_0002
[0090] "Substituted sulfonyl" as used herein contemplates a group having the structure O S R
II
0 including, but not limited to alkylsulfonyl and arylsulfonyl.
[0091] The term "thiocarbonyl," as used herein, means a carbonyl wherein an oxygen atom has been replaced with a sulfur.
[0092] Each R is independently selected from hydrogen, -OH, -CN, -N02, halogen, to C12 alkyl, Q to Q2 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide, amino, and oxo.
[0093] Each RN is independently selected from the group consisting of hydrogen, -OH, Q to C12 alkyl, Ci to C12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide. Two RN may be taken together with C, O, N or S to which they are attached to form a five to seven membered ring which may optionally contain a further heteroatom. [0094] The compounds of the present invention may be used to inhibit or reduce the activity of HCV, particularly HCV's NS5B protein. In these contexts, inhibition and reduction of activity of the NS5B protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound. In particular aspects, the inhibition or reduction in the measured activity is at least a 10% reduction or inhibition. One of skill in the art will appreciate that reduction or inhibition of the measured activity of at least 20%, 50%, 75%, 90% or 100%, or any number in between, may be preferred for particular applications.
[0095] In a first aspect of the in rmula I are provided:
Figure imgf000033_0001
wherein,
L1, L2 and L3 together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
l), L2, or L3 is independently selected from a group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(0)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
U or V is independently CH, N, CF, CC1, or CCN;
W, X, or Z is independently C or N;
Y is NRN, N, O, S, Se, or -CRaRb;
RN is hydrogen, C1-4 alkyl, C3_6 cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
Ra, Rb is independently hydrogen, methyl, or together form a C3.6 cycloalkyl bearing 0- 1 heteroatom of O or NR ;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NR7)OMe, -C(=NOMe)NHR7 7, -CH(CF3)NHR8, -
CH(CN)NHR9, -S(0)2NHR10, -C(=NCN)NHR 11 ,
Figure imgf000033_0002
R is a substituted or unsubstituted aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; R is hydrogen, allyl, C]_4 alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Ci_4 alkyl, cyclopropyl, C1-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R11 is independently hydrogen, C1-4 alkyls, cyclopropyl, d_4 alkoxys, or cyclopropoxy; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, d-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or d-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
Figure imgf000034_0001
1 2 3
L , L and L together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
L1, L2, or L3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2; R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NR7)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHRi
CH(CN)NHR9, -S(0)2NHR10, -C(=NCN)NHRl
Figure imgf000035_0001
R2 is a substituted or unsubstituted aryl or heteroaryl;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, Q_4 alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Ci_4 alkyl, cyclopropyl, CM alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R11 is independently hydrogen, C1-4 alkyls, cyclopropyl, Ci-4 alkoxys, or cyclopropoxy;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, Ci_4 alkyl, cyclopropyl, Ci-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring
Figure imgf000035_0002
L1, L2 and L3 together with the attached carbons of the aromatic ring form a 5-9 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si;
L1, L2, or L3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide; n is 0, 1 , or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NR7)OM -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
CH(CN)NHR , -S(0)2NHRJ U,
Figure imgf000036_0001
R2 is a substituted or unsubstituteed aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, C1 -4 alkyl, cyclopropyl, C alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R11 is independently hydrogen, CM alkyls, cyclopropyl, C1.4 alkoxys, or cyclopropoxy; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, C alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
[0098] In a third embodiment of the first aspect, R1 is hydrogen, halide, -C(0)OR6-, - C(0)NHR7, -C(=NR7)OMe, -C( 7, -C(=NOMe)NHR7, C(=NOH)NHR7, -
CH(CF3)NHR8, -CH(CN)NHR9,
Figure imgf000036_0002
; wherein,
R6 is hydrogen, allyl, C alkyl, cyclopropyl, or benzyl;
R is hydrogen, C alkyl, cyclopropyl, CM alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl; and
R8, R9, R10, or RH is independently hydrogen, C alkyls, cyclopropyl, C alkoxys, or cyclopropoxy.
[0099] In a fourth embodiment of the first aspect, R1 is hydrogen, Br, I, -COOH, - C(0)OMe, -C(O) OEt, -C(0)0 iBu, -C(0)NHMe, -C(0)NHOMe, -C(=NOMe)NHMe, - C(=NOH)NHMe, -C(=NMe)OMe, -C(0)N(OH)Me, -C(0)NHS(0)2Me, -CH(CF3)NHMe, -
CH(CN)NHMe, -C (=NCN)NHMe,
[0100] In a fifth embodiment of th
Figure imgf000036_0003
e first aspect, R is -C(0)NHMe or [0101] In a sixth embodiment of the first as ect, R2 is selected from the rou consisting
Figure imgf000037_0001
Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
R12 is selected from the group of hydrogen, halide, -CN, -OCHF2, -OCF3, alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
m is 0, 1 , 2, 3, or 4;
G is O, NRN, S, or CRaRb;
A is N, O, S, or or CRaRb; and
D, E is independently C or N.
[0102] In a seventh embodiment of the first aspect, R2 is selected from the group consisting
Figure imgf000037_0002
Each phenyl moiety is optionally substituted with 0-2 nitrogen atoms;
12
R is selected from the group of hydrogen, halide, -CN, -OCHF2, -OCF3, alkyl, cycloalkyl, alkoxy, cycloalkoxy, arylalkyl, aryloxy, alkenyl, alkynyl, amide, alkylsulfonyl, arylsulfonyl, sulfonamide, carbamate;
m is 0, 1, 2, 3, or 4;
G is O, NRN, S, or CRaRb;
A is N, O, S, or CRaRb; and
D, E is independently C or N. [0103] In an eighth embodiment of the first aspect, R 2 is selected from the group consisting
Figure imgf000038_0001
Figure imgf000038_0002
each phenyl moiety is optionally substituted with 0-2 nitrogen atoms.
[0104] In a ninth embodiment of the first aspect,
[0105] In a tenth embodiment of the fist aspect,
Figure imgf000038_0003
is selected from the group
consisting of &, ¾Α'θo, a?R R13 , a R"bR,s , R14"VR13 , 2 a JR ,
Figure imgf000038_0004
L1, L2, or L3 is independently selected from the group consisting of a bond, -0-, -C(R15R16), -NR3-, -S(0)n-, -P(0)„-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alky], alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - 7, -C(=NMe)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
Figure imgf000038_0005
R2 is a substituted or unsubstituted aryl or heteroaryl; R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R is hydrogen, Q_4 alkyl, cyclopropyl, Ci-4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R1 ! is independently hydrogen, Cj.4 alkyls, cyclopropyl, C1-4 alkoxys, or cyclopropoxy;
R12 is independently C]-3 alkyl, cyclorpopyl, -OMe, or -NHMe;
R13 is independently hydrogen, -Ac, or -S(0)2Me;
R14 is independently hydrogen or Me;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C^ alkyl, cyclopropyl, Q_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
A1 or A2 is independently -CRaRb-, -N(RN)-, or -0-.
[0106] ected from the group
consistin
Figure imgf000039_0001
wherein,
L1, L2, or L3 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - 7, -C(=NMe)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
Figure imgf000039_0002
R2 is a substituted or unsubstituted aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; R6 is hydrogen, allyl, CM alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Q_4 alkyl, cyclopropyl, Ci_4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkylsulfonyl;
R8, R9, R10, or R1 1 is independently hydrogen, C1-4 alkyls, cyclopropyl, C1-4 alkoxys, or cyclopropoxy;
R12 is independently Q_3 alkyl, cyclorpopyl, -OMe, or -NHMe;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, Ci_4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci- alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S ; and
A2 is independently -CRaRb-, -N(RN)-, or -0-.
[0107] In a twelfth embodiment of the fist aspect,
Figure imgf000040_0001
is r12 to wherein,
L]or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-,-C(RI5R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NMe)O -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, -
CH(CN)NHR9, -S(0)2NHR10,
Figure imgf000040_0002
R2 is a substituted or unsubstituted aryl or heteroaryl ;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; and
R15 and R16 are independently hydrogen, hydroxyl, azide, C2-4 alkyenes, C2_ alkynes, C1-4 alkyls, , cyclopropyl, C1- alkoxys, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci-4 alkenyls.
[0108] In a second aspect of the invention is a compound has the structure:
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
42
Figure imgf000044_0001
[0109] R1 may be .
One Group of exemplary high-activity compounds are identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240 in Appendix A, and a second group of high-activity compounds are identified by ID NOS: B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71, B84, B93, B100, B101, B106, B108, B109, Bill, B112, B113, B115, B116, B119, B123, B124, B134, B136, B137, B142, B144, B146, B147, B150, B151, B153, B154, B155, B156, B157, B159, B160, B161, B162, B164, B165, B166, B167, B170, B172, B173, B174, B175, B176, B178, B179, B180, B181, B183, B184, B186, B188, B189, B193, B195, B199, B200, B202, B203, B204, B205, B210, B215, B216, B217, B219, B220, B222, B223, B224, B225, B227, B228, B229, B230, B231, B234, B235, andB241.
[0110] As can be appreciated, the compounds in this embodiment may be subdivided into
Figure imgf000044_0002
subsets wherein is:
(i) a 7 or 8 member aliphatic ring, as exemplified by compounds B5, B15, B35, B67, B85, B92, B120, B130, B198, B94, and B130;
(ii) a 7 or 8 member ring having an internal oxygen atom, as exemplified by compounds B45, B118, B148, B197, B168, B187, B190; B192, B196, B207, B214, B191, B212, B218, B221, B222, B226, B232, B233, B236, B237, B238, B239, and B240;
(iii) a 7 or 8 member ring having a second internal nitrogen atom, as exemplified by compounds Bl 07, B 139, B145, Bl 71 , and B208; and (iv) a fused 7 or 8 member ring, as exemplified by compounds B 127, B128, B 131 , B 132, B 138, B 158, B 163, B 169, B 189, and B201.
[0111] In a third aspect of the invention is a compound of formula II.
Figure imgf000045_0001
Wherein,
L1, L2 and -NCSOaMe)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L*or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents, R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, Ci^ alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0112] In a fourth aspect of the invention is a compound that has the structure:
Figure imgf000045_0002
Wherein,
1 2
L , L and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R] 5R16)-, -NR3-,-S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyi, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
2 17
R is an aryl or heteroaryl and may be substituted with one or more R substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15 and R16 are independently hydrogen, hydroxyl, azide, C2-4 alkyenes, C2^4 alkynes, Ci_4 alkyls, , cyclopropyl, C1-4 alkoxys, or cyclopropoxy or R15 and R16 together are a carbonyl or C]_4 alkenyls; and
R17 is H, F, CI, or CN.
[0113] In a fifth aspect of the invention is a compound of formula IV.
Figure imgf000046_0001
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L'or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyi, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl ; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2- alkynyl,
Figure imgf000046_0002
alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0114] In a sixth aspect of the invention is a compound of formula V.
Figure imgf000047_0001
L1 , L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5- 1 2 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L'or L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, - NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(0)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
RN is hydrogen, C alkyl, C3_6 cycloalkyl, C4-5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2.4 alkenyl, C2-4 alkynyl, C] alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0115] In a seventh aspect of the d of formula VI.
Figure imgf000047_0002
Wherein, L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L*or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2.4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0116] In an eighth aspect of the invention is a compound of formula VII.
Figure imgf000048_0001
Wherein,
1 2
L , L and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
1 2
L or L is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl; R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2- alkynyl, C1-4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C].4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0117] In a ninth aspect of the invention is a compound of formula VIII.
Figure imgf000049_0001
Wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L'or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R1 R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents, R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, Cj_4 alky], cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0118] In a tenth aspect of the invention is a compound of formula X.
Figure imgf000049_0002
Wherein, L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)„-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R3 are independently methyl, ethyl, or cyclopropyl; and
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, C1.4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0119] In an eleventh aspect of the invention is a compound of formula XI.
Figure imgf000050_0001
Wherein,
L1, L2 and -N(SC>2Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L'or L2 is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1 , or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R13, R16 is independently hydrogen, hydroxyl, azide, C2.4 alkenyl, C2.4 alkynyl, Ci_4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C]_4 alkenylidene or R and R joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
[0120] In a twelfth aspect of the invention is a compound of formula XII.
Figure imgf000051_0001
Wherein,
L1, L2 and -N(SC>2Me)- together with the attached carbons of the aromatic ring form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L or L~ is independently selected from the group of divalent substituents consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
R2 is an aryl or heteroaryl and may be substituted with one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2_4 alkenyl, C2-4 alkynyl, Ci_4 alkyl, cyclopropyl, C1.4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C1-4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is H, F, CI or CN.
[0121] A thirteenth aspect of the invention provides a pharmaceutical composition comprising the compounds of the invention.
[0122] A fourteenth aspect of the invention provides use of the compounds of the invention in the manufacture of a medicament.
[0123] In a first embodiment of the fourteenth aspect the medicament is for the treatment of hepatitis C.
[0124] A fifteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention. General Synthesis
[0125] The compounds of the invention may be prepared by a variety of synthetic routes, samples of them are illustrated in the synthetic schemes outlined below. In general, the synthesis starts with constructing the central scaffolds such as benzofuran, benzothiophene, imidazopyridine or pyrazolopyridine by employing various synthetic techniquesknown to those skilled in the art. (e.g. in Heterocyclic Chemistry, J.A. Joule and K. Mills, J Wiley and Sons, 2010.) . Once the properly subustituted cores are made, further functional group manipulations including but not limited to chain elongation, amidation, esterification, cyclization are performed as necessary to lead to the target molecules. When being allowed chemically and in some cases necessary, the central cores may be preferred to be introduced toward the end of the synthesis. Often, protection-deprotection and, in some cases, orthogonal protection-deprotection strategies are required to accomplish the desired transformation. More comprehensive descriptions of these synthetic methodologies, techniques can be in found in these and other references: Comprehensive Organic Transformations, R.C. Larock Ed., Wiley-RCH, 1999. Protective Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3rd ed. J Willey and Sons, 1999. .
[0126] The following abbreviations are used throughout this application:
ACN Acetonitrile
AcOH Acetic acid
aq Aqueous
Boc tert-Butoxycarbonyl
Bu Butyl
Cbz Benzoxylcarbonoyl
Coned. Concentrated
DBU 1 , 8-Diazabicyclo[5.4.0] undec-7-ene
DCC N,N-dicyclohexylcarbodiimide
DCM Dichloromethane
DEAD Diethyl azodicarboxylate
DIEA (DIPEA) Diisopropylethylamine
DMA N,N-Dimethylacetamide
DMB 2,4-Dimethoxybenzyl
DMAP N,N-dimethyl-4-aminopyridine
DME 1 ,2-Dimethoxyethane
DMF N,N-Dimethylformamide
DMSO Dimethylsulfoxide DPPA Diphenylphosphoryl azide
dppp 1 ,3-Bis(diphenylphosphino)propane
dppf 1 , 1 '-Bis(diphenylphosphino)ferrocene
DCI l-Ethyl-3-[3-(dimethylamino) propyl]carbodiimide hydrochloride
EC50 Effective concentration to produce
50% of the maximal effect
ESI Electrospray Ionization
Et3N, TEA Triethyl amine
EtOAc, EtAc Ethyl acetate
EtOH Ethanol
g Gram(s)
h or hr Hour(s)
HATU 2-(7-Aza- IH-benzotriazole- 1 -yl)- 1 , 1 ,3,3-tetramethyluronium hexafluorophosphate
Hex Hexanes
HOBt 1-Hydroxybenzotriazole
HPLC High performance liquid chromatography
IC50 The concentration of an inhibitor that causes a 50 % reduction in a measured activity
LC-MS Liquid Chromatography-Mass Spectrometry
μΜ Micromolar(s)
Mel Methyl Iodide
MeOH Methanol
min Minute(s)
mM Millimolar(s)
mmol Millimole(s)
MaNP 2-Methoxy-2-(l-naphthyl)propionic acid
Ms Mesyl, Methyl sulfonyl
MSH 0-(mesitylsulfonyl)hydroxyamine
mw Microwave
NBS N-Bromosuccinimide
NIS N-Iodosuccinimide
nM Nanomolar(s)
NMO N-methylmorpholine-N-oxide
ΝΜΡ N-methylpyiTolidinone
NMR Nuclear magnetic resonance PE Petroleum ether
PG Protective Group
PPA Polyphosphoric Acid
PPh3 Triphenylphosphine
Py, Pyr Pyridine
rt Room temperature
SEMC1 2-(Trimethylsilyl)ethoxymethyl chloride
TBAF Tetra-n-butylammonium fluoride
TEA Triethylamine
TfOH Trifluoromethanesulfonic acid
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TLC Thin Layer Chromatography
TMSOTf Trimethylsilyl trifluoromethanesulfonate
tR Retention time
Ts Tosyl, Methylphenylsulfonyl
w/w Weight/weight
v/v Volume/volume
[0127] Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). H NMR spectra were recorded on a Bruker 400 MHz or 500 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons. Electrospray spray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HP1 100 HPLC for sample delivery. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses) or a single m/z value for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 5 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using an acetonitrile/water gradient (10%-90%) acetonitrile in water with 0.1% formic acid as delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH4OAc in acetonitrile/water as delivery solvent.
Enantiomeric purity was determined using a Hewlett-Packard Series 1050 system equipped with a chiral HLPC column (ChiralPak AD, 4.6 mm x 150 mm) and isocratic elution using 5:95 isopropanol-hexane as mobile phase.
[0128] The compounds were named using ChemDraw program from Cambridge Soft Inc.
[0129] Scheme A describes a general approach to building fused rings with different sizes that are attached to benzazole moieties and some chemical transformations on these fused rings. Reduction of N02 substituted benzazole A-l, followed by sulfonylation gives A-3, which is installed a substituted terminal alkyne to afford A-5. A [Pd]-mediated ring cyclization (Heck reaction) forms A-6. Alternatively, A-6 can be prepared using A-7 as a starting material for the Heck reaction. Hydrogenation of A-6 generates A-8, which can also be obtained from A-10 by hydrogenation. A-10 can be converted from A-6 through an isomerization. Cleavage of the double bond of A-6 using conditions such as onzonolysis gives A-9, which can be readily converted into A-11 to A-21 following typical reduction, a- alkylation, < -alkylation, elimination, and/or hydrogenation conditions.
Figure imgf000056_0001
55
Figure imgf000057_0001
[0130] Scheme B describes a general approach to B-3 bearing two substituents at the benzylic carbon. N-alkylation of A-3 with B-1 gives B-2, which is readily converted to B-3 through an intra-molecular Heck reaction when X1 is a halide. When X! is -OR (R = H, Me, z'Pr etc), B-3 can be prepared using B-4 as a precursor.
Figure imgf000057_0002
[0131] Scheme C describes a general approach to cyclopropyl-substituted analogs C-1, C 2, C-3 and C-4 from A-6, A-10, A-13 and A-18, respectively. Scheme D
Figure imgf000058_0001
[0132] Scheme D describes a general approach to analog D-2 from A-6. Hydroboration of A-6 gives D-1, in which the -OH can be readily converted into its mesylate, toyslate, or halide. Subsequent nucleophilic substitution with a nucleophile generates D-2.
Scheme E
Figure imgf000058_0002
[0133] Scheme E describes an alternative approach to build fused rings with different sizes that are attached to benzazole moieties. Sonogashira reaction of either A-1 or E-3 and E-1 gives E-2, which is hydrogenated to afford E-4. Selective sulfonylation of E-4, followed by ring closure forms A-14. Conversion the the triple bond of E-2 into a carbonyl group, followed by reduction of the -N02, sulfonylation and ring closure generates A-9. Scheme F
Figure imgf000059_0001
[0134] Scheme F describes a general approach to analogs F-4 and F-7 from A-2. Sulfonylation of F-1 with F-2 gives F-3, which undergoes cyclization to afford F-4, Similaily, F-7 can be prepared using F-6 instead of F-2 to react with F-1.
Scheme G
Figure imgf000060_0001
[0135] Scheme G describes a general approach to fused analogs G-6, G-7, G-8, G-12 and G-14. Heck reaction of A-1 with G-1 gives G-2, which can also be prepared from E-2. Reduction of G-2, followed by sulfonylation affords G-3, which is the key precursor to the following transformations that give various fused analogs G-6, G-7, G-8, G-12 and G-14. Scheme H
Figure imgf000061_0001
[0136] Scheme H describes a general way to prepare H-5, H-6 and H-7. Suzuki coupling of A-1 and H-1 gives H-2, which is converted to H-4 following the same strategy depicted in Scheme E. Further transformations of H-4 may readily afford H-5, H-6 and H-7. Similarly, H-9 can be synthesized by replacing A-1 with suitable starting materials.
Scheme I
Figure imgf000062_0001
[0137] Scheme I describes general ways to build a functionalized benzofuran moiety. O- protection of 1-1, followed by Sonogashira reaction with a substituted alkyne gives 1-3, which is de-protected in the presence of an acid to afford 1-4. This compound undergoes a [Pd]- mediated ring cyclization to form 1-5, which can be readily converted to 1-7 by following a two-step sequence of saponification and amide formation. Alternatively, 1-4 can be converted to 1-5 through a two-step transformation of NIS or NBS-promoted cyclization and [Pd] mediated carbonylation.
Scheme J
Figure imgf000062_0002
[0138] Scheme J describes a general way to build a functionalized pyrazole-pyridine moiety. N-amination of J-l gives pyridium salt J-2, which undergoes a ring cyclization with alkynecarboxylate J-3 to form substituted pyrazole-pyridine J-4. Saponification of J-4, followed by amide formation affords J-5. Scheme K
Figure imgf000063_0001
[0139] Scheme K describes a general way to build a functionalized imidazole-pyridine moiety. Cyclization of substituted aminopyridine K-1 with bromo-ketoester K-2 gives the cyclized product K-3, which can be readily converted to K-4 by following a two-step sequence of saponification and amide coupling.
Scheme L
Figure imgf000063_0002
Figure imgf000063_0003
[0140] Scheme L describes a general way to build a functionalized benzothiophene moiety. Sonogashira reaction of L-1 with a substituted alkyne gives L-2, which is converted to thio- ether L-3. An 12-promoted ring cyclization of L-3 affords benzothiophene L-4. The iodo group can be readily transformed into a carboxylate to form functionalized L-5, which undergoes saponification and amide formation to give L-6.
Scheme M
Figure imgf000063_0004
[0141] Scheme M describes general ways to build a functionalized 2H-indazole moiety. A
Cu-mediated N-arylation gives a mixture of IH-inzaole M-2 and the desired 2H-indazole M- 3. The latter can be readily converted to M-4 following a two-step sequence of saponification and amide formation. Alternatively, 2H-indazole M-5 can be brominated at the C-3 position to give M-6, which undergoes a [Pd] -mediated carbonylation to afford M-3.
Figure imgf000064_0001
[0142] Scheme N describes a general way to build a functionalized indole moiety. A condensation of N-l and keto-ester N-2 gives N-3. Reduction of N-3, followed by a ring formation affords substituted indole N-4, which can be readily converted to N-5 by following a two-step sequence of saponification and amide formation.
Figure imgf000065_0001
64
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001

Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
71
Figure imgf000073_0001
72
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
 Table 3. Substituted imid
Figure imgf000081_0001
Figure imgf000081_0002
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
83
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
87 [0146] Table 4. Substituted indole analogs
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
91
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
95 [0147] Table 5. Substituted benzothiophene analogs
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
103
Figure imgf000105_0001
104
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
107
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
ʼnll [0149] The following examples illustrate the preparation and antiviral evalution of compounds within the scope of the invention. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
Figure imgf000113_0001
[0150] Step 1. Refer to Scheme 1. To a solution of compound 1-1 (40.0 g, 325 mmol) in water (40 mL) were sequentially added compound 1-2 (12 g, 162 mmol), Cu(OAc)2 (0.6 g, 3.25 mmol) and Cul (0.6 g, 3.25 mmol). After stirring at 100 °C for 48 hrs, the reaction mixture was cooled to rt and added 30% (w/w) aq. NaOH (20 mL). The resulting mixture was extracted with EtOAc (60 mL x 3) and aq. phase was adjusted to pH 7 to 8 by adding coned, aq. HC1. The resulting mixture was concentrated to remove water in vacuo and the residue was purified by silica gel column chromatography (DCM/MeOH = 60/1 to 10/1 (v/v)) to give compound 1-3 (18 g, 57% yield) as a brown solid. LC-MS (ESI): mlz 196 [M+H]+.
[0151] Step 2. A mixture of compound 1-3 (40.0 g, 20.5 mmol) in polyphosphoric acid (PPA) (100 mL) was mechanically stirred at 90 °C for 3 hrs. The mixture was cooled to 60 °C and ice water (50 mL) was added with stirring for 30 min. Subsequently, the mixture was extracted with EtOAc (120 mL x 3). The organic extracts were combined, washed with water (40 mL) and brine (40 mL), and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (DCM/MeOH = 100/l(v/v)) to give compound 1-4 (18 g, 50% yield) as a yellow solid. LC-MS (ESI): m/z 178 [M+H]+.
[0152] Step 3. A solution of compound 1-4 (4.00 g, 22.6 mmol) and Et3N (9.40 mL, 67.8 mmol) in DCM (200 mL) was added MsCl (6.46 g, 56.4 mmol) at 0 °C. After stirring at rt for 3 hrs, the reaction was quenched by adding ice water (250 mL) and the aq. phase was extracted with DCM (100 mL x 2). The organic extracts were combined, washed with water and brine, and dried over anhydrous Na2S04. The solvent was removed that the residue was purified by silica gel column chromatography (DCM/MeOH = 400/l(v/v)) to give compound 1-5 (4.5 g, 78% yield) as a yellow solid. LC-MS (ESI): m/z 256 [M+H]+; !H NMR (500 MHz, CDC13): δ 8.02 (d, J = 9 Hz, 1H), 7.27 (d, J = 3.5 Hz, 1 H), 6.79 (dd, J, = 9 Hz, J2 = 2 Hz, 1H), 4.19 (t, J = 6.5 Hz, 2H), 3.89 (s, 3H), 3.06 (s, 3H), 2.79 (t, = 6.5 Hz, 2H) ppm.
[0153] Step 4. To a suspension of Ph3PCH3Br (14.0 g, 39.2 mmol) in 130 mL of THF was added n-BuLi (2.5 M in hexane, 15.7 mL, 39.2 mmol) at 0 °C. After stirring at 0 °C for 2 hr, a solution of compound 1-5 (4.00 g, 15.7 mmol) in anhydrous THF (30 mL) was added. After stirring at rt overnight, the reaction mixture was quenched by adding aq. NH4CI (sat., 20 mL). The mixture was extracted with EtOAc (600 mL x 2) and the combined organic extracts were washed with water (100 mL) and brine (100 mL), and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (DCM) to give compound 1-6 (1.2 g, 30% yield). LC-MS (ESI): m/z 254 [M+H]+; !H NMR (500 MHz, CDC13): δ 7.75 (d, / = 9 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 6.78 (dd, J, = 9 Hz, J2 = 3 Hz, 1H), 5.59 (s, 1H), 4.91 (s, 1H), 3.76 (s, 3H), 3.73 (t, 7 = 6 Hz, 2H), 3.08 (s, 3H), 2.70 (t, J = 6 Hz, 2H) ppm.
[0154] Step 5. To a solution of compound 1-6 (2.70 g, 10.7 mmol) in dry toluene (200 mL) was added ZnEt2 (1 M in hexane, 85.4 mL, 85.4 mmol), followed by CH2I2 (46 g, 171mmol) at 0 °C. After stirring at rt overnight, the reaction mixture was partitioned between EtOAc (100 mL) and 5% HC1 (100 mL). The organic layer was dried with anhydrous Na2S04 and concentrated and the residue was purified by silica gel column chromatography (DCM) to give compound 1-7 (2.1 g, 72% yield). LC-MS (ESI): m/z 268 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.33 (d, J = 2.5 Hz, 1H), 6.66 (dd, /; = 14 Hz, J2 = 3 Hz, 1H), 6.61 (d, J = 9 Hz, 1H), 3.95-3.92 (m, 2H), 3.78 (s, 3H), 2.91 (s, 3H), 1.81 - 1.83 (m, 2H), 1.01 (dd, Jj = 6.5 Hz, J2 = 5 Hz, 2H), 0.85 (dd, /; = 6.5 Hz, J2 = 5 Hz, 2H) ppm.
[0155] Step 6. To a solution of compound 1-7 (290 mg, 1.09 mmol) in DCM (10 mL) was added NBS (194 mg, 1.09 mmol) at 0 °C. After stirring at rt for 1 hr, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/ethyl acetate = 10/1 (v/v)) to give compound 1-8 (220 mg, 59% yield) as a yellow oil.
LC-MS (ESI): m/z 346 [M+H]+; lU NMR (500 MHz, CDC13): δ 7.39 (s, 1 H), 6.84 (s, 1 H), 3.93 (t, J = 5.5 Hz, 2H), 3.88 (s, 3H), 2.90 (s, 3H), 1.81 (t, / = 5.5 Hz, 2H), 1.03 (t, J = 5 Hz, 2H), 0.89 (t, / = 5 Hz, 2H) ppm.
[0156] Step 7. To a solution of compound 1-8 (200 mg, 0.58 mmol) in CH2CI2 (6 mL) was added BBr3 (4 N in DCM, 0.6 mL, 2.4 mmol) at -20 °C. After stirring at 0 °C for 1 hr, the reaction was quenched by adding ice-water (50 mL). The mixture was extracted with DCM (50 mL x 2) and the combined extracts were washed with water and brine, and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ethyl acetate = 10/1 (v/v)) to give compound 1-9 (120 mg, 63% yield) as a red solid. LC-MS (ESI): mlz 331 [M+Hf; Ή NMR (500 MHz, CDCI3): δ 7.44 (s, 1H), 6.77 (s, 1 H), 5.47 (br s, I H), 3.89 - 3.92 (m, 2H), 2.95 (s, 3H), 2.90 (s, 3H), 1.81 (t, 7 = 5.5 Hz, 2H), 0.89 - 1.01 (m, 2H), 0.87 - 0.89 (m, 2H) ppm.
[0157] Step 8. To a solution of compound 1-9 (1 .60 g, 4.82 mmol) in 30 mL THF was added DMAP (30 mg) and TEA (1.46 g, 14.46 mmol). The resulting mixture was cooled to 0 °C and SEMC1 (1.60 g, 9.64 mmol) was added. After stirring at rt for 10 hrs, the reaction mixture was poured into water (50 mL) and extracted with EtOAc (60 mL x 3). The combined organic extracts were washed brine (30 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 1-10 (2.2 g, 99% yield) as a yellow oil. LC-MS (ESI): mlz 485 [M+Na]+.
[0158] Step 9. To a solution of compound 1-10 (1.60 g, 3.47 mmol) in 20 mL of DMF were added 1-11 (0.50 g, 4.16 mmol), Cul (33 mg, 0.17 mmol), Pd(PPh3)2Cl2 (244 mg, 0.35 mmol), P(r-Bu)3 (140 mg, 0.69 mmol) and piperidine (1.18 g, 13.9 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. Subsequently, the reaction mixture was cooled to rt, poured into water (60 mL), and extracted with EtOAc (100 mL x 2). The combined organic extracts were washed with water (50 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 10/1 (v/v)) to give compound 1-12 (780 mg, 45% yield) as a yellow oil. LC-MS (ESI): mlz 524 [M+Naf.
[0159] Step 10. To a solution of compound 1-12 (750 mg, 1.50 mmol) in dioxane (10 mL) was added 4 N HCl/dioxane (2 mL). After stirring at rt for 2 hrs, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 1-13 (600 mg, quantitative yield) as a yellow oil. LC-MS (ESI): mlz 372 [M+H]+.
[0160] Step 11. To a solution of compound 1-13 (600 mg, 1.62 mmol) in MeOH (20 mL) was added NaOAc (265 mg, 3.24 mmol), K2C03 (448 mg, 3.24 mmol), PdCl2 (28 mg, 0.16 mmol), and CuCl2 (653 mg, 4.86 mmol). The resulting mixture was flushed with CO and stirred at rt overnight under an atmosphere of CO. The mixture was diluted with EtOAc (80 mL) and filtered through Celite®545. The filtrate was washed with water (30 mL) and brine (30 mL), and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone =16/1 (v/v)) to give compound 1-14 (70 mg, 10% yield) as a white solid. LC-MS (ESI): mlz 429 [M+H]+.
[0161] Step 12. To a solution of compound 1-14 (70 mg, 0.16 mmol) in MeOH/THF (1 mL/2 mL) was added LiOH (0.65 mmol). After stirring at 70 °C for 2 hr, the reaction mixture was cooled to rt and acidified by adding IN aq. HC1 (7 mL). The resulting mixture was filtered and the solid was dried in vacuo to give compound 1-15 (60 mg, 91% yield) as a white solid. LC-MS (ESI): mlz 454 [M+K]+.
[0162] Step 13. To a solution of compound 1-15 (60 mg, 0.14 mmol) in DMF (1.5 mL) was added HATU (66 mg, 0.17 mmol). After stirring at rt for 30 min, the mixture were added DIPEA (181 mg, 1.40 mmol) and MeNH2 HCl (47 mg, 0.70 mmol). The resulting mixture was stin-ed at rt for 20 min and poured into water (50 mL). The suspension was filtered and the obtained solid was purified by silica gel column chromatography (DCM/MeOH = 600/1 (v/v)) to give compound 1-16 (30 mg, 50% yield) as a white solid. LC-MS (ESI): mlz 429 [M+H]+; lU NMR (500 MHz, CDC13): δ 7.93 (s, 1H), 7.85 (dd, J2 = 8.5 Hz, J2 = 5.5 Hz, 2H), 7.26 (d, / = 3 Hz, 1H), 7.19 (t, J = 8.5 Hz, 2H), 5.74 (br s, 1 H), 3.99 (t, / = 6.0 Hz, 2H), 2.98 (d, / = 5.0 Hz, 3H), 2.89 (s, 3H), 1.88 (t, / = 6.0 Hz, 2H), 1.17 - 1.19 (m, 2H), 0.90 - 0.93 (m, 2H) ppm.
Figure imgf000116_0001
[0163] Step 1. Refer to Scheme 2. A suspension of NaH (16.1 g, 402 mmol) in anhydrous
DMF (300 mL) was cooled to 0 °C with stirring under argon, compound 2-1 (20.0 g, 134 mmol) in anhydrous DMF (200 mL) was added and the mixture was stirred at 0 °C under argon for 1 hr. The mixture was then allowed to warm to rt and Mel (22.8 g, 161 mmol) was added. After stirring at rt for 1 hr, the reaction was quenched by adding ice water (3000 mL). The resulting mixture was extracted with EtOAc (500 mL x 3) and the combined organic extracts were washed with water and brine and dried with anhydrous MgSC^. The solvent was removed and the residue was dried in vacuo to give crude compound 2-2 (12.5 g, 65% yield) as a brown oil. LC-MS (ESI): mlz 160 [M+H]+.
[0164] Step 2. A solution of compound 2-2(12.5 g, 79 mmol) and Pt02 (l . lg, 4.8mmol) in MeOH (500 mL) was stirred at rt for 16 hrs under an atmosphere of H2. The reaction mixture was filtered through Celite®545 and the filtrate was concentrated. The residue was purified by silica gel column chromatography (EtOAc/petroleum ether = 1/8 (v/v)) to give compound 2-3 (9.0 g, 78% yield) as a yellow oil. LC-MS (ESI): mlz 164 [M+H]+; Ή NMR (500 MHz, CDC13): δ 6.84 (d, J = 8.5 Hz, 1 H), 6.20 (dd, J, = 8.5 Hz, J2 = 2.5 Hz, 1H), 6.04 (d, J = 2.5 Hz, 1H), 3.73 (s, 3H), 3.26 - 3.28 (m, 2H), 2.69 (t, J = 6.5 Hz, 2H), 1.91 (dd, Ji = 6.5 Hz, J2 = 4.5 Hz, 2H) ppm.
[0165] Step 3. To a solution of compound 2-3 (9.0 g, 55 mmol) and TEA (13.6 g, 135 mmol) in DCM (200 mL) at 0 °C was added MsCl (9.1 g, 80 mmol). After stirring at rt for 30 min, the reaction mixture was added ice water (250 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtO Ac/Petroleum ether = 1/6 (v/v)) to give compound 2-4 (10.6 g, 80% yield) as a yellow oil. LC-MS (ESI): mlz, 242 [M+Hf.
[0166] Step 4. N-iodosuccinimide (NIS) (19.8 g, 88.0 mmol) was added to a solution of compound 2-4 (10.6 g, 44 mmol) in CHC13 (200 mL) at 0 °C. After stirring at rt for 16 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (EtOAc/Petroleum ether = 1/6 (v/v)) to give compound 2-6 (12.6 g, 80% yield). LC-MS (ESI): mlz 368 [M+H]+; !H NMR (500 MHz, CDC13): δ 7.52 (s, 1H), 7.32 (s, 1 H), 3.86 (s, 3H), 3.81 - 3.79 (m, 2H), 2.88 (s, 3H), 2.77 (t, J = 6.5 Hz, 2H), 1.95 (t, / = 5.5 Hz, 2H) ppm.
[0167] Step 5. A solution of BBr3 (13.6 mL/4.0M, 54.4 mmol) in DCM was added to a solution of compound 2-5 (5.04 g, 13.6 mmol) in CH2C12 (100 mL) at -20 °C. After stirring at -20 °C for 1 hr, the reaction mixture was added ice water (200 mL). The resulting mixture was extracted with DCM (lOOmL x 2) and the combined organic extracts were washed water and brine and dried with anhydrous Na2SC>4. The solvent was removed and the residue was purified by silica gel column chromatography (EtO Ac/Petroleum ether = 1/12 (v/v)) to give compound 2-6 (1.4 g, 25% yield) as a white solid. LC-MS (ESI): mlz 354 [M+H]+; Ή NMR (500 MHz, CDCI3): δ 7.42 (s, 2H), 5.31 (s, 1H), 3.78 (t, / = 6 Hz, 2H), 2.93 (s, 3H), 2.76 (t, / = 6.5 Hz, 2H), 1.95 (t, J = 5.5 Hz, 2H) ppm. [0168] Step 6. To a solution of compound 2-6 (1.2 g, 3.4 mmol) in 20 mL THF was added DMAP (20 mg), followed by Et3N (0.69 g, 6.8 mmol) at rt. The resulting mixture was cooled to 0 °C and SEMC1 (0.68 g, 4.08 mmol) was added. After stirring at rt for 3 hrs, the reaction mixture was poured into ice water (50 mL). The resulting mixture was extracted with EtOAc (60 mL x 3) and the combined organic extracts were washed with brine (30 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 2-7 (1.6 g, quantitative yield) as a yellow oil. LC-MS (ESI): mlz 506
[M+Na]+.
[0169] Step 7. To a solution of 2-7 (1.60 g, 3.31 mmol) in 20 mL DMF were added 2-8 (0.48 g, 4.0 mmol), Cul (32 mg, 0.17 mmol), Pd(PPh3)2Cl2 (232 mg, 0.330 mmol), P(i-Bu)3 (133 mg, 0.660 mmol) and piperidine (1.13 g, 13.2 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. The resulting mixture was poured in to ice water (60 mL) and extracted with EtOAc (100 mL x 2). The combined organic extracts were washed with water (250 mL x5) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Acetone/petroleum ether = 1/10 (v/v)) to give compound 2-9 (1.2 g, 76% yield) as a yellow oil. LC-MS (ESI): mlz 498
[M+Na]+.
[0170] Step 8. To a solution of compound 2-9 (1.2 g, 2.52 mmol) in 16 mL dioxane was added 4 N HC1 in dioxane (7.6 mL) at rt. After stirring at rt for 30 min, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 2-10 (870 mg, quantitative yield) as a yellow oil, which was used directly for the next step without purification. LC-MS (ESI): mlz 346 [M+H]+.
[0171] Step 9. To a solution of compound 2-10 (600 mg, 1.74 mmol) in MeOH (17 mL) were added NaOAc (285 mg, 3.48 mmol), K2C03 (481 mg, 3.48 mmol), PdCl2 (31.0 mg, 0.17 mmol) and CuCl2 (702 mg, 5.22 mmol) and the resulting mixture was flushed with CO. After stirring at rt overnight, the mixture was concentrated and the residue was diluted with EtOAc (100 mL) and filtered. The filtrate was washed with water (30 mL) and brine (30 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Acetone/petroleum ether = 1/10 (v/v)) to give compound 2-11 (140 mg, 20% yield) as a yellow solid. LC-MS (ESI): mlz 404 [M+H]+.
[0172] Step 10. To a solution of compound 2-11 (140 mg, 0.35 mmol) in MeOH/THF (2 mL/4 mL) was added LiOHH20 (58 mg, 1.4 mmol) at rt. After stirring at 70 °C for 1 hr, the reaction mixture was cooled to 0 °C and acidified with IN aqueous HC1 (3 mL). The suspension was filtered and the solid was dried in vacuo to give compound 2-12 (136 mg, quantitative yield) as a white solid, which was used directly for the next step without further purification. LC-MS (ESI): mlz 390 [M+H]+. [0173] Step 11. To a solution of compound 2-12 (60 mg, 0.15 mmol) in DMF (2 mL) was added HATU (68.4 mg, 0.18 mmol). The resulting mixture was stirred at rt for 30 min and then N,N-diisopropylethylamine (DIEA or DIPEA) (194 mg, 1.5 mmol) and MeNH2 HCl (52 mg, 0.77 mmol) were added. After stirring at rt for 20 min, the reaction mixture was poured into ice water (50 mL). The suspension was filtered and the collected solid was purified by silica gel column chromatography to give compound 2-13 (20 mg, 33% yield). LC-MS (ESI): mlz 403 [M+H]+; *H NMR (500 MHz, CDC13): δ 7.88 - 7.93 (m, 3H), 7.60 (s, 1H), 7.19 (t, J = 9.0 Hz, 2H), 5.80 (br s, 1H), 3.85 - 3.89 (m, 2H), 3.00 (d, J = 4.5 Hz, 3H), 2.95 (t, / = 6.5 Hz, 2H), 2.89 (s, 3H), 2.01 - 2.06 (m, 2H) ppm.
Figure imgf000119_0001
[0174] Step 1. Refer to Scheme 3. A mixture of compound 3-1 (2.00 g, 5.16 mmol) (prepared by following the procedures described in WO200759421 with some modifications) and 10% Pd/C (1.0 g) in EtOAc (40 mL) was stirred at rt for 2 hr under an atmosphere of H2. The reaction mixture was filtered and the filtrate was concentrated to give compound 3-2 (1.7 g, 92% yield). LC-MS (ESI): mlz 358 [M+H]+.
[0175] Step 2. To a solution of compound 2 (1.70 g, 4.76 mmol) and TEA (1.32 mL, 9.52 mmol) in DCM (50 mL) was added MsCl (0.660 g, 5.71 mmol) at 0 °C . After stirring at rt for 30 min, the reaction mixture was added ice water (250 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 3-3 (2.07 g, quantitative yield) as a yellow solid. LC-MS (ESI): mlz 436 [M+H]+.
[0176] Step 3. To a solution of compound 3-3 (4.00 g, 9.5 mmol) in DMF (50 mL) was added K2C03 (5.25 g, 38.0 mmol) and compound 3-4 (1.54 g, 1 1.4 mmol) at rt. After stirring at 80 °C overnight, the reaction mixture was poured into ice water (60 mL). The resulting mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 3-5 (4.2 g, 92% yield) as a yellow solid. LC-MS (ESI): mlz 512 [M+Naf.
[0177] Step 4. To a solution of compound 3-5 (2.1 g, 4.3 mmol) in CH2C12 (100 mL) was added BC13 (1 N in DCM, 12.9 mL) at -78 °C, the solution was allowed to stirred at -30 °C for 1 hr and then quenched with ice-water (200 mL). The mixture was extracted with DCM (100 mL x 2) and the combined organic extracts were washed with water and brine, and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 3-6 (1.7 g, 86% yield) as a yellow solid. LC-MS (ESI): mlz 448 [M+H]+.
[0178] Step 5. To a solution of compound 3-6 (3.30 g, 7.37 mmol) in CH2C12 (160 mL) were sequentially added DMAP (45 mg, 0.37 mmol), DIEA (2.58 mL, 14.8 mmol) and Tf20 (1.5 mL, 8.9 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction mixture was added ice-water (100 mL). The organic layer was washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 3-7 (3.2 g, 86% yield) as a yellow solid. LC-MS (ESI): mlz 602 [M+Na]+.
[0179] Step 6. To a solution of compound 3-7 (3.00 g, 5.18 mmol) in 20 mL DMF was added Pd(OAc)2 (116 mg, 0.520 mmol), PPh3 (136 mg, 0.520 mmol), LiCl (242 mg, 5.70 mmol) and Et3N (1.44 mL, 10.4 mmol) at rt. The resulting mixture was flushed with Ar and stirred at 120 °C overnight. The mixture was cooled to rt and poured into 60 mL water. The resulting mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water (50 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 6/1 (v/v)) to give a mixture of compounds 3-8 and 3-8' (1.4 g, 63% yield) as a yellow solid. LC-MS (ESI): mlz 430 [M+H]+.
[0180] Step 7. To a solution of compounds 3-8 and 3-8' (1.00 g, 2.33 mmol) in
MeOH/THF (14 mL/14 mL) was added LiOH (335 mg, 13.97 mmol). The resulting mixture was stirred at 80 °C for 1 hr, cooled to rt and acidified with IN aq. HC1 (5 mL). The suspension was filtered and the solid was washed with water and dried in vacuo to give a mixture of compounds 3-9 and 3-9' (980 mg, 98% yield) as a white solid, which was used directly for the next step. LC-MS (ESI): mlz 402 [M+H]+.
[0181] Step 8. To a solution of compounds 3-9 and 3-9' (950 mg, 2.37 mmol) in DMF (5 mL) was added HATU (1.35 g, 3.55 mmol). The resulting mixture was stirred at rt for 30 min and added DIEA (3.30 mL, 19.0 mmol) and MeNH2 HCl (639 mg, 9.47 mmol). After stirring at rt for 20 min, the reaction mixture was poured into ice water (50 mL). The suspention was filtered and the solid was purified by silica gel column chromatography to give a mixture of compounds 3-10 and 3-10' (580 mg, 59% yield). LC-MS (ESI): mlz 41 [M+H]+. Compound 3-10 was readily converted to compound 3-10' in CH2CI2 in the presence of TFA. LC-MS (ESI): mlz 415 [M+H]+; lH NMR (500 MHz, CDC13): δ 7.93 - 7.96 (m, 2H), 7.74 (s, 1H), 7.71 (s, 1H), 7.26 - 7.29 (m, 2H), 5.96 (s, 1H), 4.38 (br s, 1H), 2.98 (s, 3H), 2.74 (s, 3H), 2.23 (s, 3H) ppm.
[0182] Step 9. A mixture of compounds 3-10 and 3-10' (41.4 mg, 0.10 mmol) and Pd(OH)2 (22 mg) in EtOAc (20 mL) and MeOH (2 mL) was stirred at rt for 3 hr under an atmosphere of H2. The reaction mixture was filtered through Celite®545 and the filtrate was concentrated. The residue was purified by re-crystallization (hexane/EtOAc = 10/1 (v/v)) to give compound 3-11 (23 mg, 55% yield) as a while solid. LC-MS(ESI): mlz 417 [M+H]+; Ή NMR (500 MHz, CDCI3): δ 7.92 (s, 1H), 7.86 - 7.89 (dd, J, = 8.5 Hz, J2 = 5.5 Hz, 2H), 7.70 (s, 1H), 7.26 (s, 2H), 7.17 - 7.20 (t, J = 8.5 Hz, 2H), 5.93 (br s, 1H), 3.89 - 3.92 (m, 1H), 3.84 - 3.86 (m, 1H), 3.03 - 3.06 (m, 1H), 3.00 (d, 3H), 2.89 (s, 3H), 2.13 - 2.16 (m, 1H), 1.70 - 1.73 (m, 1H), 1.42 (d, 3H) ppm.
Figure imgf000122_0001
[0183] Step 1. Refer to Scheme 4. To a solution of compound 3-1 (4.00 g, 10.3 mmol) in CH2C12 (30 mL) was added BC13 (1 N in CH2C12, 20.6 mmol) at 0 °C. After stirring at rt for 1 hr, the reaction mixture was added ice water (100 mL). The mixture was extracted with
CH2CI2 (800 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 4-1 (3.4 g, 96% yield) as a yellow solid. LC-MS (ESI): mlz 346 [M+H]+.
[0184] Step 2. To a solution of compound 4-1 (3.4 g, 9.8 mmol) in CH2C12 (100 mL) were added DMAP (120 mg, 0.980 mmol) and DIEA (1.52 g, 1 1.8 mmol), followed Tf20 (3.20 g, 11.3 mmol) at 0 °C. After stirring at 0 °C for 2 hrs, the reaction mixture was added ice water (100 mL). The organic layer was separated, washed with water and brine, and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 4-2 (4.6 g, quantitative yield) as a yellow solid. LC-MS (ESI): mlz 478 [M+H]+.
[0185] Step 3. To a solution of 4-2 (2.0 g, 4.2 mmol) in 20 mL DMF was added 4-3 (0.44 g, 6.3 mmol), Cul (0.16 g, 0.84 mmol), Pd(PPh3)2Cl2 (0.29 g, 0.42 mmol) and Et3N (20 mL). The resulting mixture was flushed with Ar, stirred at rt for 1 hr and poured into ice water (100 mL). The mixture was extracted with EtOAc (50 mL x 5) and the combined organic extracts were washed with water and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 4/1 (v/v) to 3/2 (v/v)) to give compound 4-4 (1.10 g, 69% yield) as a gray solid. LC-MS (ESI): mlz 398 [M+H]+.
[0186] Step 4.To a solution of compound 4-4 (2.00 g, 5.03 mmol) in EtOAc (150 mL) was added 10% Pd C (2.0 g). The resulting mixture was flushed with ¾ and stirred at rt for 1.5 hrs. Subsequently, the reaction mixture was filtered through Celite®545 and the filtrate was concentrated and dried in vacuo to give compound 4-5 (1.8 g, 97% yield). LC-MS (ESI): mlz 372 [M+H]+; ¾ NMR (500 MHz, CDC13): δ 7.98 - 8.01 (m, 2H), 7.70 (s, 1H), 7.12 - 7.16 (m, 2H), 6.82 (s, 1H), 4.39 (dd, /, = 14.5 Hz, J2 = 7 Hz, 2H), 3.73 (t, J = 6 Hz, 3H), 2.66 (t, J = 7.5 Hz, 2H), 1.69 - 1.80 (m, 4H), 1.40 (t, J = 7 Hz, 3H) ppm.
[0187] Step 5. To a solution of compound 4-5 (1.80 g, 4.85 mmol) in CH2C12 (50 mL) was added DMAP (6 mg) and anhydrous pyridine (3.07 g, 38.8 mmol), followed by MsCl (1.60 g, 14.5 mmol) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added ice water (50 mL). The organic layer was separated, washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 5/1 (v/v)) to give compound 4-6 (1.4 g, 55% yield) as a yellow solid. LC-MS (ESI): mlz 449 [M-Ms+H]+; lW NMR (500 MHz, CDC13): δ 8.02 - 8.05(m, 2H), 7.90 (s, 1H), 7.71 (s, 1H), 7.16 - 7.19 (m, 2H), 6.61 (s, 1H), 4.42 (dd, /;= 14 Hz, J2 = 7.0 Hz, 2H), 4.34 (t, / = 5.5 Hz, 2H), 3.04 - 3.08 (m, 6H), 2.83 (t, J = 8.0 Hz, 2H), 1.81 - 1.92 (m, 4H), 1.41 (t, J = 7.0 Hz, 3H) ppm.
[0188] Step 6. To a suspension of NaH (0.21 g, 60% in mineral oil, 5.31 mmol) in anhydrous THF (160 mL) was added a solution of compound 4-6 (1.40 g, 2.65 mmol) in anhydrous THF (40 mL) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added sat. aq. NH4CI (10 mL). The resulting mixture was concentrated and the residue was diluted with EtOAc (100 mL). The mixture was washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 5/1 (v/v)) to give compound 4-7 (1.1 g, 96% yield) as a yellow solid. LC-MS (ESI): mlz 432 [M+H]+; Ή NMR (500 MHz, CDC13): 6 8.02 - 8.06 (m, 2H), 7.90 (s, 1H), 7.60 (s, 1H), 7.15 - 7.20 (m, 2H), 4.42 (dd, /, = 14 Hz, J2 = 6.5 Hz, 2H), 3.69 (t, J = 6.0 Hz, 2H), 3.07 (s, 3H), 3.02 (t, / = 6.0 Hz, 2H), 1.94 (dd, J} = l l Hz, J2 = 5.5 Hz, 2H), 1.77 (br s, 2H), 1.40 - 1.43 (m, 3H) ppm.
[0189] Step 7. To a solution of compound 4-7 (50 mg, 0.12 mmol) in MeOH/THF (2 mL/4 mL) was added LiOH (2,0 N, 0.46 mmol). The resulting mixture was stirred at 70 °C for 2 hrs, cooled to rt and acidified with 1 N aq. HC1 (5 mL). Subsequently, the suspension was filtered and the solid was washed with waster and dried in vacuo to give crude compound 4-8 (46 mg, 95% yield) as a white solid, which was used directly for the next step without further purification. LC-MS (ESI): mlz 404 [M+H]+.
[0190] Step 8. To a solution of compound 4-8 (46 mg, 0.12 mmol) in DMF (2 mL) was added HATU (54 mg, 0.14 mmol). The resulting mixture was stirred at rt for 30 min and added DIEA (154 mg, 1.20 mmol) and MeNH2 HCl (41 mg, 0.60 mmol). After stirring at rt for 20 min, the reaction mixture was poured into ice water (50 mL). The suspension was filtered and the solid was purified by silica gel column chromatography (Petroleum ether/acetone = 3/1 (v/v)) to give compound 4-9 (30 mg, 61 % yield) as a white solid. LC-MS (ESI): mlz 417 [M+H]+; 1H NMR (500 MHz, CDC13): δ 7.89 - 7.92 (m, 2H), 7.68 (s, 1H), 7.59 (s, 1H), 7.19 (t, J = 9.0 Hz, 2H), 5.80 (d, J = 4.0 Hz, 1H), 3.69 (d, J = 6.0 Hz, 2H), 3.06 (s, 3H), 2.98-3.03 (m, 5H), 1.93 (dd, ;= 11 Hz, J2 = 5.5 Hz, 2H), 1.75 (d, J = 2.5 Hz, 2H) ppm.
Figure imgf000124_0001
[0191] Synthesis of compound 4-9'. Following Scheme 4 by replacing compound 4-3 (but-3-yn-l-ol) with pen-4-yn-l-ol, compound 4-9' was obtained as a pale yellow solid. LC- MS (ESI): mlz 431 [M+H]+; 1H NMR (500 MHz, CDC13): δ 7.92 (m, 2H), 7.71 (s, 1 H), 7.43 (s, 1H), 7.19 (t, J = 8.5 Hz, 2H), 5.86 (s, 1H), 3.08 (m, 5H), 3.01 (d, J = 4.5 Hz, 3H), 1.59 (m, 6H) ppm.
Figure imgf000124_0002
[0192] Synthesis of compound 4-9". Following Scheme 4 by replacing compound 4-3 (but-3-yn-l-ol) with hex-5-yn-l-ol, compound 4-9" was obtained as a yellow solid. LC-MS (ESI): mlz 447 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.93 (m, 2H), 7.68 (s, 1H), 7.35 (s, 1H), 7.18 (t, J =8.5 Hz, 2H), 5.86 (s, 1H), 4.05 (m, 1H), 3.47 (m, 1H), 3.37 (m, 1H), 3.00 - 3.02 (m, 6H), 2.76 (m, 1H), 1.90 - 1.95 (m, 2H), 1.73 - 1.79 (m, 1H), 1.26 - 1.65 (m, 4H), 1.06 (m, 1H) ppm.
[0193] Synthesis of compound 4-10. A mixture of compound 4-8 (50 mg, 0.12 mmol) in SOCl2 (1.5 mL) was stirred at 80 °C for 2 hrs. The solvent was removed and the residue dried in vacuo to give the crude acid chloride, which was used for the next step without further purification. Subsequently, the cmde acid chloride was dissolved in anhydrous pyridine (1.5 mL), followed by O-methylhydroxy] amine hydrochloride (124 mg, 0.490 mmol). After stirring at 100 °C for 1.5 hrs, the reaction mixture was concentrated and the residue was purified by preparative HPLC to give compound 4-10 (20 mg, 37% yield) as a white powder. LC-MS (ESI): mJz 433 [M+H]+; 1H NMR (500 MHz, CDC13): δ 8.31 (s, 1H), 7.90 - 7.93 (m, 2H), 7.66 (s, 1H), 7.20 (t, J = 8.5 Hz, 2H), 3.85 (s, 3H), 3.03 (s, 3H), 2.97 - 3.00 (m, 2H), 1.93 - 1.96 (m, 2H), 1.69 - 1.76 (m, 2H) ppm.
Figure imgf000125_0001
[0194] Step 1. Refer to Scheme 5. To a suspension of Zn (3.92 g, 60.3 mmol) in EtOH (80 mL) was added HOAc (3 mL), followed by solution of compound 5-1 (2.0 g, 8.6 mmol) in EtOH (20 mL) at rt. After stirring at rt overnight, the reaction mixture was filtered. The filtrate was concentrated and the residue was diluted with EtOAc (150 mL). The mixture was washed with water (200 mL) and brine (100 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether /EtOAc = 19/1 (v/v)) to give compound 5-2 (1.15 g, 48% yield) as a yellow oil. LC-MS (ESI): mlz 202 [M+H]+.
[0195] Step 2. A solution of compound 5-2 (10.0 g, 49.8 mmol) in anhydrous pyridine (50 mL) was added MsCl (4.04 mL, 52.2 mmol) at 0 °C. After stirring at rt for 30 min, the reaction mixture was diluted with EtOAc (200 mL). The mixture was washed with 1 N aq.
HCl (100 mL x 3) and brine (100 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 10/1 (v/v)) to give compound 5-3 (9.3 g, 67% yield) as a white solid. LC-MS (ESI): m/z 280 [M+H]+.
[0196] Step 3. To a solution of compound 5-3 (800 mg, 2.86 mmol) in DMF (10 mL) were added compound 5-4 (51 1 mg, 3.43 mmol) and K2CO3 (1.58 g, 1 1.4 mmol). After stirring at 80 °C for 4 hrs, the reaction mixture was added ice-water (50 mL) and EtOAc (50 mL). The organic layer was washed with water (50 mL x 5) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 10/1 (v/v)) to give compound 5-5 (980 mg, 99% yield). LC-MS (ESI): m/z 347 [M+H]+.
[0197] Step 4. To a solution of compound 5-5 (980 mg, 2.83 mmol) in DMF (5 mL) were added Pd(OAc)2 (64 mg, 0.28 mmol), PPh3 (297 mg, 1.13 mmol), LiCl (132 mg, 3.1 1 mmol) and Et3N (572 mg, 5.66 mmol) and the resulting mixture was flushed with Ar and stirred at 120 °C for 1.5 hrs. Subsequently, the reaction mixture was cooled to rt and poured into water (60 mL). The mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water (50 mL x 5) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 10/1 (v/v)) to give compound 5-6 (600 mg, 79% yield) as a yellow oil. LC- MS (ESI): m/z 268 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.20 d, J = 8.5 Hz, 1 H), 7.04 (d, J = 2 Hz, 1H), 6.84 (dd, Jt = 8.5 Hz, J2 = 2,5 Hz, 1H), 5.17 (s, 1H), 5.06 (s, 1H), 3.80 - 3.83 (m, 5H), 2.85 (s, 3H), 2.45 (t, J = 6 Hz, 2H), 1.89 - 1.93 (m, 2H) ppm.
[0198] Step 5. To a solution of compound 5-6 (3.60 g, 13.5 mmol) in toluene (60 mL) were added ZnEt2 (1 M in hexane, 108 mmol) and CH2I2 (57.6 g, 216 mmol) at 0 °C. After stirring at rt overnight, the reaction mixture was diluted with EtOAc (100 mL) and the resulting mixture was washed with 5% (w/w) aq. HC1 (100 mL) and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 20/1 to 8/1 (v/v)) to give compound 5-7 (2,5 g, 66% yield) as a yellow solid. LC-MS (ESI): m/z 282 [M+H]+; !H NMR (500 MHz, CDC13) δ 7.18 (d, J = 8.5 Hz, 1H), 6.92 (d, / = 1.5 Hz, 1H), 6.75 (dd, /, = 8.5 Hz, J2 = 2 Hz, 1H), 3.78 (s, 3H), 3.61 (br s, 2H), 3.06 (s, 3H), 1 .92 (br s, 2H), 1.52 (br s, 2H), 0.90 (br s, 2H), 0.73 (br s, 2H) ppm.
[0199] Step 6. To a solution of compound 5-7 (1.80 g, 6.43 mmol) in DCM (65 mL) was added NBS (2.28 g, 12.9 mmol) at 0 °C. After stirring at rt for 24 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography
(Petroleum ether/EtOAc = 15/1 (v/v)) to give compound 5-8 (860 mg, 38% yield) as a white solid. LC-MS (ESI): m/z 360 [M+H]+; !H NMR (500 MHz, CDC13): δ 7.44 (s, 1H), 6.98 (s, 1H), 3.88 (s, 3H), 3.65 (br s, 2H), 3.09 (s, 3H), 1.90 (br s, 2H), 1.52 (br s, 2H), 0.90 (br s, 2H), 0.75 (br s, 2H) ppm.
[0200] Step 7. To a solution of compound 5-8 (800 mg, 2.23 mmol) in CH2C12 (30 mL) was added BBr3 (4 N in DCM, 8.91 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction ixture was poured into ice-water (150 mL). The resulding mixture was extracted with DCM (50 mL x 2) and the combined organic extracts were washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 5-9 (670 mg, 87% yield) as a white solid. LC-MS (ESI): m/z 346
[M+H]+.
[0201] Step 8. To a solution of compound 5-9 (670 mg, 1.94 mmol) in THF (30 mL) were added DMAP (20 mg) and TEA (588 mg, 5.82 mmol). The resulting mixture was cooled to 0 °C and SEMC1 (643 mg, 3.87 mmol) was added. After stirring at rt for 1.5 hrs, the reaction mixture was poured into water (50 mL). The mixture was extracted with EtOAc (60 mL x 3) and the combined organic extracts were washed with brine (30 mL) and dried anhydrous Na2SC . The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 10/1 (v/v)) to give compound 5-10 (460 mg, 50% yield) as a white solid. LC-MS (ESI): m/z 498 [M+Na]+.
[0202] Step 9. To a solution of compound 5-10 (460 mg, 0.970 mmol) in DMF (6 mL) were added compound 1-11 (139 mg, 1 .16 mmol), Cul (9.3 mg, 0.050 mmol), Pd(PPh3)2Cl2 (68 mg, 0.097 mmol), P(f-Bu)3 (39 mg, 0.19 mmol) and piperidine (330 mg, 3.88 mmol). The resulting mixture was flushed with Ar and stirred at 80 °C overnight. Subsequently, the reaction mixture was added into water (60 mL) and extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with water (50 mL x 5) and dried with anhydrous Na2S04. The solvent was removed and the residue purified by column chromatography (Petroleum ether EtOAc = 10/1 to 6/1 (v/v)) to give compound 5-11 (300 mg, 60% yield) as a yellow oil. LC-MS (ESI): m/z 538 [M+Na]+.
[0203] Step 10. To a solution of compound 5-11 (280 mg, 0.54 mmol) in THF (15 mL) was added TBAF (851 mg, 3.26 mmol) under an atmosphere of Ar. After refluxing overnight, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 8/1 (v/v)) to give compound 5-12 (100 mg, 48% yield) as a yellow solid. LC-MS (ESI): m/z 86 [M+H]+; ¾ NMR (500 MHz, CDC13): δ 7.78
- 7.83 (m, 2H), 7.51 (s, 1H), 7.48 (s, 1H), 7.1 1 - 7.16 (m, 2H), 6.89 (s, 1 H), 3.64 - 3.69 (m,
2H), 3.16 (s, 3H), 1.96 (br s, 2H), 1.59 (br s, 2H), 1.01 (br s, 2H), 0.81 (br s, 2H) ppm.
[0204] Step 11. To a solution of compound 5-12 (80 mg, 0.21 mmol) in TFA (0.5 mL) and
CHC13 (0.5 mL) was added NIS (70 mg, 0.31 mmol) at rt. After stirring at for 3 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 6/1 (v/v)) to give compound 5-13 (80 mg, 75% yield) as a yellow solid. LC-MS (ESI): mlz 512 [M+H]+.
[0205] Step 12. To a solution of compound 5-13 (80 mg, 0.16 mmol) in DMF (3 mL) and MeOH (3 mL) were added Pd(PPh3)4 (91 mg, 0.080 mmol) and Et3N (64 mg, 0.64 mmol). The resulting mixture was flushed with CO and stirred at 60 °C for 4 hrs under an atmosphere of CO. Subsequently, the mixture was water (20 mL) and extracted with EtOAc (60 mL x 2). The combined organic extracts were washed with water (60 mL x 5) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 8/1 (v/v)) to give compound 5-14 (70 mg, quantitative yield) as a yellow solid. LC-MS (ESI): mlz 444 [M+H]+.
[0206] Step 13. To a solution of compound 5-14 (70 mg, 0.16 mmol) in MeOH/THF (1 mL/2 mL) was added LiOH (0.63 mmol). After stirring at 70 °C overnight, the reaction mixture was cooled to 0 °C and acidified with 1 N aq. HC1 (7 mL). The suspention was filtered and the solid was washed with water and dried in vacuo to give crude compound 5-15 (60 mg, quantitative yield) as a white solid, which was used for the next step without further purification. LC-MS (ESI): mlz 430 [M+H]+.
[0207] Step 14. To a solution of compound 5-15 (60 mg, 0.14 mmol) in DMF (1.5 mL) was added HATU (66 mg, 0.17 mmol). The resulting mixture was stirred at rt for 30 min and then DIPEA (181 mg, 1.40 mmol) and MeNH2 HCl (47 mg, 0.70 mmol) were added. The resulting mixture was stirred at rt for 20 min and poured into water (50 mL). The suspension was filtered and the solid was purified by silica gel column chromatography (Petroleum ether/ Acetone = 9/1 (v/v)) to give compound 5-16 (10.5 mg, 18% yield) as a white solid. LC- MS (ESI): mlz 443 [M+H]+; lH NMR (500 MHz, CDC13): δ 7.87 (m, 2H), 7.75 (s, 1H), 7.53 (s, 1H), 7.18 (m, 2H), 5.79 (s, 1 H), 3.64 (br s, 2H), 3.15 (s, 3H), 3.01 (d, / = 5 Hz, 3H), 1.95 (br s, 2H), 1.61 (br s, 2H), 1.02 (br s, 2H), 0.82 (s, 2H) ppm.
Figure imgf000129_0001
[0208] Step 1. Refer to Scheme 6. To a solution of compound 3-3 (4.35 g, 10.0 mmol) in DMF (40 mL) was added K2C03 (5.52 g, 40.0 mmol) and compound 6-1(1.79 g, 12.0 mmol). After stirring at 80 °C overnight, the reaction mixture was cooled to rt and poured into water (60 mL). The mixture was extracted with EtOAc (100 mL x 2) and the combined organic extracts were washed with water and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 10/1 (v/v)) to give compound 6-2 (4.53 g, 90% yield) as a yellow oil. LC-MS (ESI): m/z 526 [M+Na]+.
[0209] Step 2. To a solution of compound 6-2 (2.0 g, 4.0 mmol) in CH2C12 (80 mL) was added BC13 (1 N in DCM, 8.0 mmol) at -30 °C. After stirring at -30 to -20 °C for 30 rain, the reaction mixture was poured into ice-water (100 mL). The mixture was extracted with DCM (80 mL x 2) and combined organic extracts were washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 7/1 (v/v)) to give compound 6-3 (1.4 g, 76% yield) as a yellow solid. LC-MS (ESI): m/z 462 [M+H]+.
[0210] Step 3. To a solution of compound 6-3 (1.40 g, 3.04 mmol) in CH2C12 (40 mL) were added DMAP (19 mg, 0.15 mmol) and DIEA (0.590 g, 4.56 mmol), followed by Tf20 (1.03 g, 3.64 mmol) at 0 °C. After stirring at 0 °C for 20 min, the reaction mixture was added into ice water (50 mL). The organic layer was washed with water and brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 20/1 (v/v)) to give compound 6-4 (1 .6 g, 89% yield) as a colorless oil. LC-MS (ESI): mlz 594 [M+H]+.
[0211] Step 5. To a solution of compound 6-4 (1.00 g, 1.69 mmol) in 20 mL DMF was added Pd(OAc)2 (38 mg, 0.17 mmol), PPh3 (177 mg, 0.680 mmol), LiCl (79.0 mg, 1.86 mmol) and Et3N (1.00 mL, 6.75 mmol). The resulting mixture was flushed with Ar and stirred at 120 °C overnight. Subsequently, the mixture was cooled to rt and poured into 60 mL water. The resulting mixture was extracted with EtOAc (80 mL x 2) and the combined organic extracts was washed with water and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether EtOAc = 15/1 (v/v)) to give compound 6-5 (610 mg, 81 % yield) as a yellow solid. LC- MS (ESI): mlz 444 [M+H]+; Ή NMR (500 MHz, CDC13): δ 8.04 - 8.07 (m, 2H), 7.96 (s, 1H), 7.69 (s, 1H), 7.17 - 7.20 (m, 2H), 5.30 (s, 1H), 5.21 (d, / = 2.0 Hz, 1H), 4.42 (dd, Jj = 14.5 Hz, J2 = 7.0 Hz, 2H), 3.85 (br s, 2H), 2.87 (s, 3H), 2.53 (t, = 5.0 Hz, 2H), 1.96 (dd, // = 12 Hz, J2 = 6.0 Hz, 2H), 1.41 (t, J = 6.5 Hz, 3H) ppm.
[0212] Step 6. To a solution of compound 6-5 (300 mg, 0.680 mmol) in MeOH/THF (4 mL/8 mL) was added 2.0 N aq. LiOH (2.72 mL, 1.36 mmol). After stirring at 75 °C for 2 hrs, the reaction mixture was colled to rt and acidified with 2 N aq. HC1 to pH 5 - 6. The suspension was filtered and the solid was washed with water and dried in vacuo to give compound 6-6 (260 mg, 92% yield) as a white solid, which was used directiy for the next step without further purification. LC-MS (ESI): mlz 416 [M+H]+.
[0213] Step 7. To a solution of Et2Zn (1.1 M in toluene, 10 mL, 11 mmol) in 1 , 2- dichloroethane (10 mL) was added a solution of CH2I2 (5.87 g, 22 mmol) in 1, 2- dichloroethane (10 mL) at -78 °C under an atmosphere of N2. After stirring at -15 °C for 30 min, the mixture was cooled to -78 °C. Subsequently, a solution of compound 6-6 (200 mg, 0.481 mmol) in 1, 2-dichloroethane (15 mL) was added. The reaction mixture was then stirred at room temperature for 40 hrs and added 1 M aq. HC1 at 0 °C. The mixture was extracted with DCM (50 mL x 2) and the combined organic extracts were concentrated in vacuo. The residue was added THF (20 mL), MeOH (2.5 mL), water (2.5 mL) and LiOH (76 mg). After stirring at 70 °C for 2 hrs, the mixture was treated with 1 M aq. HC1 (1.5 mL) at 0 °C. The mixture was concentrated and the residue was extracted with DCM (50 mL x 4) and the combined organic extracts were dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel chromatography to give compound 5-15 (113 mg, 55% yield). LC-MS (ESI): m/z 430 [M+H]+; 1H NMR (500 MHz, CDC13): 6 8.04 (m, 3H), 7.57 (s, 1H), 7.20 (m, 2H), 3.68 (br s, 2H), 3.17 (s, 3H), 1.97 (br s, 2H), 1.64 (br s, 2H), 1.06 (br s, 2H). 0.86 (s, 2H) ppm. [0214] Step 8. To a solution of the compound 5-15 (60 mg, 0.14 mmol) in DMF (3.00 mL) was added HATU (64.0 mg, 0.168 mmol). The resulting mixture was stirred at rt for 30 min and 2 M CH3NH2 in THF (1.4 mmol) was added. After stimng at rt for 30 min, the reaction mixture was concentrated and the residue was purified by preparative HPLC to give compound 5-16 (20 mg, 32% yield) as a white powder. LC-MS (ESI): m/z 443 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.87 (m, 2H), 7.75 (s, 1H), 7.53 (s, 1H), 7.18 (m, 2H), 5.79 (s, 1H), 3.64 (br s, 2H), 3.15 (s, 3H), 3.01 (d, J = 5 Hz, 3H), 1.95 (br s, 2H), 1.61 (br s, 2H), 1.02 (br s, 2H), 0.82 (s, 2H) ppm.
[0215] Synthesis of compound 6-7. A solution of Et2Zn (1.1 M in toluene, 0.22 mmol) in DCM (2 mL) was drop-wisely added CH2I2 (1 17 mg, 0.440 mmol) at -78 °C under an atmosphere of N2. After stirring at -78 °C for 30 min, to the reaction mixture was drop-wisely added a mixture of compound 6-5 (4.43 mg, 0.01 mmol) and TFA (0.01 mL) in DCM (1 mL). Subsequently, the reaction mixture was stirred at 60 °C for 30 min and then cooled to rt and diluted with water (25 mL) and DCM (50 mL). The organic layer was separated, washed with brine (25 mL), and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 6-7. LC-MS (ESI): m/z 458.1 [M+H]+.
Figure imgf000131_0001
[0216] Synthesis of compound 7-1. Refer to Scheme 7. To a solution of compound 6-6 (250 mg, 0.60 mmol) in DMF (5 mL) was added HATU (275 mg, 0.72 mmol). The resulting mixture was stirred at rt for 30 min before DIEA (154 mg, 1.2 mmol) and MeNH2 HCl (122 mg, 1.8 mmol) were added in. After stirring at rt for 20 min, the reaction mixture was poured into water (50 mL). The suspension was filtered and the solid was washed with water and dried in vacuo. The solid was dissolved in DCM (2 mL) and the resulting solution was added into hexane (80 mL). The suspension was filtered and the solid was dried in vacuo to give compound 7-1 (230 mg, 90% yield) as a white solid. LC-MS (ESI): m/z 429 [M+H]+; H NMR (500 MHz, CDC13): δ 7.88 - 7.91 (m, 2H), 7.74 (s, 1H), 7.67 (s, 1H), 7.19 (t, J = 9.0 Hz, 2H), 5.82 (br s, 1H), 5.28 (s, 1H), 5.19 (d, J = 1.0 Hz, 1 H), 3.83 (br s, 2H), 3.01 (d, J = 5.5 Hz, 3H), 2.86 (s, 3H), 2.51 (t, J = 5.0 Hz, 2H), 1.92 - 1 .96 (m, 2H) ppm.
[0217] Synthesis of compound 7-2. To a solution of compound 7-1 (40 mg, 0.094 mmol) in DCM (4 mL) was flushed with 03 at -78 °C until compound 7-1 disappeared (about 1 min). Subsequently, the reaction mixture was saturated with N2 and PPh3 (591 mg, 0.26 mmol) was added. After stirring at rt for 3 hrs, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography to give compound 7-2 (20 mg, 50% yield). LC-MS (ESI): m/z 431 [M+H]+; lU NMR (500 MHz, CDC13): δ 7.88 (dd, J; = 8.5 Hz, J2 = 6.0 Hz, 2H), 7.71 (s, 1H), 7.54 (s, 1H), 7.19 (t, = 8.5 Hz, 2H), 5.80 (br s, 1H), 4.08 - 4.13 (m, 1H), 3.25 - 3.28 (m, 2H), 3.08 (s, 3H), 3.01 (d, / = 4.5 Hz, 3H), 1.89 - 2.04 (m, 2H), 1.67 (br s, 2H), 1.47 (d, J = 7.0 Hz, 3H) ppm.
[0218] Synthesis of compound 7-3. To a solution of compound 7-1 (70 mg, 0.16 mmol) in EtOAc (30 mL) was added 10% Pd/C (20 mg). The resulting mixture was flushed with H2 and stirred at rt for 3 hr. The reaction mixture was filtered; the filtrate was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 7-3 (40 mg, 58% yield) as a white solid. LC-MS (ESI): m/z 431 [M+HJVH NMR (500 MHz, CDC13): δ 8.17 (s, 1H), 7.99 (dd, J; = 8.5 Hz, J2 = 6.0 Hz, 2H), 7.68 (s, 1 H), 7.21 (t, 8.5 Hz, 2H), 5.89 (br s, 1H), 3.90 (t, = 6.0 Hz, 2H), 3.03 - 3.05 (m, 6H), 2.85 (t, = 6.0 Hz, 2H), 2.04 - 2.08 (m, 2H) ppm. Compound 7-3 was separated into a pair of enantiomers: enantiomer 7-3_A (tR = 9.420 min) and enantiomer 7-3JB (tR = 12.173 min) detected by UV absorption at 214 nm on a ChiralPak® IA 4.0 mm x 150 mm x 5 μηι column (eluent: hexane/EtOH = 70/30 (v/v) with 0.1 % diethylamine (v/v) and flow rate: 1 mL/min).
[0219] Synthesis of compound 7-4. To a solution of compound 7-1 (50 mg, 0.12 mmol) in
DCM (4 mL) was added CF3COOH (0.02 mL). After stirring at rt overnight, the reacti0n mixture was concentrated. The residue was dissolved in DCM (0.5 mL) and the resulting solution was added into hexane (20 mL). The suspension was filtered and the solid was dried in vacuo to give compound 7-4 (30 mg, 58% yield). LC-MS (ESI): m/z 429 [M+H]+; lH
NMR (500 MHz, CDC13): δ 7.89 (dd, J} = 8 Hz, J2 = 5.5 Hz, 2H), 7.82 (s, 1 H), 7.67 (s, 1H),
7.22 (t, / = 8.5 Hz, 2H), 6.06 (t, J = 6.5 Hz, 1 H), 5.80 (br s, 1H), 3.75 - 4.50 (m, 2H), 3.01 (d,
/ = 4.5 Hz, 3H), 2.78 (s, 3H), 2.22 (s, 3H), 2.18 (t, J = 6 Hz, 2H) ppm.
[0220] Synthesis of compound 7-5. To a solution of compound 7-2 (40 mg, 0.093 mmol) in MeOH (1 mL) and THF (1 mL) was added NaBH4 (10 mg, 0.28 mmol). After stirring at 0
°C for 10 min, the reaction was quenched by adding several drops of acetone. The solvent was removed and the residue was dissolved in EtOAc (25 mL). The mixture was washed with water and dried with anhydrous Na2S04. The solvent was removed; the residue was dissolved in DCM (0.5 mL) and the resulting solution was added into hexane (20 mL). The suspension was filtered and the .solid was dried in vacuo to give compound 7-5 (10 mg, 25% yield) as a white solid. LC-MS (ESI): m/z 433 [M+H]+; lH NMR (500 MHz, CDC13): δ 7.92-7.94 (m, 3H), 7.56 (s, 1H), 7.18 (t, J = 8.5 Hz, 2H), 5.87 (br s, 1H), 5.15 (br s, 1 H), 3.83 (br s, 1H), 3.12 (s, 3H), 3.01 - 3.02 (m, 4H), 2.32 (br s, 1 H), 2.03 (br s, 3H) ppm.
Figure imgf000133_0001
[0221] Step 1. Refer to Scheme 8. To a stirred solution of compound 4-2 (9.00 g, 18.9 mmol) in DMF (100 mL) were added Et3N (7.84 mL, 56.6 mmol), Pd(OAc)2 (212 mg, 0.94 mmol), dppp (469 mg, 1.13 mmol) and butyl vinyl ether (12.1 mL, 94.4 mmol) under an atmosphere of Ar. After stirring at 100 °C for 2 hrs, the reaction mixture was concentrated. The residue was diluted with EtOAc (250 mL) and the resulting mixture was washed with water (100 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 16/1 (v v)) to give compound 8-1 (3.9 g, 48% yield) as a yellow solid. LC-MS (ESI): m/z All [M+H]+.
[0222] Step 2. A solution of compound 8-1 (3.90 g, 9.13 mmol) in THF (60 mL) was added 1 N aq. HC1 (10 mL) at rt. After stirring at rt for 15 min, the reaction mixture was concentrated and the residue was diluted with DCM (100 mL). The resulting mixture was washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 8-2 (3.27 g, 96% yield) as a yellow solid, which was used for the next step without further purification. LC-MS (ESI): m/z 372 [M+H]+.
[0223] Step 3. To a stirred solution of compound 8-2 (2.00 g, 5.38 mmol) in EtOAc (50 mL) was added SnCl22H20 (3.47 g, 16.2 mmol). After stirring at 80 °C for 1 hr, the reaction mixture was added sat. aq. NaHC03 (50 mL) and the resulting mixture was stirred at rt for 30 min. Subsequently, the mixture was filtered through Celite®545 and the the filtered cake was washed with EtOAc (50 mL x 3). The organic layer of the filtrate was washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 8-3 (1.8 g, 98% yield) as a brown solid, which was used for the next step without further purification. LC-MS (ESI): m/z 342 [M+H]+.
[0224] Step 4. To a stirred solution of compound 8-3 (900 mg, 2.64 mmol) in anhydrous pyridine (15 mL) was added MsCl (0.25 mL, 3.17 mmol) at 0 °C. After stirring at rt for 1 hr, the reaction mixture was diluted with EtOAc (100 mL) and the resulting mixture was washed with 2 N aq. HC1 (20 mL x 2) and H20 (50 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/DCM/EtOAc = 8/4/1 (v/v ) to compound 8-4 (520 mg, 47% yield) as a yellow solid. LC-MS (ESI): m/z 442 [M+Na]+.
[0225] Step 5. To a solution of compound 8-4 (380 mg, 0.91 mmol) in MeOH (10 mL) and THF (10 mL) was added NaBH4 (172 mg, 4.54 mmol) in several portions at 0 °C. After stirring at 0 °C for 15 min, the reaction was quenched by adding acetone (1 mL). The mixture was concentrated and the residue was diluted with EtOAc (100 mL). The resulting mixture was washed with 2 N aq. HC1 (20 mL) and H20 (50 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 8-5 (240 mg, 63% yield), which was used for the next step without further purification. LC-MS (ESI): m/z 444 [M+Na]+.
[0226] Step 6. To a stirring solution of compound 8-5 (50 mg, 0.12 mmol) in THF (15 mL) was added NaH (24 mg, 0.6 mmol) at 0 °C under an atmosphere of Ar. After stirring at rt for 15 min, the mixture was added compound 8-6 (106 mg, 0.24 mmol) (prepared following the procedure described in Angew. Chem. Intl. Ed. 2008, 47, 3784) at 0 °C and the resulting mixture was stirred at 0 °C for 3 hrs and rt overnight. Subsequently, saturated aq. NH4C1 (10 mL) was added to quench the reaction and the mixture was concentrated. The residue was diluted with EtOAc (50 mL) and the mixture was washed with brine (10 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 4/1 (v/v)) to give compound 8-7 (30 mg, 56% yield) as a white solid. LC-MS (ESI): m/z 448 [M+H]+. [0227] Step 7. To a solution of compound 8-7 (40 mg, 0.09 mmol) in MeOH/THF (2 mL/4 mL) was added 2.0 N aq. LiOH (0.18 mmol, 0.36 mmol). After stirring at 75 °C for 3 hrs, the reaction mixture was cooled to 0 °C and acidified with 2N aq. HC1 adjust pH value to 5-6. Subsequently, the suspension was filtered and the solid was washed with water and dried in vacuo to give compound 8-8 (38 mg, 97% yield) as a white solid, which was used for the next step without further purification. LC-MS (ESI): mlz 442 [M+Na]+.
[0228] Step 8. To a solution of compound 8-8 (40 mg, 0.10 mmol) in DMF (3 mL) was added HATU (43 mg, 0.12 mmol). The resulting mixture was stirred at rt for 60 min and DIEA (0.16 mL, 0.95 mmol) and MeNH2 HCl (20 mg, 0.29 mmol) were added. After stirring at rt for 15 min, the reaction mixture was added into water (30 mL). The suspension was filtered and the solid was washed with water and dried in vacuo. The residue was dissolved in DCM (1.5 mL) and the solution was added into hexane (40 mL). The resulting suspension was filtered and the solid was dried in vacuo to give compound 8-9 (23 mg, 56% yield). LC- MS (ESI): mlz 433 [M+H]+; 1H NMR (500 MHz, CDC13): δ 7.88 - 7.91 (m, 3H), 7.62 (s, 1H), 7.20 (t, / = 8.5 Hz, 2H), 5.80 (br s, 1H), 4.96 (q, J = 6.5 Hz, 1H), 4.15 - 4.18 (m, 1H), 4.02 - 4.09 (m, 2H), 3.29 - 3.34 (m, 1H), 3.15 (s, 3H), 3.01 (d, J = 5.0 Hz, 3H), 1.74 (d, J = 6.5 Hz, 3H) ppm. Compound 8-9 was separated into a pair of enantiomers: enantiomer 8-9_A (tR = 3.34 min) and enantiomer 8-9_B (tR = 3.89 min) detected by UV absorption at 214 nm on a Daicel CHIRALPAK AS-H column (eluent: MeOH/liquid C02 = 10/90 (v/v), flow rate: 60 g/min and back pressure : 100 bar).
Figure imgf000136_0001
[0229] Step 1. Refer to Scheme 9. To a solution of compound 4-2 (2.37 g, 5.00 mmol) in anhydrous THF (70 mL) were added commercially available 2-ally-4,4,5,5-tetramethyl-l,3,2- dioxaborolane (1.09 g, 6.50 mmol), Pd(PPh3)4 (0.58 g, 0.50 mmol) and CsF (3.0 g, 19.87 mmol) under an atmosphere of Ar. The resulting mixture stirred at 80 °C 3 hrs and concentrated. The residue was diluted with water (100 mL) and extracted with EtOAc (50 mL x 3). The combined organic extracts were washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 200/1 (v/v)) to give compound 9-1 (670 mg, 36% yield) as a yellow solid. LC-MS (ESI): m/z 370 [M+H]+.
[0230] Step 2. A solution of compound 9-1 (670 mg, 1.82 mmol) in DCM (110 mL) was purged with O3 until reaction solution turned to be light blue at -78 °C. Subsequently, PPh3 (1.19 g, 4.5 mmol) was added and the mixture was stirred at rt overnight. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether EtOAc = 20/1 to 10/1 (v/v)) to give compound 9-2 (570 mg, 82% yield) as a yellow solid. LC-MS (ESI): m/z 372 [M+H]+.
[0231] Step 3. To a solution of compound 9-2 (420 mg, 1.13 mmol) in MeOH (11 mL) and THF (1 1 mL) was added NaBH4 (172 mg, 4.53 mmol) at 0 °C. After stirring at 0 °C for 30 min, several drops of acetone was added to quench the reaction. The mixture was concentrated and the residue was diluted with water (50 mL) and EtOAc (50 mL). The aq. phase was extracted with EtOAc (50 mL x 2) and the combined organic extracts were washed with brine and dried with anhydrous Na9S04. The solvent was removed and the residue was dried in vacuo to give crude compound 9-3 (422 mg, quantitative yield), which was used for the next step without further purification. LC-MS (ESI): m/z 374 [M+H]+.
[0232] Step 4. To a solution of compound 9-3 (410 mg, 1.10 mmol) in EtOAc (150 mL) was added 10% Pd/C (400 mg). The resulting mixture was flushed with H2 and stirred at rt overnight under an atmosphere of H2. Subsequently, the reaction mixture was filtered through Celite®545 and the filtered cake was washed with EtOAc (50 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 9-4 (372 mg, 99% yield). LC-MS (ESI): m/z 344 [M+H]+.
[0233] Step 5. To a solution of compound 9-4 (372 mg, 1.08 mmol) in CH2C12 (10 mL) were added DMAP (20 mg), Et3N (654 mg, 6.48 mmol) and MsCl (500 mg, 4.33 mmol) at 0 °C. After stirring at 0 °C for 30 min and rt for 1.5 hrs, the reaction mixture was added saturated aq. NaHC03 (5 mL). The mixture was diluted with DCM (50 mL) and the organic layer was washed with brine and dried with anhydrous Na2SC>4. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 4/1 (v/v)) to give compound 9-5 (200 mg, 46% yield) as a yellow solid. LC-MS (ESI): m/z 404 [M+H]+.
[0234] Step 6. To a solution of compound 9-5 (200 mg, 0.500 mmol) in MeOH/THF (6 niL/12 mL) was added LiOH (2.0 N aq. solution, 2.0 mmol). The resulting mixture was stirred at 70 °C for overnight and then acidified with IN aq. HC1 (aq, 4 mL) at 0 °C. The suspension was filtered and the solid was washed with water and dried in vacuo to give crude compound 9-6 (170 mg, 90% yield) as a white solid, which was used for the next step without further purification. LC-MS (ESI): m/z 376 [M+H]+.
[0235] Step 7. To a solution of compound 9-6 (70 mg, 0.18 mmol) in DMF (4 mL) was added HATU (85 mg, 0.22 mmol). The resulting mixture was stirred at rt for 30 min, followed by adding DIEA (0.33 mL, 1.8 mmol) and MeNH2 HCl (76.0 mg, 1.12 mmol). After stirring at rt for 20 min, the reaction mixture was added into water (50 mL). The resulting suspension was filtered and the solid was washed with water and dried in vacuo.
Subsequently, the residue was dissolved in DCM and the solution was added into hexane to precipitate the product. The resulting suspension was filtered and the solid was dried in vacuo to give compound 9-7 (40 mg, 55% yield) as a white solid. LC-MS (ESI): m/z 389 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.85 - 7.88 (m, 2H), 7.64 (s, 1H), 7.57 (s, 1H), 7.18 (t, / = 8.5 Hz, 2H), 5.82 (br s, 1H), 4.06 (t, J = 8.0 Hz, 2H), 3.23 (t, / = 8.0 Hz, 2H), 2.99 (d, / = 4.5 Hz, 3H), 2.90 (s, 3H) ppm.
Figure imgf000138_0001
Cs2C03, NWIP
[0236] Step 1. Refer to Scheme 10. To a mixture of ;Pr2NH (27 mL, 190.7 mmol) in THF (140 mL) was dropwisely added nBuLi (2.5M in Hexanes, 73 mL, 181.6 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 min, then warmed up to rt with stirring for another 20 min. Subsequently, to a mixture of compound 10-1 (10 g, 45.4 mmol) (prepared by following the procedure described in WO2009051306) and I2 (28.5g, 114 mmol) in THF (70 mL) was dropwisely added LDA solution freshly prepared at -78 °C. Compound 10-1 was consumed when 3.5 equiv of LDA was added and the reaction was quenched by adding sat. aq. NH4CI. The mixture was wanned up to rt and concentrated. The residue was diluted with water and extracted by EtOAc (100 mL x 3). The organic extracts were combined, washed by brine, and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Hexanes/EtOAc = 5/1 (v/v)) to give compound 10-2 (13 g, 83% yield) as a yellow solid. :H NMR (300 MHz, CDC13): δ 7.48 (d, 1H), 7.39 (dd, 1H), 6.84 (dd, 1H), 4.42 (q, 2H), 3.83 (s, 3H), 1.45 (t, 3H) ppm.
[0237] Step 2. A mixture of compound 10-1 (3.34 g, 10 mmol), 10-2 (1.40 g, 10 mmol) and Pd(PPh3)4 (0.58 g, 0.5 mmol) in 2 M aq. Na2C03 (15 mL) and dioxane (75 mL) was degassed and refilled with nitrogen. The process was repeated 3 times. The mixture was then stirred at 90 °C in a sealed flask for 24 hrs. After being cooled down, the reaction mixture was concentrated. The residue was partitioned between DCM and water. The aqueous layer was extracted with DCM several times. The combined organic extracts were dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/hexanes = 1/20 to 1/15 (v/v)) to give compound 10-3 (2.54 g, 88% yield). LC-MS (ESI): m/z 315 [M+H]+; lU NMR (300 MHz, CDC13): δ 7.68 (m, 1H), 7.57 (d, 7 = 1.3 Hz, 1H), 7.46 (m, 1H), 7.44 (d, 7 = 8.9 Hz, 1H), 7.16 - 7.30 (m, 2H), 6.98 (dd, 7 = 1.3 and 8.9 Hz, 1H), 4.32 (q, 7 = 7.3 Hz, 2H), 3.92 (s, 3H), 1.27 (t, 7 = 7.3 Hz) ppm.
[0238] Step 3. To a solution of compound 10-3 (2.54 g, 8.7 mmol) in chloroform at was slowly added 70% HN03 (w/w, 4.7 mL, 105 mmol). After completing the addition, the solution was stirred at -20 °C for 30 min and rt overnight. The reaction mixture was diluted with dichloromethane (150 mL), washed with water (50 mL x 5), and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/hexanes = 1/9 to 1/6 (v/v)) to give compound 10-4 (1.98 g, 68% yield). !H NMR (300 MHz, CDC¾): δ 8.10 (s, IH), 7.79 (s, IH), 7.69 (m, IH), 7.56 (m, IH), 7.20 - 7.36 (m, 2H), 4.35 (q, J = 7.3 Hz, 2H), 4.05 (s, 3H), 1.25 (t, J = 7.3 Hz) ppm.
[0239] Step 4. To a solution of compound 10-4 (1.98 g, 5.91 mmol) in dichloromethane at - 45 °C was slowly added a solution of BBr3 (0.68 mL, 7.1 mmol) in dichloromethane (6 mL). The resulting mixture was stirred at the temperature for 30 min, and then in an ice-water bath for 30 min. Subsequently, the cold reaction mixture was diluted with dichloromethane (100 mL), and ice water (10 mL) was slowly added into the solution to destroy the excess amount of BBr3. The organic layer was washed with water and dried over anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give a crude de -methylated intermediate of compound 10-4, which was used for the next step without further purification. LCMS (ESI): m/z 344 [M-l]+. Subsequently, Cs2C03 (3.85 g, 12 mmol) was added into a solution of the above crude product in NMP (20 mL). After stirring at rt for 10 min, the reaction mixture was added 2-bromopropane (0.67 mL, 7.1 mmol) and the resulting mixture was stirred at rt for 2 hrs and at 50 °C for 18 hrs. The reaction mixture was added into ice water (150 mL) and the mixture was extracted with EtOAc (50 mL x 3). The combined extracts were washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 10-5 (2.15 g, 94% yield). Ή NMR (300 MHz, CDC13): δ 8.04 (s, IH), 7.78 (s, IH), 7.68 (m, IH), 7.57 (m, IH), 7.18 - 7.36 (m, 2H), 7.73 (m, IH), 4.34 (q, J = 7.3 Hz, 2H), 1.44 (d, J = 7.4 Hz, 6H), 1.27 ( t, / = 7.3 Hz, 3H) ppm.
Figure imgf000139_0001
[0240] Synthesis of compound 11-2. Refer to Scheme 1 1. To a solution of compound 11-1 (100 mg, 0.22 mmol) in THF (6.0 mL) and water (1.5 mL), Os04 (1.5 mL, 4 % in water, 0.23 mmol) was added at rt. The reaction was stirred for 5 min and then NMO (0.028 mL, 0.027 mmol) was added. After stirring for 4 hrs, the reaction was quenched by adding Na2S03 (454 mg, 3.6 mmol). The reaction was extracted with dichloromethane (25 mL x 2) and the extracts were combined, washed with brine, and dried anhydrous Na2S04. The solvent was removed and the residue was re-dissolved in dichloromethane (5 mL). Subsequently, NaI04 (103 mg, 0.48 mmol), silica gel (650 mg) and water (0.2 mL) were added to the mixture at rt. After stirring for 4 hrs, the reaction was diluted with dichloromethane (50 mL), washed with brine, and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/hexanes = 1/10 (v/v)) to give compound 11-2 (70 mg, 70% yield). LC-MS (ESI): m/z 449 [M+H]+; Ή NMR (300 MHz, CDC13): δ 8.23 (s, 1H), 7.68 - 7.80 (m, 1H), 7.67 (s, 1H), 6.95 - 7.10 (m, 2H), 5.80 - 5.81 (m, 1H), 3.89 (t, J = 6.3 Hz, 2H), 3.03 (s, 3H), 2.99 (d, J = 4.9 Hz, 3H), 2.83 - 2.97 (m, 2H), 2.02 - 2.08 (m, 2H) ppm.
[0241] Synthesis of compound 11-3. To a solution of compound 11-1 (65 mg, 0.14 mmol) in THF (6.0 mL), BH3 SMe2 (2M in THF, 0.22 mL, 0.44 mmol) was added at rt. After stirring at rt overnight, 3 N aq. NaOH (0.42 mL, 1.26 mmol) was slowly added. After stirring at rt for 30 min, H202 (30% (w/w) in water, 0.42 mL) was added and the resulting mixture was stirred at rt for another 30 min. Subsequently, the reaction mixture was diluted with EtOAc (50 mL) and the organic layer was washed with brine and water and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/hexanes = 1/10 (v/v)) to give compound 11-3 (50 mg, 77% yield). LC-MS (ESI): m/z 465 [M+H]+; lU NMR (300 MHz, CDC13): δ 7.64 - 7.69 (m, 1H), 7.26 (s, 1 H), 7.45 (br. s, 1 H), 6.85 - 6.98 (m, 2H), 4.04 - 4.15 (m, 1H), 3.55 - 3.80 (m, 3H), 3.83 - - 1.95 (m, 4H) ppm.
Figure imgf000140_0001
[0242] Step 1. Refer to Scheme 12. A solution of Br2 (1 M in AcOH, 10 mL, 10 mmol) was slowly added into a solution commercially available compound 12-1 (1.24 g, 10 mmol) in AcOH (35 mL) at rt. After stirring at rt for 1 hr, the reaction mixture was filtered and the solid was dried in vacuo to give compound 12-2 (1.41 g, 69% yield). Ή NMR (300 MHz, CD3OD): δ 7.84 (s, 1 H), 6.29 (s, 1 H), 3.87 (s, 3H) ppm.
[0243] Step 2. A mixture of compound 12-2 (1.41 g, 6.9 mmol) and 2-bromo-3-(4-fluoro- phenyl)-3-oxo-propionic acid ethyl ester (12-3) (1.01 g, 3.5 mmol) in ethanol (100 mL) was stirred at 70 °C for 22 hrs. The solvent was removed and the residue was partitioned between DCM (50 mL) and water (25 mL). The organic layer was washed with sat. aq. Na2C03 solution and water and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/DCM = 1/10 (v/v)) to give compound 12-4 (0.90 g, 65% yield). lH NMR (300 MHz, CDC13): δ 9.57 (s, 1H), 7.74 - 7.78 (m, 2H), 7.09 - 7.15 (m, 2H), 7.04 (s, 1H), 4.31 (q, J = 7.2 Hz, 2H), 4.00 (s, 3H), 1.25 (t, / = 7.2 Hz, 3H) ppm.
[0244] Step 3. A solution of Li OH (0.25 g, 6.0 mmol) in water (4.5 mL) was added into a solution of compound 12-4 (0.90 g, 2.3 mmol) in THF (9 mL). After stirring at 50 °C for 24 hrs, the reaction mixture was acidified to pH ~ 3.0 by adding 1 N aq. HC1. The solvent was removed and the residue was dried in vacuo to give crude compound 12-5, which was used for the next step without further purification. LC-MS: m/z 365 [M+H]+.
[0245] Step 4. A mixture of compound 12-5 (0.83 g, 2.28 mmol), CH3NH2 HC1 (0.31 g, 4.56 mmol), EDC HCl (0.66 g, 3.42 mmol), HOBt H20 (0.52 g, 3.4 mmol) and DIPEA (1.88 mL, 1 1.4 mmol) in DMF (22 mL) was stirred at 50 °C for 18 hrs. The reaction mixture was added into ice water (250 L) and filtered. The solid was washed with water and dried in vacuo to give crude compound 12-6. Ή NMR (300 MHz, CDC13): δ 9.70 (s, 1 H), 7.66 - 7.72 (m, 2H), 7.18 -7.24 (m, 2H), 6.97 (s, 1H), 5.65 (broad s, 1H, NH), 4.00 (s, 3H), 2.88 (d, J = 5.1 Hz, 3H) ppm.
[0246] Step 5. BBr3 (1.73 mL, 19 mmol) was slowly added into a solution of compound 12-6 (0.68 g, 1.8 mmol) in DCM (4 mL) at 0 °C. The resulting reaction mixture was stirred at rt for 16 hrs under an atmosphere of N2 and treated with ice water (25 mL). After adjusting the pH of the mixture to basic using 5 N aq. NaOH, the mixture was extracted with DCM (25 mL x 3). The combined organic extracts dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 12-7 (0.36 g, 55% yield). LC-MS: m/z 366 [M+H]+.
[0247] Step 6. A mixture of compound 12-7 (0.36 g, 1. 0 mmol), 5-bromo-l-pentene (163 mg, 1.1 mmol) and K2C03 (113 mg, 2.0 mmol) in DMF (12 mL) was stirred at 50 °C for 8 hrs. The reaction mixture was poured into water and the precipitate was collected by filtration. The crude product was purified by silica gel column chromatography (EtOAc/DCM = 1/7 (v/v)) to give compound 12-8 (0.21 g, 49% yield). LC-MS: m/z 432 [M+H]+; Ή NMR (300 MHz, CDCI3): δ 9.67 (s, 1H), 7.66 - 7.72 (m, 2H), 7.17 - 7.24 (m, 2H), 6.93 (s, 1H),
5.69 - 5.97 (m, 1H), 5.68 (br s, 1H), 5.02 - 5.16 (m, 2H), 4.08 (t, J = 6.8 Hz, 2H), 2.88 (d, / = 5.2 Hz, 3H), 2.28 - 2.37 (m, 2H), 1.96 - 2.06(m, 2H) ppm.
[0248] Step 7. A mixture of compound 12-8 (200 mg, 0.46 mmol), Pd(OAc)2 (10.3 mg, 0.046 mmol), PPh3 (48.5 mg, 0.19 mmol), LiCl (21.5 mg, 0.51 mmol) and Et3N (0.26 mL, 1.8 mmol) in DMF (6.0 mL) was degassed and refilled with N2. The process was repeated for 3 times. After stirring at 120 °C for 18 hrs, the mixture was added into ice water (100 mL). The suspension was filtered and the solid was purified by silica gel column chromatography (EtOAc/DCM =1/7 (v/v)) to give a mixture of compounds 12-9 and 12-10 (100 mg, 62% yield) at a ratio of 3/1 determined by proton NMR. LC-MS: m/z 352 [M+H]+. Compound 12- 9: XH NMR (300 MHz, CDC13): δ 9.48 (s, 1H), 6.68 - 7.72 (m, 2H), 7.18 - 7.24 (m, 2H), 7.13 (s, 1H), 5.65 (br s, 1H), 5.37 (s, 1H), 5.16 (s, 1H), 4.28 - 4.34 (m, 2H), 2.87 (d, / = 5.2 Hz, 3H), 2.58 - 2.66 (m, 2H), 2.05 - 2.12 (m, 2H) ppm.
[0249] Synthesis of compound 12-11. A mixture of compounds 12-9 and 12-10 (10 mg,
0.028 mmol) and 10% Pd C (5 mg) in ethanol (4 mL) was stirred at rt for 6 hrs under an atmosphere of H2. The mixture was filtered through Celite®545 and the filtered cake was washed with DCM (20 mL x 2). The filtrate was concentrated and the residue was purified by column chromatography (EtOAc/DCM = 1/7 (v/v)) to give compound 13-11 (8 mg, 80% yield). LC-MS: m/z 354 [M+H]+; Ή NMR (300 MHz, CDC13): δ 9.28 (s, 1H), 7.72 - 7.78 (m, 2H), 7.63 (s, 1 H), 7.16 - 7.28 (m, 2H), 6.06 - 6.14 (m, 1H), 4.16 - 4.20 (m, 2H), 3.18 - 3.28 (m, 1H), 2.91 (d, / = 5.2 Hz, 3H), 2.08 - 2.20 (m, 1H), 1.90 - 2.05 (m, 2H), 1.68 - 1.78 (m, 1H), 1.42 (d, / = 7.2 Hz, 3H) ppm.
[0250] Synthesis of compound 12-10. A solution of compounds 12-9 and 12-10 (28 mg) in
CF3C02H (3 mL) was stirred at 70 °C for 48 hrs. The solvent was removed and the residue was diluted with DCM (25 mL). The mixture was with sat. aq. NaHC03 and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (EtOAc/DCM = 1/7 (v/v)) to give compound 12-10 (22 mg, 79% yield). LC-MS (ESI): m/z 352 [M+H]+; XH NMR (300 MHz, CDC13): 5 9.63 (s, 1H), 7.65 -
7.70 (m, 2H), 7.18 - 7.26 (m, 3H), 6.04 - 6.08 (m, 1H), 5.66 - 5.74 (m, 1H), 4.29 (t, J = 5.4 Hz, 2H), 2.60 (d, / = 4.8 Hz, 3H), 2.64 - 2.70 (m, 2H), 2.26 (s, 3H) ppm.
Figure imgf000143_0001
Figure imgf000143_0002
[0251] Step 1. Refer to Scheme 13, to a solution of compound 13-1 (10.0 g, 64.9 mmol) in EtOH (400 mL) was added 10% Pd/C (w/w) (4.60 g). The reaction mixture was allowed to stir at rt under an atmosphere of ¾ for 24 hrs. Subsequently, the reaction mixture was filtered through Celite®545 and the filtered cake was washed with EtOAc (100 mL x 3). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 13-2 (8.0 g, 99% yield) as a dark red oil, which was used for the next step without further purification. LC-MS (ESI): m/z 125 [M+H]+.
[0252] Step 2. To a stirring solution of compound 13-2 (7.99 g, 64.4 mmol) and Et3N (59.4 mL, 386 mmol) in DCM (100 mL) was dropwisely added MsCl (6.50 mL, 193 mmol) at 0 °C over 30 min. After stirring at rt for 2 hrs, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Petroleum ether/acetone = 6/1 to 3/2 (v/v)) to give compound 13-3 (6.9 g, 38% yield) as a yellow solid. LC-MS (ESI): m/z 281 [M+H]+; Ή NMR (500 MHz, CDC13): δ 8.56 - 8.57 (d, / = 5 Hz, 1H), 8.42 (s, 1H), 6.97 - 6.98 (d, / - 5 Hz, 1H), 4.00 (s, 3H), 3.45 (s, 6H) ppm.
[0253] Step 3. To a solution of 0-(mesitylsulfonyl)hydroxy amine (MSH) (17.8 mmol) in DCM (100 mL) was added compound 13-3 (5.00 g, 17.8 mmol). After stirring at rt overnight, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 13-4, which was used for the next step without further purification. LC-MS (ESI): m/z 297 [M+Hf. [0254] Step 4. To a solution of compound 13-4 (crude, 17.8 mmol) and ethyl 3-(4- fluorophenyl)propiolate (3.43 g, 17.8 mmol) in DMF (80 mL) was added K2C03 (9.82 g, 71.2 mmol) in one portion. After stirring at rt for 2hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 5/1 to 3/1 (v/v)) to give compound 13-5. LC-MS (ESI): m/z 408 [M+H]+.
[0255] Step 5. To a solution of compound 13-5 (1.00 g, 2.45 mmol) in DMF (25 mL) were added K2C03 (1.02 g, 7.36 mmol) and 5-bromopent-l-ene (732 mg, 4.91 mmol) at rt. After stirring at 80 °C for 2 hrs, the reaction mixture was poured into ice water (100 mL). The resulting solution was extracted with EtOAc (100 mL x 3) and the organic extracts were combined, washed with water (50 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 3/1 (v/v)) to give compound 13-6 (1.0 g, 86% yield) as a yellow oil. LC-MS (ESI): m/z 476 [M+H]+.
[0256] Step 6. A mixture of 2-(diethylamino)ethanefhiol-HCl (535 mg, 3.15 mmol) and t- BuONa (637 g, 6.62 mmol) in anhydrous DMF (25 mL) was stirred at rt for 15 min under an atmosphere of N2. Subsequently, a solution of compound 13-6 (1.0 g, 2.1 mmol) in anhydrous DMF (5 mL) was added and the resulting mixture was refluxed for 30 min, poured into ice water (50 mL) and kept at 0 °C. The pH value of the reaction mixture was adjusted to 3 to 4 by adding 1 N aq. HC1 and the resulting mixture was extracted with EtOAc (50 mL x 3). The organic extracts were combined, washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Hexanes/EtOAc = 2/1 (v/v)) to give compound 13-7 (370 mg, 38% yield) as a yellow oil. LC-MS (ESI): m/z 462 [M+H]+.
[0257] Step 7. To a solution of compound 13-7 (164 mg, 0.35 mmol) and DMAP (2.0 mg, 0.016 mmol) in CH2C12 (6 mL) was added Et3N (100 μL·, 0.72 mmol), followed by TfzO (70 \lh, 0.42 mmol) at 0 °C. After stirring at 0 °C for 30 min, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 7/1 (v/v)) to give compound 13-8 (102 mg, 48% yield) as a yellow oil. LC-MS (ESI): m/z 594 [M+H]+.
[0258] Step 8. A solution of compound 13-8 (215 mg, 0.36 mmol), Pd(OAc)2 (8 mg, 0.036 mmol), dppf (66 mg, 0.12 mmol) and sodium acetate (36 mg, 0.43 mmol) in DMF (20 mL) was heated at 80 °C for 3 hrs under an atmosphere of N2. The reaction mixturewas concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 13-9 (1 15 mg, 61 % yield) as a white solid. LC- MS (ESI): m/z 444 [M+H]+; lH NMR (500 MHz, CDC13): 5 8.70 (s, 1H), 8.12 (s, 1H), 7.78 (m, 2H), 7.15 (m, 2H), 5.38 (s, 1H), 5.37 (s, 1H), 4.32 (q, J = 7.0 Hz, 2H), 3.87 (m, 2H), 2.91 (s, 3H), 2.58 (m, 2H), 1.99 (m, 2H), 1.31 (t, J = 7.0 Hz, 3H) ppm.
[0259] Step 9. To a solution of compound 13-9 (95 mg, 0.21 mmol) in EtOH (40 niL) and THF (10 mL) was added 10% Pd/C (40 mg). The resulting mixture was stirred at rt for 16 hrs under an atmosphere of ¾. The resulting mixture was filtered and the filtrate was concentrated and dried in vacuo to give crude compound 13-10, which was used for the next step without further purification. LC-MS (ESI): m/z 446 [M+H]+.
[0260] Step 10. A mixture of compound 13-10 (95 mg, 0.213 mmol) and LiOH (2.0 M, 0.852 mmol) in MeOH (4 mL) and THF (8 mL) was stirred at 75 °C for 48 hrs. The mixture was cooled to rt and concentrated. The residue was diluted with water (30 mL) and adjusted its pH value to 5-6 by adding 2 N aq. HC1. The resulting mixture was extracted EtOAc (50 mL x 3) and the organic extracts were combined, washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 13-11(85 mg, 95% yield) as a white solid, which was used directly for the next step without further purification. LC-MS (ESI): m/z 418 [M+H]+.
[0261] Step 11. To a solution of compound 13-11 (85.0 mg, 0.20 mmol) in DMF (2 mL) was added HATU (93.0 mg, 0.24 mmol). After stirring at rt for 30 min, the reaction mixture was added DIPEA (53 mg, 0.41 mmol) and MeNH2 'HCl (17 mg, 0.24 mmol) and the resulting mixture was stirred at rt for 30 min. Subsequently, the reaction mixture was poured into ice water and the suspension was filtered. The solid was collected and dried in vacuo to give crude compound 13-12. LC-MS (ESI): m/z 431 [M+H]+; 1H NMR (500 Hz, CDC13): δ 8.51 (s, 1 H), 8.21 (s, 1H), 7.66 (dd, J{ = 5.5 Hz, J2 = 8.5 Hz, 2H), 7.23 (t, .7 = 8.5 Hz, 2H), 5.5 (m, 1H), 4.19 (m, 1H), 3.21 (m, 2H), 3.16 (s, 3H), 2.86 (d, / = 4.5 Hz, 3H), 1.97 - 2.06 (m, 2H), 1.63 - 1 .78 (m, 2H), 1.49 (d, J = 6.5 Hz, 3H) ppm. Compound 13-12 was separated into a pair of enantiomers: enantiomer 13-12_A (tR = 11.306 min) and enantiomer 13-12J5 (tR = 14.966 min) detected by UV absorption at 214 nm on a Daicel CHIRALPAK IA 4.0 mm x 150 mm χ 5 μιη column (eluent: hexane/EtOH = 70/30 (v/v) with 0.1 % (v/v) diethylamine and flow rate: 1 mL/min).
Figure imgf000146_0001
[0262] Step 1. Refer to Scheme 14. A mixture of compound 14-1 (10.0 g, 43.28 mmol) and LiOH (5.46 g, 129.8 mmol) in THF (400 mL), MeOH (200 mL) and water (100 mL) was stirred at 70 °C for 2 hrs under an atmosphere of N2. Subsequently, the reaction mixture was cooled to 0 °C and adjusted its pH value to 6 by adding coned, aq. HC1. The resulting suspension was filtered and the solid was dried in vacuo to give compound 14-2 (7.8 g, 83% yield). LC-MS (ESI): m/z 211 [M+H]+.
[0263] Step 2. A mixture of compound 14-2 (7.81 g, 35.6 mmol), DPPA (9.40 mL, 43.5 mmol) and Et3N (5.90 mL, 42.5 mmol) in i-BuOH (300 mL) was stirred at 90 °C for 6 hrs under an atmosphere of N2. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 to 4/1 (v/v)) to give compound 14-3 (4.9 g, 47% yield) as a white solid. LC-MS (ESI): m/z 234 [M-56+H]+.
[0264] Step 3. A mixture of compound 14-3 (5.10 g, 17.7 mmol) and methyl 2-bromo-3-(4- fluorophenyl)-3-oxopropanoate (5.84 g, 21.2 mmol) in DMF (80 mL) was stirred at 80 °C for 42 hrs under an atmosphere of N2. Subsequently, the reaction mixture was cooled to 0 °C, followed by adding a solution of NaHC03 (1.9 g) in water (20 mL). After stirring at 0 °C for 15 min, the mixture was diluted with water (100 mL) and the resulting suspension was extracted with EtOAc (100 mL x 3). The organic extracts were combined, washed with water (10 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether EtOAc = 40/1 to 20/1 (v/v)) to give compound 14-4 (1.9 g, 23% yield). LC-MS (ESI): m/z 464 [M+H]+. [0265] Step 4. To a solution of compound 14-4 (1.8 g, 3.9 mmol) in dioxane (10 mL) was added 4N HCl in dioxane (10 mL). After stirring at rt for 3 hrs, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 14-5, which was used for the next step without further purification. LC-MS (ESI): mlz 364 [M+H]+.
[0266] Step 5. To a stirred solution of compound 14-5 (1.4 g, 3.86 mmol) in pyridine (30 ml) was added MsCl (1.33 g, 1 1.6 mmol) at 0 °C. After stirring at rt for 1.5 hrs, the reaction mixture was concentrated and the residue was diluted with water (50 mL). Subsequently, the mixture was adjusted its pH value to 5-6 by adding 2N aq. HCl. The resulting suspension was filtered and the solid was dried in vacuo to give compound 14-6, which was used for the next step without further purification. LC-MS (ESI): mlz 520 [M+H]+.
[0267] Step 6. A solution of compound 14-6 (2.00 g, 3.86 mmol) and K2C03 (532 mg, 3.86 mmol) in MeOH (100 mL) was stirred at rt for 30 min. The suspension was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (Petroleum ether/acetone = 2/1 to 1/2 (v/v)) to give compound 14-7 (970 mg, 56% yield) as a yellow solid. LC-MS (ESI): mlz 442 [M+H]+.
[0268] Step 7. To a solution of compound 14-7 (970 mg, 2.19 mmol) in DMF (30 mL) was added K2CO3 (1.21 g, 8.76 mmol) and 5-bromopent-l-ene (784 mg, 5.26 mmol) at rt. After stirring at 80 °C for 16 hrs and at 90 °C for 24 hrs, the reaction mixture was concentrated and the residue was diluted with water (50 mL). The mixture was extracted with EtOAc (50 mL x 2). The organic extracts were combined, washed with water (50 mL x 2) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/acetone = 5/1 (v/v)) to give compound 14-8 (380 mg, 34% yield) as a yellow solid. LC-MS (ESI): mlz 510 [M+H]+.
[0269] Step 8. Following the procedure described for the synthesis of compound 13-11 and replacing compound 13-8 with 14-8, compound 14-12 was obtained. LC-MS (ESI): mlz 431 [M+H]+; !H NMR (500 Hz, CDC13): δ 9.37 (s, 1H), 7.67 (m, 2H), 7.60 (s, 1H), 7.21 (t, J = 8.5 Hz, 2H), 5.72 (m, 1H), 3.24 (m, 2H), 3.16 (s, 3H), 2.87 (d, J = 5.0 Hz, 3H), 1 .74-2.02 (m, 4H), 1.48 (d, / = 7.0 Hz, 3H) ppm. Scheme 15
Figure imgf000148_0001
[0270] Step 1. Refer to Scheme 15. To a solution of NaH (80 g, 60% mineral oil dispersion, 2 mol) in toluene (1.2 L) was added diethyl carbonate (295 g, 2.50 mol) at 0 °C. After stirring at rt for 2 hrs, the mixture was added drop wise to a solution of compound 15-1 (99 g, 0.50 mol) in toluene (400 mL) at reflux. After refluxing overnight, the reaction mixture was cooled to rt and sequentially treated with HOAc (140 mL) and aq. HC1 (2 M, 864 mL). The resulting mixture was extracted with EtOAc (400 mL x 3) and the combined organic extracts were washed with water (500 mL x 4) and brine (200 mL x 2) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 15-2 (122 g, 90% yield) as an oil. LC-MS (ESI): m/z 271.0 [M+H]+.
[0271] Step 2. To a solution of compound 15-2 (100 g, 369 mmol) in DMF (70 mL) was added p-benzoquinone (40 g, 369 mmol), followed by ZnCl2 (50 g, 369 mmol) in portions at rt. After stirring at 105 °C for 3.5 hrs, the reaction mixture was partitioned between water (800 mL) and EtOAc (800 mL) and filtered. The aqueous phase was extracted with EtOAc (500 mL x 2). The combined organic extracts were washed with water (1000 mL x 2) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 10/1 (v/v)) to give compound 15-3 (26 g, 20% yield) as a yellow solid. LC-MS (ESI): m/z 361.0 [M+H]+.
[0272] Step 3. To a solution of compound 15-3 (26 g, 72 mmol) in NMP (200 mL) was added CS2CO3 (47.0 g, 144 mmol). After stirring at rt for 20 min, 2-bromopropane (20.0 ml, 216 mmol) was added. The resulting mixture was stirred at 80 °C for 4 hrs, then diluted with ammonia and agitated for 30 min. The mixture was diluted with water (200 mL) and the aqueous phase was extracted with EtOAc (150 mL x 3). The combined organic extracts were washed with water (200 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 15-4 (27.5 g, 95% yield) as a colorless oil. LC-MS (ESI): m/z 403.0 [M+H]+.
[0273] Step 4. To a solution of HNO3 (cone. 66 mL, 0.89 mol) and CH2C12 (300 mL) a solution of compound 15-4 was added drop wise (27.5 g, 68.2 mmol) in CH2C12 (120 mL) at
0 °C over 1 hr. After stirring at rt for 30 min, the reaction mixture was diluted with water
(200 mL) and extracted with DCM (150 mL x 3). The combined organic extracts were washed with water (200 mL x 3) and dried with anhydrous Na2S04. The solvent was removed and the residue was re-crystallized in methyl i-butyl ether (MTBE) to give compound 15-5
(24.6 g, 80% yield) as a pale yellow solid. LC-MS (ESI): m/z 448.0 [M+H]+; lH NMR (500
MHz, CDCI3): δ 7.92 (d, / = 8.5 Hz, 2H), 7.87 (m, 2H), 7.76 (s, 1H), 7.65 (d, J = 8.5 Hz, 2H),
4.69 - 4.74 (m, 1H), 4.40 - 4.44 (m, 2H), 1.54 (s, 6H), 1.41 - 1.45 (t, 3H) ppm.
[0274] Step 5. A mixture of compound 15-5 (5.0 g, 1 1.2 mmol), 4-fluorophenol (1.7 g, 14.5 mmol), Pd(OAc)2 (250 mg, 1.12 mmol), f-BuXphose (380 mg, 0.9 mmol) and K3PO4 (4.8 g,
22.4 mmol) in toluene (50 mL) was stirred at 100°C under an atmosphere of Ar and monitored by LC-MS. After 2 hrs, the reaction mixture was concentrated and the residue was diluted with water (100 mL). The mixture was extracted with EtOAc (100 mL x 3) and the combined organic extracts were washed with water (100 mL x 2) and dried with anhydrous
Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 15-6 (4.8 g, 90% yield) as a yellow powder. LC-MS (ESI): m/z 480.1 [M+H]+.
[0275] Step 6. To a solution of compound 15-6 (2.0 g, 4.2 mmol) in DCM (30 mL) drop wise was added BC13 (8.4 mL, 8.4 mmol) at -78 °C. After stirring at -40 °C for 1 hr, the reaction was quenched by adding sat. aq. NH4C1 (20 mL). The resulting mixture was extracted with DCM (50 mL x 2) and the combined organic extracts were washed with water
(50 mL x 3) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 15-7 (1.6 g, 90% yield) as a yellow solid. LC-MS (ESI): m/z 438.1 [M+H]+.
[0276] Step 7. To a solution of compound 15-7 (1.6 g, 3.9 mmol) and DMAP (24 mg, 0.2 mmol) in DCM (30 mL) at 0 °C was added Et3N (790 mg, 7.8 mmol), followed by Tf20 (1.6 g, 5.82 mmol). After stirring at rt for 1 hr, LC-MS analysis indicated that the reaction went completion. The mixture was diluted with DCM (100 mL), washed water (50 mL x 3) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 15-8 (1.8 g, 94% yield) as a yellow solid. LC-MS (ESI): m/z 570.0 [M+H]+.
[0277] Step 8. To a solution of compound 15-8 (1.8 g, 3.2 mmol) in CH3CN (50 mL) was added NaOAc (1.6 g, 16 mmol.), dppf (180 mg, 0.32 mmol), and Pd(OAc)2 (150 mg, 0.64 mmol), and the resulting mixture was saturated with Ar. After l-(vinyloxy)butane (1.6 g, 16 mmol) was added, the mixture was stirred at 100 °C for 2 hrs under an atmosphere of Ar. Subsequently, the reaction mixture was cooled to rt, concentrated, and diluted with EtOAc (100 mL). The resulting mixture was washed with water (50 mL x 2) and brine ( 100 mL) and dried with anhydrous Na2SC>4. The solvent was removed and the residue was dissolved in THF (50 mL) and aq. HC1 (2N, 12 mL). After refluxing for 1 hr, the mixture was cooled to rt and concentrated to remove most of the organic solvent. The resulting mixture was extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with water (50 mL x 3) and brine (50 mL) and dried with anhydrous Na2S0 . The solvent was removed and the residue was dried in vacuo to give crude compound 15-9 (1.4 g, 98% yield). LC-MS (ESI): m/z 464.1 [M+H]+.
[0278] Step 9. To a solution of compound 15-9 (1.4 g, 3.4 mmol) in EtOAc (50 mL) was added SnCl22H20 (2.8 g, 13.6 mmol) at rt and the resulting mixture was stirred at 80 °C for 1 hr. The mixture was cooled to rt and d its pH value was adjusted to 8 ~ 9 by adding sat. aq. NaHC03. The mixture was filtered and the filtrate was extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with water (50 mL x 3) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 15-10 (1.1 g, 85% yield) as a yellow solid. LC-MS (ESI): m/z 434.1 [M+H]+.
[0279] Step 10. To a solution of compound 15-10 (1.1 g, 2.5 mmol) in anhydrous pyridine
(20 mL) was added MsCl (1.8 mL) at 0 °C. After the mixture was stirred at 30 °C for 2 hrs,
LC-MS analysis indicated that the reaction went to completion. The mixture was diluted with water (100 mL) and EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL x
3). The combined organic extracts were washed with sat. aq. NH4C1 (50 mL x 3) and brine
(50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 15-11 (1.1 g, 90% yield) as a yellow solid. LC-MS (ESI): mlz 512.1 [M+H]+.
[0280] Step 11. To a solution of compound 15-11 (1.1 g, 2.1 mmol) in THF (30 mL) was added NaBH4 (560 mg, 14.7 mmol) in portions at 0 °C. After stirring at 0 °C for 30 min, LC- MS analysis indicated that the reaction went to completion and acetone (2 mL) was added to quench excess amount of NaBH4. The mixture was concentrated and the residue was diluted with EtOAc (100 mL). The resulting mixture was washed with water (50 mL x 3) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 15-12 (0.9 g, 90% yield) as a yellow solid. LC-MS (ESI): mlz 514.1 [M+H]+.
[0281] Step 12. To a solution of compound 15-12 (0.9g, 1.7 mmol) in anhydrous DCM (30 mL) was added NaH (60% in paraoil, 200 mg, 5 mmol) at 0 °C, followed by compound 8-6 (1.1 g, 2.55 mmol). After stirring at 0 °C for 3 hrs and at rt for 12 hrs, the reaction was quenched by adding sat. aq. NH4C1 (10 mL). The resulting mixture was extracted with DCM (30 mL x 3) and the combined organic extracts were washed with brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 6/1 (v/v)) to give compound 15-13 (520 mg, 55% yield) as a white solid. LC-MS (ESI): mlz 540.1 [M+H]+.
[0282] Step 13. To a solution of compound 15-13 (520 mg, 0.96 mmol) in MeOH/THF (4 niL/8 mL) was added aq. LiOH (2.0 M, 2 mL) at rt. After stirring at 80 °C for 12 hrs, the reaction mixture was cooled to rt and adjusted its pH value to 2 ~ 3 by adding aq. HC1 (2.0
M). The organic solvent was removed and the residue was diluted with EtOAc (50 mL). The organic layer was isolated, washed with brine (25 mL) and dried with anhydrous Na2S04.
The solvent was removed and the residue was dried in vacuo to give crude compound 15-14
(442 mg, 90% yield) as a white solid. LC-MS: (ESI): mlz 512.1 [M+H]+.
[0283] Step 14. Compound 15-14 (442 mg, 0.86 mmol) was dissolved in DMF (5 mL), followed by addition of HATU (450 mg, 1.17 mmol). After stirring at rt for 1 hr, the reaction mixture was added DIPEA (503 mg, 3.9 mmol) and MeNH2 HCl (157 mg, 2.34 mmol). The resulting mixture was stirred at rt for another 1 hr before being concentrated. The residue was diluted with water (25 mL) and EtOAc (50 mL). The organic layer was isolated, washed with brine (25 mL), and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 15-15 (360 mg, 80% yield) as a white solid. LC-MS (ESI): mlz 525.1 [M+H]+; !H
NMR (500 MHz, CDC13): δ 7.89 (s, 1H), 7.82 - 7.84 (m, 2H), 7.26 (s, 1H), 7.04 - 7.12 (m,
6H), 5.85 (m, 1H), 4.94 - 4.98 (m, 1H), 4.14 - 4.18 (m, 1H), 4.02 - 4.06 (m, 2H), 3.31 (m,
1H), 3.15 (d, J = 8.5 Hz, 3H), 3.00 (d, / = 5.0 Hz, 3H), 2.07 - 1.73 (d, / = 6.5 Hz, 3H) ppm. Compound 15-15 was separated into a pair of enantiomers: enantiomer 15-15a (tR = 3.66 min) and enantiomer 15-15b (tR = 4.25 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μηι Daicel CHIRALPAK AS-H column (column temperature: 39.7 °C; eluent: MeOH/liquid C02 = 20/80 (v/v); C02 flow rate: 2.4 g/min and co-solvent flow rate: 0.6 g/min; front pressure: 198 bar and back pressure: 150 bar).
Scheme 16
Figure imgf000153_0001
[0284] Step 1. Refer to Scheme 16. To a solution of compound 16-1 (1.00 g, 7.14 mmol) and SEMCI (0.670 mL, 7.14 mmol) in CH3CN (10 mL) was slowly added Cs2C03 (1.57 g, 7.86 mmol). After stirring at rt for 3 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 3/1 to 1/1 (v/v)) to give compound 16-2 (1 .35 g, 70% yield) as a yellow solid. LC-MS (ESI): mJz 271.1 [M+H]+.
[0285] Step 2. To a solution of compound 16-2 (1.25 g, 4.61 mmol) in EtOH (20 mL) was added 10% Pd C (31 1 mg), the reaction mixture was stirred at rt overnight under an atmosphere of hydrogen. The mixture was filtered through Celite® 545 and the filtered cake was washed with EtOH (20 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 16-3 (1.10 g, 99% yield) as a yellow oil. LC-MS (ESI): m/z 241.1 [M+H]+.
[0286] Step 3. To a solution of compound 16-3 (1.10 g, 4.58 mmol) and Et3N (3.72 mL, 26.7 mmol) in DCM (15 mL) was added drop-wise a solution of MsCI (0.63 mL, 8.0 mmol) in DCM (30 mL) over 30 min at 0 °C. After stirring at rt overnight, the reaction mixture was filtered through Celite® 545 and the filtered cake was washed with DCM (30 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give a mixture of compounds 16-4 and 16-4' (2.30 g) as a yellow oil, which was used directly for next step without further purification. LC-MS (ESI): m/z 319.1 [M+H]+ and 397.1 [M+H]+ for compounds 16-4 and 16-4', respectively.
[0287] Step 4. To a solution of compounds 16-4 and 16-4' (2.30 g, 5.81 mmol) in DMF (20 mL) and H20 (4 mL) were added 2C03 (2.94 g, 21.3 mmol) and 5-bromopent-l -ene (1.31 g, 8.83 mmol) at rt. After Stirling at 80 °C for 3 hrs, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 4/1 to l/l(v/v)) to give compound 16-5 (1.60 g, 90% yield, two steps from compound 16-3) as a white solid. LC-MS (ESI): m/z 387.2 [M+H]+.
[0288] Step 5. To a solution of compound 16-5 (1.15 g, 2.98 mmol) in THF (25 mL) was added tetrabutylammonium floride (TBAF) (2.33 g, 8.93 mmol) at rt. After stirring at 45 °C overnight, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 3/1 tol/1 (v/v)) to give compound 16-6 (564 mg, 74% yield) as a white solid. LC-MS (ESI): m/z 257.1 [M+H]+.
[0289] Step 6. To a solution of compound 16-6 (564 mg, 2.20 mmol) in DMF (30 mL) was added PBr3 (1.77 g, 6.61 mmol) and the resulting mixture was stirred at rt for 30 min under an atmosphere of Ar. Subsequently, the reaction was quenched by adding sat. aq. NaHC03 (100 mL). The mixture was extracted with EtOAc (100 mL x 3) and the combined organic extracts were washed with water (100 mL x 5) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 16-7 (350 mg, 50% yield) as a yellow powder. LC-MS (ESI): m/z 319.0 [M+H]+.
[0290] Step 7. A mixture of compound 16-7 (400 mg, 1.26 mmol), Pd(OAc)2 (30 mg, 0.13 mmol), PPh3 (66 mg, 0.25 mmol), n-Bu4Cl (350 mg, 1.26 mmol) and K2C03 (442 mg, 3.20 mmol) in MeCN /H20 (10 mL/1 mL) was stirred at 80 °C overnight under an atmosphere of N2. The mixture was cooled to rt and concentrated. The residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 5/1 to 2/1 (v/v)) to give compound 16-8 (135 mg, 45% yield) as a yellow solid. LC-MS (ESI): m/z 239.1 [M+H]+; JH NMR (500 MHz, CDC13): 8.68 (s, 1H), 8.50 - 8.51 (d, / = 5 Ηζ,ΙΗ), 7.23 - 7.24 (d, / = 5 Ηζ, Ι Η), 5.35 (s, 1H), 5.27 (s, 1H), 3.79 ( br, 2H), 2.91 (s, 3H), 2,49 - 2.51 (m, 2H), 1.96 - 1.99 (m, 2H) ppm.
[0291] Step 8. A mixture of compound 16-8 (130 mg, 0.544 mmol) and 10% Pd/C (50 mg) in MeOH (30 mL) was stirred at rt for 24 hrs under an atmosphere of H2. The reaction mixture was filtered through Celite® 545 and the filtered cake was washed with MeOH (30 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 16-9 (120 mg, 92% yield) as an off-white solid. LC-MS (ESI): m/z 241.1 [M+H]+.
[0292] Step 9. To a solution of 0-(mesitylsulfonyl)hydroxylamine (MSH) (0.498 mmol) in DCM (10 mL) was added compound 16-9 (120 mg, 0.498 mmol). After stirring at rt overnight, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 16-10 as a pale-yellow solid, which was used directly for the next reaction without further purification. LC-MS (ESI): m/z 257 '.1 [M+H]+.
[0293] Step 10. To a solution of compounds 16-10 (0.50 mmol) and 16-11 (128 mg, 0.50 mmol) in DMF (6 mL) was added K2C03 (275 mg, 2.0 mmol) in one portion. After stirring at rt for 24 hrs, the reaction mixture was concentrated and the residue was partitioned between EtOAc (100 mL) and water (100 mL). The organic layer was washed with water (50 mL x 3) and brine (50 mL) and dried with anhydrous Na2SC>4. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 10/1 to 6/1 (v/v)) to give compound 16-12 (90 mg, 35% yield) as a yellow solid. LC-MS (ESI): m/z 506.1 [M+H]+.
[0294] Step 11. To a mixture of compound 16-12 (80 mg, 0.16 mmol) in MeOH (1 mL) and THF (2 mL) was added aq. LiOH (2.0 M, 1 .3 mmol). After stirring at 70 °C for 24 hrs, the mixture was cooled to rt and adjusted its pH value to 5-6 by adding 2 M aq. HC1.
Subsequently, H20 (30 mL) was added and the resulting mixture was extracted with DCM (50 mL x 3). The combined organic extracts were washed with water (50 mL x 2) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 16-13 (80 mg) as a yellow solid, which was used directly for the next step without further purification. LC-MS (ESI): m/z 478.0 [M+H]+.
[0295] Step 12. To a solution of compound 16-13 (80 mg, 0.16 mmol) in DMF (2 mL) was added HATU (71 mg, 0.19 mmol). After stirring at rt for 10 min, to the reaction mixture was added Et3N (81 mg, 0.80 mmol), followed by MeNH2 HCl (13 mg, 0.19 mmol). The resulting mixture was stirred at rt for 30 min and then partitioned between EtOAc (25 mL) and water (25 mL). The organic layer was isolated, washed with water (25 mL x 3) and brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 10/1 to 6/1 (v/v)) to give compound 16-14 (65 mg, 83% yield) as a yellow solid. LC-MS (ESI): m/z 491.1 [M+H]+; 1H NMR (500 MHz, CDC13): 8 8.53 (s, 1H), 8.21 (s, 1H), 7.68 (dd, J, =2.0 Hz, J2 =6.8 Hz, 2H), 7.57 (dd, // =1.5 Hz, J2 =6.5 Hz, 2H), 5.51 (m, 1H), 4.18 (m, 1H), 3.23 (m, 2H), 3.1 1 (s, 3H), 2.89 (d, / = 5.0 Hz, 3H), 1.99 - 2.09 (m, 2H), 1.81 (m, 2H), 1.50 (d, J = 7.0 Hz, 3H) ppm. [0296] Step 13. A mixture of compound 16-14 (60.0 mg, 0.122 mmol), 4-fluorophenol (16.4 mg, 0.146 mmol), Pd(OAc)2 (2.7 mg, 0.012 mmol), i-BuXphos (2.6 mg, 0.0061 mmol) and K3PO4 (51.7 mg, 0.244 mmol) in toluene (4 mL) was stirred at 80 °C for 4 hrs under an atmosphere of N2. The mixture was concentrated and the residue was diluted with EtOAc (25 mL) and filtered through Celite® 545. The filtrate was concentrated and the residue was purified by preparative HPLC to give compound 16-15 (13 mg, 20% yield) as a white solid. LC-MS (ESI): mlz 523.2 [M+H]+; lH NMR (500 MHz, CDC13): δ 8.46 (s, I H), 8.19 (s, IH), 7.61 - 7.63 (m, 2H), 7.58 - 7.60 (m, 6H), 7.19 - 7.49 (m, 3H), 5.50 - 5.51 (d, J = 5.0 Hz, IH), 4.11 (br, IH), 3.14 - 3.17 (m, 2H), 3.03 (s, 3H), 2.76 - 2.77 (d, 7 = 5.0 Hz, 3H), 1.99 (m, 2H), 1.72 - 1.91 (m, 2H), 1.42 - 1.44 (d, 7 = 7.0 Hz, 3H) ppm.
[0297] Syntheses of analogs of compound 16-15. Following the same procedure as described in Step 12 and replacing 4-fluorophenol with the respective substituted phenols (ArOH), the following analogs of compound 16-15 were obtained.
Figure imgf000156_0001
Figure imgf000157_0001
(m, 1H), 3.14 (m, 2H), 3.30 (s,
3H), 2.80 (d, 7 = 5.0 Hz, 3H), 1.93 - 2.00 (m, 2H), 1.72 (m, 1 H), 1.51 (m, 1H), 1.42 (d, 7 = 7.0 Hz, 3H)
[0298] Synthesis of compound 16-16. Compound 16-16 was obtained as a white solid from the hydrogenation of compound 16-14 in the presence of 5% Pd/C in EtOH. LC-MS (ESI): mlz 413.2 [M+H]+; Ή NMR (500 MHz, CDC13): δ 8.45 (s, 1H), 8.19 (s, 1H), 7.58— 7.59 (m, 2H), 7.45 - 7.49 (m, 3H), 5.51 (m 1H), 4.11 (m, 1H), 3.16 (m, 2H), 3.14 (s, 3H), 2.76 (d, 7 = 4.5 Hz, 3H), 1.90 - 1.99 (m, 2H), 1.73 (m, 1H), 1.48 (m, 1 H), 1.43 (d, 7 = 6.5 Hz, 3H) ppm.
Scheme 17
Figure imgf000158_0001
[0299] Step 1. Refer to Scheme 17. A mixture of compound 17-1 (100 mg, 0.225 mmol) (readily prepared by onzonlysis of compound 6-5), paraformaldehyde (20 mg, 0.67 mmol) and morpholine (2 μΕ, 0.02 mmol) in acetic acid (2 mL) was heated at 120 °C for 2 hrs under an atmosphere of N2. The reaction mixture was concentrated and the residue was dissolved in THF/EtOH (10 mL/10 mL) and Pt02 (22 mg) was added. After stirring at rt overnight under an atmosphere of H2, the reaction mixture was filtered through Celite® 545 and the filtered cake was washed with EtOH (20 mL x 2). The filtrate was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 4/1 (v/v)) to give compound 17-3 (45 mg, 33% yield, two steps from 17-1) as a white solid. LC-MS (ESI): mlz 460.1 [M+H]+; Ή NMR (500 MHz, CDC13): δ 8.40 (s, 1H), 8.12 (m, 2H), 7.71 (s, 1H), 7.20 (m, 2H), 4.45 (q, J = 7.0 Hz, 2H), 4.15 (m, 1H), 3.62 (m, 1H), 3.07 (s+m, 3+1H), 2.33 (m, 1 H), 1.79 (m, 1 H), 1.45 (t, 7 = 7.0 Hz, 3H), 1.32 (d, / = 7.0 Hz, 3H) ppm.
[0300] Step 2. A mixture of compound 17-3 (182 mg, 0.396 mmol) and LiOH (50 mg, 1.19 mmol) in THF (20 mL), MeOH (5 mL), and water (5 mL) was refluxed and monitored by LC-MS. After the reaction went completion, the reaction mixture was cooled to 0 °C and adjusted its pH value to 7 by adding 1 M aq. HC1. The organic solvent was removed and the residue was triturated with water (15 mL) and then filtered. The solid was washed with water (10 mL x 3) and dried in vacuo to give compound 17-4, which was used in the next step without further purification. LC-MS (ESI): m/z 432.1 [M+H]+.
[0301] Step 3. To a solution of compound 17-4 (about 0.396 mmol, crude) and HATU (181 mg, 0.475 mmol) in DMF (4 mL) was added DIPEA (131 L, 0.792 mmol). After stirring at rt for 15 min, the mixture was added to DIPEA (196 μί, 1.19 mmol), followed by methylamine hydrochloride (80 mg, 1.19 mmol) and the resulting mixture was stirred at rt for 2 hrs. Subsequently, the mixture was concentrated and the residue was diluted with water and filtered. The solid was collected and purified by preparative HPLC to give compound 17-5 as a white solid. LC-MS (ESI): m/z 445.1 [M+H]+; Ή NMR (500 MHz, CDC13): δ 8.13 (s, 1H), 8.00 (m, 2H), 7.21 (m, 2H), 7.71 (s, 1H), 5.90 (brs, 1H), 4.15 (m, 1H), 3.64 (m, 1H), 3.08 (s, 3H), 3.05 (d, / = 5.0 Hz, 3H), 3.03 (m, 1H), 2.32 (m, 1H), 1.80 (m, 1 H), 1.32 (d, J = 6.5 Hz, 3H) ppm.
[0302] Step 4. To a solution of compound 17-5 (40 mg, 0.090 mmol) in MeOH (4 mL) was added NaBH4 (10 mg, 0.27 mmol) at 0 °C. After stirring at 0 °C for 30 min, the reaction was quenched by adding several drops of acetone. The solvent was removed and the residue was diluted with water (25 mL) and extracted with DCM (25 mL x 2). The combined organic extracts were washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by preparative HPLC to give compound 17-6 as a white solid and as a mixture of cis- and rraws-isomers. LC-MS (ESI): m/z 447.1 [M+H]+; ¾ NMR (500 MHz, CDC13, major isomer): δ 7.93 (s, 2H), 7.87 (s, 1H), 7.58 (s, 1H), 7.20 (m, 2H), 5.93 (brs, 1H), 4.78 (d, = 7.0 Hz, 1H), 3.70 (m, 1 H), 3.11 (s, 3H), 3.02 (d, 7 = 5.0 Hz, 3H), 2.08 (brs, 1H), 1.61 (brs, 1 H), 1.03 (brs, 3H) ppm.
[0303] Step 5. A mixture of compound 17-6 (88 mg, 0.20 mmol) and TsOH (8 mg, 0.04 mmol) in toluene (6 mL) was refluxed for 2 hrs under an atmosphere of N2. The solvent was removed and the residue was purified by preparative HPLC to give compound 17-7 as a white solid. LC-MS (ESI): m/z 429.1 [M+H]+; ]H NMR (500 MHz, CDC13): δ 7.90 (m, 2H), 7.71 (m, 1H), 7.67 (s, 1H), 7.19 (m, 2H), 6.44 (s, 1H), 5.81 (brs, 1H), 3.87 (brs, 2H), 3.01 (d, / = 5.0 Hz, 3H), 2.74 (s, 3H), 2.68 (m, 2H), 2.00 (s, 3H) ppm.
[0304] Step 6. A mixture of compound 17-7 (56 mg, 0.13 mmol) and Pt02 (23 mg) in THF (4 mL) and MeOH (4 mL) was stirred at rt overnight under an atmosphere of H2. The mixture was filtered through Celite® 545 and the filtered cake was washed with MeOH (25 mL x 2). The filtrate was concentrated and the residue was purified by preparative HPLC to give compound 17-8 as a white solid. LC-MS (ESI): mlz 431.1 [M+H]+; lU NMR (500 MHz, CDC13): 5 7.90 (s, 2H), 7.67 (s, 1H), 7.58 (s, 1H), 7.19 (m, 2H), 5.79 (brs, 1 H), 4.10 (brs, 1H), 3.31 (brs, 1H), 3.06 (s, 3H), 3.01 (d, / = 5.0 Hz, 3H), 2.87 (m, 2H), 1.68 - 1.90 (m, 3H), 1.04 (d, J = 6.0 Hz, 3H) ppm.
Scheme 18
Figure imgf000160_0001
[0305] Step 1. Refer to Scheme 18. A solution of compound 8-4 (656 mg, 1.57 mmol) and aminopropene (3.70 mL, 50.0 mmol) in THF (dry) was slowly added Ti(0'Pr)4 (16.5 mL, 20.0 mmol) and the resulting mixture was stirred at rt for 4 hrs. Subsequently, EtOH (30 mL) and NaBH4 (760 mg, 20.0 mmol) were added and the mixture was stirred at rt overnight. Subsequently, the mixture was poured into ice-water (100 mL) and the suspension was filtered. The filtrate was concentrated and the residue was diluted with EtOAc (200 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 6/1 (v/v)) to give compound 18- 1 (7.0 g, 87% yield) as a yellow solid. LC-MS (ESI): mlz 459.2 [M+HJ+.
[0306] Step 2. To a solution of compound 18-1 in anhydrous DCM (30 mL) was added NaH (172 mg, 43.0 mmol) at 0 °C. After stirring at 0 °C for 30 min, compound 8-6 (640 mg, 1.44mmol) was added and the resulting mixture was stirred at 0 °C for 3 hrs and at rt overnight. Subsequently, sat. aq. NH4CI (lOmL) was added and the aqueous phase was extracted with DCM (25 mL x 3). The combined organic extracts were washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 6/1 (v/v)) to give compound 18-2 (200 mg, 71 % yield) as a white solid. LC-MS (ESI): m/z 487.1 [M+H]+.
[0307] Step 3. To a solution of compound 18-2 (100 mg, 0.100 mmol) in MeOH THF (1 mL/2 mL) was added aq. LiOH (2.0 M, 0.5 mL). After stirring at 80 °C for 12 hrs, the reaction mixture was acidified to pH 2-3 by adding aq. HQ (2.0 M), and then concentrated. The residue was dissolved in EtOAc (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude acid, which was used in the next step without further purification. LC-MS (ESI): m/z 459.1 [M+H]+. Subsequently, the crude acid was dissolved in DMF (3 mL) and HATU (74 mg, 0.25 mmol) was added. The mixture was stirred at rt for 1 hr and then DIPEA (0.40 mL, 2.02 mmol) and MeNH2 HCl (82 mg, 1.2 mmol) were added. After stirring at rt for 1 hr, the reaction mixture was concentrated and the residue was diluted with EtOAc (50 mL). The solution was washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 5/1 (v/v)) to give compound 18-3 (70 mg, 55% yield) as a white solid. LC-MS (ESI): m/z 472.1 [M+H]+.
[0308] Step 4. To a solution of compound 18-3 (42 mg) in THF (1 mL) were added polymethylhydrosiloxane (PMHS) (0.18 mmol), ZnCl2 (3.0 mg, 0.02 mmol) and Pd[PPh3]4 (1.04 mg, 0.009 mmol), the mixture was stirred at 25 °C for 12 hrs under an atmosphere of N2. The solvent was removed and the residue was purified by preparative HPLC to give compound 18-5 (9 mg, 23% yield) as a white solid. LC-MS (ESI): m/z 432.1 [M+H]+; lH NMR (500 MHz, -DMSO): δ 8.49 (m, 1H), 7.94 (dd, / = 5.0 Hz, J2 = 8.3 Hz, 2H), 7.74 (s, 1H), 7.50 (s, 1H), 7.39 (t, / = 9.0 Hz, 2H), 4.13 (m, 1H), 3.25 (m, 5H), 3.04 (m, 2H), 2.84 (d, J = 4.5 Hz, 3H), 1.49 (d, / = 6.5 Hz, 3H) ppm.
[0309] Synthesis of compound 18-4. Following the same procedure as described in Step 4 and replacing compound 18-3 with 18-2, compound 18-4 was obtained. LC-MS (ESI): m/z 447.1 [M+H]+.
Figure imgf000161_0001
[0310] Synthesis of compound 18-6. Method A. To a solution of compound 18-4 (120 mg, 0.248 mmol) and NaHC03 (42 mg, 0.50 mmol) in DMF (3 mL) was added CF3CH2OTf (69 mg, 0.30 mmol). The resulting mixture was stirred at rt overnight. The solvent was removed and the residue was diluted with EtOAc (50 mL). The mixture was washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give an ester, LC-MS (ESI): mlz 529.1 [M+H]+, which was subsequently hydrolyzed and performed methyl amide formation, following the conditions described in Step 3, to give compound 18-6. LC-MS (ESI): mlz 514.1 [M+H]+; ¾ NMR (500 MHz, d6- DMSO): δ 8.51 (m, IH), 7.97 (m, 2H), 7.80 (s, IH), 7.58 (s, IH), 7.40 (m, 2H), 4.44 (m, I H), 3.85 (m, IH), 3.33 - 3.38 (m, 6H), 2.99 (m, 2H), 2.86 (d, J = 5.0 Hz, 3H), 1.51 (d, / = 5.5 Hz, 3H) ppm.
Figure imgf000162_0001
[0311] Synthesis of compound 18-7. Method B. To a solution of compound 18-4 (100 mg, 0.224 mmol) and pyridine (106 mg, 1.34 mmol) in DCM (5 mL) was added methyl chloroformate (37 mg, 0.47 mmol) at 0 °C and the resulting mixture was stirred at rt for 30 min. The reaction was quenched by adding several drops of sat. aq. NaHC03 and the mixture was concentrated. The residue was diluted with DCM (60 mL) and the mixture was washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give an ester, LC-MS (ESI): mlz 505.1 [M+H]+, which was subsequently hydrolyzed and performed methyl amide formation, following the conditions described in Step 3, to give compound 18-7. LC-MS (ESI): mlz 490.1 [M+H]+; *H NMR (500 MHz, CD3CN): δ 7.96 (m, 2H), 7.71 (s, IH), 7.55 (s, IH), 7.28 (m, 2H), 6.78 (br, IH), 5.45 - 5.54 (m, IH), 4.14 (m, 2H), 3.99 - 4.04 (m, 4H), 3.24 - 3.28 (m, 4H), 2.91 (d, J = 4.5 Hz, 3H), 1.68 (br, 3H) ppm.
Figure imgf000162_0002
[0312] Synthesis of compound 18-8. Method C. To a solution of compound 18-4 (70 mg,
0.16 mmol) in MeOH (5 mL) were added 37% aq. HCHO (0.050 mL, 0.63 mmol) and HOAc
(0.020 mL, 0.31 mmol). The reaction mixture was stirred at 40 °C for 2 hrs and then cooled to rt. Subsequently, NaB¾ (50 mg, 0.79 mmol) was slowly added and the mixture was stirred at rt for 30 min. The solvent was removed and the residue was diluted with EtOAc (25 mL).
The mixture was washed with brine (10 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give a crude ester (70 mg) as a yellow solid, LC-MS: (ESI) m/z 461.1 [M+H]+, which was subsequently hydrolyzed and performed methyl amide formation, following the conditions described in Step 3, to give compound 18- 8. LC-MS (ESI): mlz, 446.1 [M+H]+; lH NMR (300 MHz, -DMSO): δ 7.92 (m, 2H), 7.66 (s, 1H), 7.49 (s, 1H), 7.33 (m, 2H), 4.20 (m, 1H), 3.50 - 3.53 (m, 2H), 3.42 (br, 3H), 3.29 - 3.30 (m, 2H), 2.84 (d, J = 4.5 Hz, 3H), 2.10 (br, 3H), 1.49 (d, J = 7.2 Hz, 3H) ppm.
Figure imgf000163_0001
[0313] Synthesis of compound 18-9. Following the same procedure as described in Method C and replacing 37% aq. HCHO with ( 1 -ethoxycyclopropoxy)trimethylsilane, compound 18-9 was obtained. LC-MS (ESI): mlz 472.1 [M+H]+.
Figure imgf000163_0002
[0314] Synthesis of compound 18-10. Following the same procedure as described in Method C and replacing 37% aq. HCHO with cyclopropanecarbaldehyde, compound 18-10 was obtained. LC-MS (ESI): mlz 486.2 [M+H]+.
Scheme 18a
Figure imgf000163_0003
[0315] Step 1. Refer to Scheme 18a. To a solution of compound 8-4 (2.1 g, 5 mmol) in dry THF (20 mL) was added MeNH2 (2 M in THF, 20 mL, 40 mmol), followed by Ti(OfPr)4 (6 mL, 20 mmol) under an atmosphere of N2. After stirring at rt overnight, the reaction mixture was cooled to 0 °C and sequentially added EtOH (20 mL) and NaBH4 (945 mg, 25 mmol). The reaction mixture was stirred at 0 °C for 2 hrs and slowly added H20 (20 mL). The suspension was filtered and the filtrate was extracted with DCM (100 mL x 3). The combined organic extracts were washed with brine (50 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 18a-2a (2.17 g) as a yellow solid, which was used directly for the next step without further purification. LC-MS (ESI): m/z 435.1 [M+H]+.
[0316] Step 2. To a solution of compound 18a-2a (2.17 g, 5.0 mmol) in DCM (40 mL) at 0 °C was added anhydrous pyridine (0.8 mL, 10 mmol), followed by 2-chloroacetyl chloride (0.75 mL, 10 mmol). After stirring at 0 °C for 2 hrs, the reaction mixture was warmed to rt and treated with 1 M aq. HC1 (10 mL). The mixture was extracted with EtOAc (100 mL x 3) and the combined organic extracts were washed with H20 (50 mL) and brine (50 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc =1/1 (v/v)) to give compound 18a-3a (1.8 g, 71% yield) as a light yellow solid. LC-MS (ESI): m/z 51 1.1 [M+H]+.
[0317] Step 3. To a solution of compound 18a-3a (2.55 g, 5.0 mmol) in toluene (50 mL) was added K2C03 (1.38 g, 10 mmol). After stirring at 80 °C stirred for 4 hrs, the reaction mixture was cooled to rt and filtered. The filtrate was concentrated and the residue was dried in vacuo to give crude compound 18a-4a (2.4 g) as a yellow solid, which was used for the next step without further purification. LC-MS (ESI): m/z 475.1 [M+H]+.
[0318] Step 4. Following the same procedure as that for the preparation of compound 18-3 described in Scheme 18 and replacing compound 18-2 with 18a-4a, compound 18a-5a (1.1 g, 57% yield) was obtained as a white solid. LC-MS (ESI): m/z 460.1 [M+H]+; H NMR (500 MHz, CD3OD): δ 7.82 (br, 2H), 7.63 (s, 1H), 7.59 (s, 1H), 7.14 (t, J = 1 Hz, 2H). 4.69 (q, / = 6 Hz, 1H), 4.59 (d, 7 = 18 Hz, 1H), 3.96 (d, 7 = 18 Hz, 1H), 3.27 (s, 3H), 3.06 (s, 3H), 2.82 (s, 3H), 1.66 (d, J = 6 Hz, 3H) ppm. Compound 18a-5a was separated into a pair of enantiomers: enantiomer 18a-5a_A (tR = 2.48 min) and enantiomer 18a-5a_B (t = 3.28 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 ηιηι χ 5 μηι Daicel CHIRALPAK® OD-H column (column temperature: 39.3 °C; eluent: MeOH/liquid C02 = 50/50 (v/v); C02 flow rate: 1.5 g/min and co-solvent flow rate: 1.5 g min; front pressure: 235 bar and back pressure: 152 bar).
[0319] Synthesis of compound 18b-2b. Following the same procedure as that for the synthesis of compound 18a-2a described in Scheme 18a and replacing methylamine with 2,4- dimethoxybenzylamine, compound 18a-2b (6.5 g crude product) was obtained as a yellow solid. LC-MS (ESI): m/z 571.2 [M+H]+. [0320] Synthesis of compound 18b-3b. Following the same procedure as that for the synthesis of compound 18a-3a described in Scheme 18a and replacing compound 18a-2a with 18a-2b, compound 18a-3b (4.9 g, 75% yield) was obtained as a light yellow solid. LC- MS (ESI): m/z 647.2 [M+H]+.
[0321] Synthesis of compound 18a-4b. Following the same procedure as that for the synthesis of compound 18a-4a described in Scheme 18a and replacing compound 18a-3a with 18a-3b, compound 18a-4b (3.4 g crude product) was obtained as a yellow solid. LC- MS (ESI): m/z 611.2 [M+H]+.
[0322] Synthesis of compound 18a-4c. To a stirred solution of compound 18a-4b (3.4 g, 7.3 mmol) in DCM (10 mL) was added TFA (20 mL). After stirring at rt overnight, the reaction mixture was concentrated and the residue was purified by column chromatography to give compound 18a-4c as a pale yellow solid. LC-MS (ESI): m/z 461.1 [M+H]+.
[0323] Synthesis of compound 18a-5b. Following the same procedure as that for the preparation of compound 18-3 described in Scheme 18 and replacing compound 18-2 with 18a-4c, compound 18a-5b (700 mg, 40% yield) was obtained as a white solid. LC-MS (ESI): m/z 446.1 [M+H]+; ]H NMR (500 MHz, CDC13): δ 7.91 (s, 1H), 7.84 - 7.87 (m, 2H). 7.59 (s, 1H), 7.22 (t, J = 8 Hz, 2H), 5.95 (s, 1H), 5.79 (br, 1H), 5.24 - 5.26 (m, 1H), 4.92 (d, 7 = 18 Hz, 1H), 3.93 (d, 7= 18 Hz, 1H), 3.20 (s, 3H), 2.99 (d, J = 5 Hz, 3H), 1.74 (d, / = 7 Hz, 3H) ppm. Compound 18a-5a was separated into a pair of enantiomers: enantiomer 18a-5b_A (tR = 3.67 min) and enantiomer 18a-5b_B (tR = 4.53 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μπι ChiralPak® OD-H column (column temperature: 39.7 °C; eluent: MeOH/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; front pressure: 207 bar and back pressure: 150 bar).
Scheme 19
Figure imgf000165_0001
[0324] Step 1. Refer to Scheme 19. A mixture of compound 6-5 (1.00 g, 2.25 mmol) and 5% Pd/C (1.0 g) in THF/MeOH (50 mL/50 mL) was stirred at rt overnight under an atmosphere of ¾. The mixture was filtered through Celite® 545 and the filtered cake was washed with MeOH (25 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 19-1 (970 mg, 97% yield). LC-MS (ESI): m/z 446.1 [M+H]+.
[0325] Step 2. To a solution of compound 19-1 (970 mg, 2.18 mmol) in MeOH/THF ( 10 mL/10 mL) was added aq. LiOH (2.0 N, 4.36 mmol, 8.72 mmol). After stirring at 75 °C for 2 hrs, the reaction mixture was cooled to rt and adjusted to pH 5-6 by adding aq. HC1 (2.0 N). The mixture was concentrated and the residue was diluted with EtOAc (100 mL) and H20 (25 mL). The organic layer was dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 19-2 (880 mg, 96% yield) as a white solid. LC-MS (ESI): m/z 418.1 [M+H]+.
[0326] Step 3. To a solution of compound 19-2 (830 mg, 2.0 mmol) in DCM (50 ml) was added (COCl)2 (379 mg, 3.0 mmol) at rt and the resulting mixture was stirred at rt for 1 hr. Subsequently, the mixture was cooled to 0 °C and ethyl enediamine was added (359 mg, 6.0 mmol). The resulting mixture was stirred at rt for 30 min and then concentrated to give crude compound 19-3, which was used for the next step without further purification. LC-MS (ESI): m/z 460.2 [M+H]+.
[0327] Step 4. A solution of compound 19-3 (900 mg, 1.96 mmol) and POCl3 (1.20 g, 7.84 mmol) in toluene (30 mL) was stirred at 90 °C overnight under an atmosphere of N2. The reaction mixture was concentrated and the residue was added sat. aq. NaHC03 to adjust to pH 7-8. The resulting suspension was filtered and the solid was dried in vacuo to give crude compound 19-4 as a white solid. LC-MS (ESI): m/z 442.2 [M+H]+.
[0328] Step 5. A solution of compound 19-4 (250 mg, 0.57 mmol), PhI(OAc)2 (201 mg, 0.62 mmol) and K2C03 (86 mg, 0.62 mmol) in DMSO (5 mL) was stirred at 25 °C for 24 hrs. The mixture was concentrated and the residue was purified by preparative HPLC to give compound 19-5 (30 mg, 12% yield) as a white solid. LC-MS (ESI): m/z 440.1 [M+H]+; Ή NMR (500 MHz, -DMSO): δ 12.43 (br, 1H), 7.95 - 7.98 (m, 2H), 7.48 (s, 1H), 7.34 (m, 3H), 7.20 (s, 1H), 4.08 (br, 2H), 3.21 (s, 3H), 3.04 (s, 1H), 1.92 (br, 4H), 1.36 (d, 2H, / = 7.0 Hz) ppm.
Figure imgf000166_0001
[0329] Synthesis of compound 19-6. Following the same procedure as described in the synthesis of compound 19-5 and replacing compound 19-2 with the corresponding de- methylated analog, compound 19-6 was obtained. LC-MS (ESI): m/z 426.1 [M+H]+.
Figure imgf000167_0001
[0330] Synthesis of compound 19-7. Following the same procedure as described in the synthesis of compound 19-5 and replacing compound 19-2 with the corresponding de- methylated eight-member ring analog, compound 19-7 was obtained. LC-MS (ESI): m/z 440.1 [M+H]+.
Figure imgf000167_0002
[0331] Synthesis of compound 19a-2. Refer to Scheme 19a. A solution of compound 19a- 1 (250 mg, 0.54 mmol) (prepared from compound 8-8 by following the procedure for the conversion of compound 19-2 to 19-3 described in Scheme 19) in POCl3 (5 mL) was stirred at 75 °C for 3 hrs under an atmosphere of N2 and then was concentrated to remove POCI3 under a reduced pressure. Subsequently, the residue was added sat. aq. NaHC03 (25 mL) and the resulting suspension was extracted with EtOAc (40 mL x 3). The combined organic extracts were washed with brine (50 mL) dried over anhydrous Na2SC>4. The solvent was removed and the residue was dried in vacuo to give crude compound 19a-2 (100 mg) as a white solid, which was used for the next aromatization step without further purification. LC- MS (ESI): m/z 444.1 [M+H]+.
Figure imgf000167_0003
[0332] Synthesis of compound 19-8. Following the same procedure as described in the preparation of compound 19-5 described in Scheme 19 and replacing compound 19-4 with 19a-2, compound 19-8 was obtained. LC-MS (ESI): m/z 442.1 [M+H]+; !H NMR (500 MHz,
Figure imgf000168_0001
7.5 Hz, 1H), 7.33 - 7.37 (m,3H), 7.20 (s, 1H), 4.87 - 4.88 (m, 1H), 3.87 - 4.06 (m, 4H), 3.38 (s, 3H), 1.59 (d, J = 7.0 Hz, 3H) ppm.
Figure imgf000168_0002
[0333] Synthesis of compound 19-9. Following the same procedure as described in the preparation of compound 19-5 described in Scheme 19, replacing compound 19-2 with 15-14, and taking the modified condition for dihydroimidazole formation shown in Scheme 19a, compound 19-8 was obtained. LC-MS (ESI): mlz 534.1 [M+H]+; lB NMR (500 MHz, cf- DMSO): δ 12.46 (s, 1H), 7.95 (d, J = 8.5 Hz, 2H), 7.84 (s, 1H), 7.60 (s, 1 H), 7.36 (s, 1 H), 7.26 - 7.30 (m, 2H), 7.15 - 7.19 (m, 3H), 7.06 (d, J = 8.5 Hz, 2H), 4.87 (m, 1 H), 4.00 - 4.03 (m, 1H), 3.88 - 3.93 (m, 2H), 3.38 (s, 3H), 3.18 - 3.19 (m, 1H), 1.58 (d, J = 6.5 Hz, 3H) ppm.
Figure imgf000168_0003
[0334] Synthesis of compound 19-10. Following the same procedure as described in the preparation of compound 19-5 described in Scheme 19, replacing compound 19-2 with the full carbon analog of compound 15-14 (prepared from compound 23-6 shown in Scheme 23 by hydrogenation of the terminal alkene residue and hydrolysis of the ethyl ester moiety), and taking the modified condition for dihydroimidazole formation shown in Scheme 19a, compound 19-10 was obtained. LC-MS (ESI): mlz 532.2 [M+H]+.
Scheme 20
Figure imgf000169_0001
[0335] Step 1. Refer to Scheme 20. To a solution of compound 4-4 (1.0 g, 2.5 mmol), DMAP (20 mg), and anhydrous pyridine (1.98 g, 25.0 mmol) in CH2C12 (20 mL) MsCl was added drop wise (0.86 g, 7.6 mmol) at 0 °C. After stirring at rt for 2 hrs, ice-water was added to the reaction mixture (100 mL). The organic layer was washed with water (20 mL) and brine (20 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 4/1 (v/v)) to give compound 20-1 (1.15 g, 96% yield). LC-MS (ESI): m/z 476.1 [M+H]+.
[0336] Step 2. A mixture of compound 20-1 (1.1 g, 2.3 mmol) and 10% Pd/C (1.1 g) in EtOAc (100 mL) was stirred at rt overnight under an atmosphere of H2. The mixture was filtered through Celite® 545 and the filtered cake was washed with EtOAc (25 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 20-2 (1.0 g, 98% yield). LC-MS (ESI): m/z 450.1 [M+ H]+.
[0337] Step 3. To a solution of compound 20-2 (1.00 g, 2.23 mmol) in THF (35 mL) was added DIPEA (7 mL) and the resulting mixture was refluxed overnight. The solvent was removed and the residue was dried in vacuo to give crude compound 20-3 (760 mg, 78% yield) as a yellow solid. LC-MS (ESI): m/z 354.1 [M+Hf.
[0338] Step 4. A solution of chlorosulfonyl isocyanate (0.3 mL, 3.4 mmol) in anhydrous DCM (3 mL) was added drop wise to tert-butanol (0.3 mL, 3.4 mmol) at 0 °C and the resulting mixture was stirred at rt for 2 hrs. Subsequently, the mixture was cooled to 0 °C and a solution of compound 20-3 (60 mg, 0.17 mmol) and TEA (0.6 mL) in anhydrous DCM (3 mL) was added drop wise. After stirring at rt for 3 hrs, the reaction mixture was diluted with water (10 mL) and DCM (20 mL). The organic layer was washed with brine and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 20-4 (70 mg, 77% yield) as a yellow solid. LC-MS (ESI): mlz 477.1 [M- C4H9+H]+.
[0339] Step 5. A mixture of compound 20-4 (70 mg, 0.13 mmol) and LiOH- H20 (28 mg, 0.66 mmol) in EtOH/THF/H20 (1.5 mL/3 mL/1.5 mL) was stirred at 70 °C for 2 hrs.
Subsequently, the mixture was added 2 N aq. HC1 to adjust the pH value to 3 and the resulting suspension was filtered. The solid was washed with water and dried in vacuo to give compound 20-5 (60 mg, 90% yield) as a yellow solid. LC-MS (ESI): mlz 449.1 [M-C4H9+H]+.
[0340] Step 6. To a solution of compound 20-5 (60 mg, 0.12 mmol) in DMF (2 mL) was added HATU (90 mg, 0.24 mmol). The resulting mixture was stirred at rt for 1 hr before DIPEA (154 mg, 1.19 mmol) and MeNH2 HCl (40 mg, 0.60 mmol) were added. After stirring at rt for 1 hr, the reaction mixture was added into ice-water (30 mL) and the resulting suspension was filtered. The solid was washed with water and dried in vacuo to give crude compound 20-6 (60 mg, 97% yield). LC-MS (ESI): mlz, 462.1 [M-C4H9+H]+.
[0341] Step 7. To a solution of compound 20-6 (60 mg, 0.12 mmol) in MeOH (1 mL) was added 3.5 M HC1 in dioxane (20 mL). After stirring at rt overnight, the mixture was concentrated and the residue was purified by preparative HPLC to give compound 20-7 (35 mg, 72% yield). LC-MS (ESI): mlz, 418.1 [M+H]+; lH NMR (500 MHz, MeOD):5 7.95 - 7.92 (m, 2H), 7.73 (s, 1H), 7.52 (s, 1H), 7.26 (t, 7 = 9.0 Hz, 2H), 3.63 (br , 2H), 3.05 (s, 2H), 2.97 (s, 3H), 1.96 (d, J = 6.5 Hz, 2H), 1.76 (br, 2H) ppm.
[0342] Syntheses of analogs of compound 20-7. Following the same synthetic strategy by treating compound 20-3 with various acyl chlorides or sulfonyl chlorides instead of chlorosulfonyl isocyanate, followed by hydrolyzation and methyl amide formation, the following analogs of compound 20-7 were obtained.
Figure imgf000170_0001
Figure imgf000171_0001
[0343] Step 1. Refer to Scheme 21. To a solution of compound 8-3 (600 mg, 1.76 mmol) in MeOH (150 mL) were added (S)-feri-butyl 2-formylpyrrolidine-l-carboxylate (1.05 g, 5.27 mmol) and glacial AcOH (106 mg, 1.76 mmol). After stirring at 35 °C for 2 hrs, the mixture was cooled to 0 °C and NaCNBH3 (220 mg, 3.52 mmol) was added. Subsequently, the mixture was refluxed for 2 hrs and concentrated. The residue was dissolved in EtOAc (100 mL) and the solution was washed with H20 (50 mL x 3) and dried with anhydrous Na2SC<4. The solvent was removed and the residue was purified by reverse phase preparative HPLC to give compound 21-1 (630 mg, 68% yield) as yellow fluffy solid. LC-MS (ESI): m/z 525.2 [M+H]+.
[0344] Step 2. To a solution of compound 21-1 (600 mg, 1.15 mmol) in dioxane (10 mL) was added 4 N HC1 in dioxane (20 mL). After stirring at 35 °C for 2 hrs, the reaction mixture was concentrated and the residue was dried in vacuo to give crude compound 21-2 (500 mg, quantitative yield) as a yellow solid. LC-MS (ESI): m/z 425.2 [M+H]+.
[0345] Step 3. To a stirred solution of compound 21-2 (500 mg, 1.2 mmol) in EtOH (30 mL) was added 1 N HC1 in dioxane (2 mL). After stirring at 35 °C for 2 hrs, the reaction mixture was cooled to 0 °C and NaCNBH3 (148 mg, 2.4 mmol) was added. The mixture was stirred at rt for 2 hrs and concentrated. The residue was dissolved in EtOAc (100 mL) and the solution was washed with brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by reverse phase preparative HPLC to give compound 21-3 (420 mg, 87% yield) as a yellow foam. LC-MS (ESI): m/z 409.2 [M+H]+. Long column (30 min) HPLC and Chiral HPLC showed there was only one diastereomer formed during the reductive-elimination step; however, the chirality of the benzylic carbon in compound 21-3 was not determined.
[0346] Step 4. To a solution of compound 21-3 (300 mg, 0.73 mmol) and Et3N (0.3 mL) in DCM (30 mL) was added MsCl drop wise (85 mg, 0.73 mmol) at 0 °C. After stirring at rt for 30 min, the reaction mixture was washed with H20 (20 mL x 3) and dried with anhydrous Na2SC»4. The solvent was removed and the residue was purified by reverse phase preparative HPLC to give compound 21-4 (186 mg, 52% yield) as a yellow solid. LC-MS (ESI): m/z 487.2 [M+H]+.
[0347] Step 5. A mixture of compound 21-4 (180 mg, 0.371 mmol) and LiOH H20 (47 mg, 1.1 mmol) in MeOH/THF/H20 (2 mL/4 mL/1 mL) was stirred at 75 °C for 30 min. The resulting mixture was acidified to pH 5-6 by adding 2 N aq. HC1. The suspension was filtered and the solid was dried in vacuo to give compound 21-5 (150 mg, 93% yield) as a white solid. LC-MS (ESI): m/z 459.1 [M+H]+.
[0348] Step 6. To a solution of compound 21-5 (150 mg, 0.327 mmol) in DMF (5 mL) was added HATU (187 mg, 0.491 mmol). After stirring at rt for 30 min, the mixture was added DDPEA (127 mg, 0.982 mmol) and MeNH2 HCl (66 mg, 0.98 mmol). Subsequently, the mixture was stirred at rt for 30 min and poured into ice-water (50 mL). The suspension was filtered and the solid was purified by preparative HPLC to give compound 21-6 (32 mg, 21% yield) as a white solid. LC-MS (ESI): m/z 472.2 [M+H]+.
Figure imgf000173_0001
[0349] Synthesis of compound 21-7. Following the same scheme and replacing (S)-tert- butyl 2-formylpyrrolidine-l-carboxylate with its (R)-enantiomer, compound 21-7 was obtained. LC-MS (ESI): mlz 472.2 [M+H]+. Long column (30 min) HPLC and Chiral HPLC showed there was only one diastereomer formed during the reductive-elimination step; however, the chirality of the benzylic carbon in compound 21-7 was not determined.
Scheme 22
Figure imgf000174_0001
[0350] Step 1. Refer to Scheme 22. A solution of compound 6-5 (1.0 g, 2.28 mmol) in DCM (200 mL) was cooled to -78 °C and (¾ was flushed through until the starting material disappeared as monitored by TLC. Excessive 03 was removed completely by flushing the reaction mixture with N2. Subsequently, NaBH4 (866 mg, 22.8 mmol) and MeOH (40 mL) were added to the mixture. After stirring at -78 °C for 3 hrs, the reaction mixture was warmed to rt and water (200 mL) was added. The aqueous phase was extracted with DCM (50 mL x 3) and the combined organic extracts were washed with water (100 mL x 2) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 22-1 (958 mg, 94% yield) as a white solid. LC-MS (ESI): m/z 430.1 [M-H20]+.
[0351] Step 2. A mixture of compound 22-1 (1.0 g, 2.24 mmol) and TsOH H20 (170 mg, 0.90 mmol) in toluene (40 mL) was refluxed overnight. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 10/1) to give compound 22-2 (600 mg, 63% yield) as a white solid. LC-MS (ESI): m/z 430.1
[M+H]+.
[0352] Step 3. A solution of Et Zn (1.1 M in hexane, 27.5 mL, 27.5 mmol) was added into
DCM (30 mL) dropwise at -78 °C under an atmosphere of N2, followed by addition of CH2I2
(4.4 mL, 55.0 mmol). After the reaction mixture was stirred at -78 °C for 30 min, a solution of compound 22-2 (536 mg, 1.25 mmol) and TFA (0.5 mL) in DCM (10 mL) was added. The resulting mixture was stirred at -78 °C for 3 hrs and then partitioned between water (80 mL) and DCM (80 mL). The aqueous phase was extracted with DCM (50 mL x 3). The combined organic extracts were washed with water (100 mL x 3) and brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 10/1 (v/v)) to give compound 22-3 (190 mg, 35% yield) as a yellow solid. LCMS (ESI): m/z, 444.1 [M+H]+; 'H NMR (500 MHz, CDC13): 5 8.1 1 (m, 1H), 8.02 - 8.04 (m, 2H), 7.53 (s, 1H), 7.16 - 7.20 (m, 2H), 4.41 - 4.44 (m, 2H), 4.1 l(m, 1H), 3.40 (m, 1 H), 3.02 (s, 3H), 2.28 (m, 1H), 2.18 (m, 2H), 1.42 (t, 3H), 1.20 (m, 2H), 0.63 (m, 1H , 0.41 (m, 1H) ppm.
[0353] Step 4. To a solution of compound 22-3 (190 mg, 0.429 mmol) in MeOH/THF (5 mL/5 mL) was added 2 N aq. LiOH (0.857 mL, 1.761 mmol). The resulting mixture was stirred at 75 °C overnight, then cooled to rt, acidified with 2 N aq. HC1 to pH 5-6, and extracted with EtOAc (30 mL x 2). The combined organic extracts were washed with H20 (25 mL) and brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 22-4 (178 mg, 99% yield) as a white solid, which was used directly in the next step without further purification. LC-MS (ESI): m/z 337.1 [M-Ms].
[0354] Step 5. To a solution of compound 22-4 (138 mg, 0.33 mmol) in DMF (3 mL) was added HATU (152 mg, 0.40 mmol) at rt. The resulting mixture was stirred for 30 min and then added DIPEA (86 mg, 0.67 mmol) and CH3NH2 HC1 (45 mg, 0.67 mmol). After stirring at rt for 20 min, the reaction mixture was poured into water and the suspension was filtered. The solid was washed with water, dried in vacuo, and re-crystallized in EtOAc and hexane to give compound 22-5 as white solid (120 mg, 84% yield). LC-MS (ESI): m/z 429.1 [M+H]+; ]H NMR (500 MHz, DMSO): δ 8.49 (s, 1H), 7.94-7.97 (m, 2H), 7.63 (s, 1H), 7.57 (s, 1H), 7.39 (t, J = 9.0 Hz, 2H), 3.95-4.00 (m, 1H), 3.26-3.29 (m, 1H), 3.14 (s, 3H), 2.84 (d, J = 4.5 Hz, 3H), 2.14-2.23 (m, 2H), 1.11-1.22 (m, 2H), 0.44-0.52 ( m, 1H), 0.30-0.33 (m, 1H) ppm. Compound 22-5 was separated to give a pair of enantiomers: enantiomer 22-5_A (_R = 2.48 min) and enantiomer 22-5JB (tR = 4.90 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μπι Lux Amylose-2 column (column temperature: 40.2 °C; eluent:
MeOH/liquid C02 = 40/60 (v/v); C02 flow rate: 1.8 g/min and co-solvent flow rate: 1.2 g/min; front pressure: 207 bar and back pressure: 151 bar). Scheme 23
Figure imgf000176_0001
[0355] Step 1. Refer to Scheme 23. A mixture of compound 15-6 (8.0 g, 16.7 mmol) and 10% Pd/C (4.0 g) in EtOAc (200 mL) was stirred at rt for 3 hrs under an atmosphere of H2. The reaction mixture was filtered through a Celite® 545 pad and the filtered cake was washed with EtOAc (50 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 23-1 (7.5 g, quantitative yield as a yellow solid. LC-MS (ESI): m/z. 450.2 [M+H]+.
[0356] Step 2. To a solution of compound 23-1 (7.5 g, 16.7 mmol) in anhydrous pyridine (100 mL) was added dropwise a solution of MsCl (1.4 mL, 17.54 mmol) in anhydrous DCM (20 mL) at 0 °C. After stirring at 0 °C for 3 hrs, the reaction mixture was diluted with EtOAc (500 mL). The resulting mixture was washed with 1 M aq. HQ (200 mL x 3) and brine (100 mL x 2) and dried with anhydrous Na2S0 . The solvent was removed and the residue was re- crystallized in EtOAc to give compound 23-2 (7.9 g, 90% yield) as a pale brown solid. LC- MS (ESI): m/z 528.1 [M+H]+.
[0357] Step 3. To a solution of compound 23-2 (7.9 g, 15.0 mmol) in DMF (150 mL) was added K2C03 (8.3 g, 60.0 mmol), followed by 5-bromo-l-pentene (2.68 g, 18.0 mmol). After stirring at 80 °C for 2 hrs, the reaction mixture was concentrated. The residue was diluted with EtOAc (200 mL) and water (200 mL). The aqueous phase was extracted with EtOAc (150 mL x 3). The combined organic extracts were washed with (250 mL) and brine (250 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 23-3 (7.9 g, 93% yield) as a yellow solid. LC-MS (ESI): m/z 618.2 [M+Na]+.
[0358] Step 4. To a solution of compound 23-3 (7.6 g, 12.8 mmol) in DCM (100 mL) was added dropwise BC13 in DCM (31.9 g, 31.9 mmol.) at -30 °C under an atmosphere of N2. After stirring at -30 °C for 2 hrs, the reaction mixture was poured into ice-water (300 mL) and the resulting mixture was extracted with DCM (150 mL x 3). The combined organic extracts were washed with water (100 mL x 3) and brine ( 100 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 23-4 (7.2 g, 98% yield) as a yellow solid. LC-MS (ESI): m/z 554.2 [M+H]+.
[0359] Step 5. To a solution of compound 23-4 (7.5 g, 13.6 mmol) in DCM (100 mL) were added DIPEA (5.25 g, 40.7 mmol) and DMAP ( 165 mg, 1.4 mmol), followed by a solution of Tf20 (5.0 g, 17.6 mmol) in DCM (25 mL) at 0 °C. After stirring at rt overnight, the reaction mixture was diluted with DCM (300 mL) and water (300 mL). The aqueous phase was extracted with DCM (300 mL x 2). The combined organic extracts were washed with water (250 mL x 3) and brine (250 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 20/1 (v/v)) to give compound 23-5 (8.0 g, 90% yield) as a yellow solid. LC- MS (ESI): m z 686.1 [M+H]+.
[0360] Step 6. A mixture of compound 23-5 (8.0 g, 11.7 mmol), LiCl (539 mg, 12.8 mmol), Et3N (3.24 mL, 23.3 mmol), Pd(OAc)2 (392 mg, 1.8 mmol), and PPh3 (1.22 g, 4.7 mmol) in DMF (80 mL) was stirred at 120 °C for 2 hrs under an atmosphere of Ar. Subsequently, the reaction mixture was concentrated and the residue was partitioned between water (200 mL) and EtOAc (200 mL). The aqueous phase was extracted with EtOAc (150 mL x 3) and the combined organic extracts were washed with water (250 mL x 3) and brine (250 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 10/1 (v/v)) to give compound 23-6 (4.0 g, 64% yield) as a yellow solid. LC-MS (ESI): m/z, 536.1 [M+H]+; 1H NMR (500 MHz, CDC13): δ 8.02 - 8.04 (m, 2H), 7.95 (s, 1H), 7.68 (s, 1H), 7.07 - 7.10 (m, 4H), 7.03 - 7.05 (m, 2H), 5.30 (m, 1H), 5.20 (d, 1H), 4.40 - 4.44 (t, 2H), 3.85 (m, 2H), 2.87 (s, 3H), 2.52 (m, 2H), 1.95 (m, 2H), 1.42 (t, / = 5.5 Hz, 3H) ppm.
[0361] Synthesis of compound 23-7. Following the same procedures of hydrolyzation and methylamide formation as described in the synthesis of compounds 6-6 and 7-1, respectively, compound 23-7 was obtained. LC-MS (ESI): m/z 521.1 [M+H]+; JH NMR (300 MHz,
CDCI3): δ 7.83 (dd, 7, = 1.6 Hz, J2 = 6.2 Hz, 2H), 7.75 (s, 1 H), 7.65 (s, 1 H), 7.02-7.10 (m, 6H), 5.86 (m, 1 H), 5.29 (s, 1 H), 5.17 (d, J = 1.8 Hz, 1H), 3.82 (m, 2H), 2.99 (d, 7 = 5.7 Hz, 3H), 2.85 (3, 3H), 2.47 (m, 2H), 1.93 (m, 2H) ppm.
[0362] Synthesis of compound 23-8. Following the same procedure of isomerization as described in the synthesis of compound 7-4, compound 23-8 was obtained. LC-MS (ESI): m/z
521.1 [M+H]+; Ή NMR (300 MHz, CDC13): δ 7.81 (dd, = 1.8 Hz, J2 = 5.9 Hz, 2H), 7.63 (s, 1H), 7.26 (s, 1H), 70.3-7.10 (m, 6H), 6.04 (m, 1H), 5.85 (m, 1H), 4.15 (m 2H), 2.98 (d, J =
5.1 Hz, 3H), 2.76 (s, 3H), 2,20 (s, 3H), 2.17 (m, 2H) ppm.
[0363] Synthesis of compound 23-9. Following the same procedure of hydrogenation as described in the synthesis of compound 7-3, compound 23-9 was obtained. LC-MS (ESI): m/z,
523.2 [M+H]+; !H NMR (300 MHz, CDCI3): δ 7.82 (d, / = 8.7 Hz, 2H), 7.72 (s, 1H), 7.54 (s, 1H), 7.03-7.10 (m, 6H), 5.84 (m, 1H), 4.10 (m, 1H), 3.24 (m, 2H), 3.08 (s, 3H), 3.00 (d, J =
5.2 Hz, 3H), 1.92-2.02 (m, 4H), 1.46 (d, J = 6.7 Hz, 3H) ppm. Compound 23-9 was separated into a pair of enantiomers: enantiomer 23-9_A (tR = 3.82 min) and enantiomer 23-9_B (tR = 4.99 min) detected by UV absorption at 214 nm on a ChiralPak® IB column (column temperature: 40.3 °C; eluent: MeOH/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; front back pressure: 152 bar).
[0364] Synthesis of compound 23-10. Follwoing the same procedure of cyclopropanation as described in the synthesis of compound 6-7, followed by hydrolyzation and methyl amide formation, compound 23-10 was obtained. LC-MS (ESI): m/z 535.2 [M+H]+; *H NMR (500 MHz, CDCI3): δ 7.82 (dd, Jx = 2.0 Hz, h = 5.0 Hz, 2H), 7.79 (d, J = 3.0 Hz, 1H), 7.52 (s, 1H), 6.97 - 7.10 (m 6H), 5.84 (m, 1H), 3.58 - 3.71 (m, 2H), 3.15 (s, 3H), 3.00 (d, J = 4.5 Hz, 3H), 1,94 (m, 2H), 1.61 (m, 2H), 1.04 (m, 2H), 0.92 (m, 2H) ppm.
Scheme 24
Figure imgf000179_0001
[0365] Step 1. Refer to Scheme 24. Following the same procedure as described in the synthesis of compound 22-1, compound 24-1 was obtained as a yellow solid in 80% yield. LC-MS (ESI): m/z = 540.1 [M+H]+.
[0366] Step 2. Following the same procedure as described in the synthesis of compound 22-2, compound 24-2 was obtained as a yellow solid in 57% yield. LC-MS (ESI): m/z = 522.1 [M+Hf; Ή NMR (500 MHz, CDC13): δ 8.03 - 8.06 (m, 2H), 7.77 (s, 1H), 7.07 - 7.09 (m, 4H), 7.03 - 7.05 (m, 2H), 6.63 (d, 1H), 6.01(d, 1H), 4.41 - 4.45 (m, 2H), 3.85 - 3.91 (brs, 2H), 2.80 (brs, 2H), 2.76 (s, 3H), 1.43 (t, / = 7.0 Hz, 3H) ppm.
[0367] Synthesis of compound 24-3. Following the same procedure as described in the synthesis of compound 23-7, compound 24-3 was obtained as a white solid in 88% yield. LC- MS (ESI): m/z 507.1 [M+H]+; 1H NMR (500 MHz, CDCI3): δ 7.84 (d, / = 9.0 Hz, 2H), 7.77 (d, / = 12.0 Hz, 2H), 7.04 - 7.10 (m, 6H), 6.60 (d, J = 12.5 Hz, 1H), 5.97 - 5.99 (m, 1H), 5.81 (br, lH), 3.26 - 3.29 (m, 1H), 3.89 (br, 2H), 2.99 (d, J = 5.0 Hz, 3H), 2.78 (br, 2H), 2.75 (s, 3H) ppm.
[0368] Synthesis of compound 24-4. Following the same procedure as described in the synthesis of compound 23-9, compound 24-4 was obtained as a white solid in 50% yield. LC- MS (ESI): m/z 509.1 [M+H]+; *H NMR (500 MHz, CDC13): δ 7.84 (d, / = 9.0 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.03 - 7.1 1 (m, 6H), 5.83 (br.lH), 3.69 (br, 2H), 3.06 (s, 3H), 2.97 - 3.00 (m, 5H), 1.92 - 1.94 (m, 2H), 1.74 (br, 2H) ppm.
[0369] Synthesis of compound 24-5. Following the same procedure as described for the synthesis of compound 23-10, compound 24-5 was obtained. LC-MS (ESI): m/z 521.1
[M+H]+; Ή NMR (500 MHz, CDCI3): 5 7.91 (s, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.50 (s, 1H), 7.05 - 7.11 (m, 6H), 5.84 (m, 1H), 4.10 (dt, = 5.0 Hz, J2 = 15.0 Hz, 1H), 3.39 (dd, /, = 5.0 Hz, h = 13.0 Hz, 1H), 3.00 (s and d, / = 3.5 Hz, 6H), 2.25 (m, 1H), 2.14 (m, 1H), 1.15 (m, 2H), 0.63 (m, 1H), 0.39 (m, 1H) ppm. Compound 24-5 was separated into a pair of enantiomers: enantiomer 24-5_A (IR = 7.237 min) and enantiomer 24-5_B (t = 10.044 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μιη ChiralPak® AS-H column (column temperature: 40 °C; eluent: n-Hexane/EtOH/DEA = 70/30/0.1 (v/v/v); flow rate: 1.0 mL/min).
Figure imgf000180_0001
[0370] Step 1. Refer to Scheme 25. A mixture of compound 25-1 (600 mg, 3.8 mmol), 4- pentyn-l-ol (620 mg, 7.4 mmol), Cul (141 mg, 0.74 mmol), Et3N (1.57 g, 1 1 .4 mmol), and Pd(dppf)Cl2 (266 mg, 0.38 mmol) in DMF (30 mL) was stirred at rt overnight under an atmosphere of N2. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/ Acetone = 4/1 to 2/1 (v/v)) to give compound 25-2 (250 mg, 32% yield) as a yellow oil. LC-MS: (ESI) m/z 207.1 [M+H]+.
[0371] Step 2. A mixture of compound 25-2 (250 mg, 1.2 mmol) and 10% Pd/C (150 mg) in MeOH (20 mL) was stirred at rt overnight under an atmosphere of ¾. The mixture was filtered through a Celite® 545 pad and the filtered cake was washed with MeOH (25 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give compound 25-3 (200 mg, 91% yield) as a yellow oil. LC-MS: (ESI) m/z 181.1 [M+H]+.
[0372] Step 3. To a solution of compound 25-3 (200 mg, 1.1 mmol) and Et3N (0.90 mL, 6.6 mmol) in DCM (10 mL) was added dropwise a solution of MsCl (376 mg , 3.3 mmol) in DCM (5 mL) over 10 min at 0 °C. After stirring at rt for 1 hr, the reaction mixture was filtered through a Celite® 545 pad and the filtered cake was washed with DCM (25 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 25- 4 (495 mg) as yellow solid, which was used for the next step without further purification. LC- MS: (ESI) m/z 415.1 [M+H]+.
[0373] Step 4. A mixture of compound 25-4 (495 mg, 1.1 mmol) and K2C03 (607 mg, 4.4 mmol) in DMF (10 mL) and H20 (2 mL) was stirred at 80 °C overnight. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/Acetone = 3/1 to 1/1 (v/v)) to give compound 25-5 (100 mg, 37% yield, two steps from compound 25-3) as a white oil. LC-MS (ESI): m/z 241.1 [M+H]+; JH NMR (500 MHz, CDC13): 5 8.40 (s, 1H), 8.34 - 8.35 (d, / = 5.0 Hz, 1 H), 7.29 - 7.30 (d, J = 5.0 Ηζ, ΙΗ), 3.52 (br, 2H), 3.06 (s, 3H), 2.81 ( br, 2H), 1.63 (br, 2H), 1.50 (br, 2H), 1.40 (br, 2H) ppm.
[0374] Synthesis of compound 25-7. Following the same procedure as described in the synthesis of compound 13-5 from 13-3, compound 25-7 was obtained as a yellow solid in 33% yield (two steps from 25-5). LC-MS: (ESI) m/z 446.1 [M+H]+.
[0375] Synthesis of compound 25-9. Following the same procedure as described in the synthesis of compound 13-12 from 13-10, compound 25-9 was obtained as a yellow solid in 62% yield (two steps from 25-7). LC-MS: (ESI) m/z 431.1 [M+H]+; ]H NMR (500 MHz, CDC13): δ 8.44 (s, 1H), 8.23 (s, lH), 7.65 - 7.68 (m, 2H), 7.21 - 7.25 (m, 2H), 5.48 (br, 1H), 3.65 (br, 2H), 3.09 ( s, 3H), 2.95 (br, 2H), 2.85 - 2.86 (d, / = 5.0 Hz, 3H), 1.54 - 1.65 (m, 6H) ppm.
[0376] Synthesis of compound 25-10. Following the same procedure as described in the synthesis of compound 19-5 from 19-2, compound 25-10 was obtained as a white solid. LC- MS: (ESI) m/z 440.1 [M+H]+; H NMR (500 MHz, -DMSO): δ 9.04 (s, 1H,), 7.70 (s, 2H), 7.69 (s, 3H), 7.59 - 7.62 (m, 2H), 7.25 (t, / = 8.5 Hz, 2H), 3.71 (br, 2H), 3.24 (s, 3H), 3.01(br, 2H), 1.70 (br, 6H) ppm.
Scheme 26
Figure imgf000182_0001
[0377] Step 1. Refer to Scheme 26. To a solution of prop-2-yn-l-ol (2.24 g, 40 mmol) in DME (80 mL) was added KOH (2.7 g, 48 mmol) at 0 °C. After stirring at 0 °C for 30 min, the mixture was drop- wisely added a solution of TsCl (8.36 g, 44 mmol) in DME (40 mL) and the resulting mixture was stirred at 0 °C for 4 hrs. Subsequently, the reaction mixture was concentrated and the residue was added DCM (50 mL) and water (50 mL). The aqueous phase was extracted with DCM (100 mL x 3) and the combined organic extracts were washed with water (100 mL) and brine (100 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography to give compound 26-1 (4.3 g, 51 % yield) as a colorless oil. LC-MS (ESI): m/z 211.0 [M+H]+.
[0378] Step 2. To a solution of compound 8-4 (712 mg, 1.7 mmol) in DMF (30 mL) was added K2C03 (414 mg, 3 mmol) under an atmosphere of argon. After stirring at rt for 1 hr, the reaction mixture was added 26-1 (714 mg, 3.4 mmol) and the resulting mixture was stirred at 60 °C for 2 hrs. The mixture was concentrated and the residue was partitioned between EtOAc (100 mL) and water (100 mL). The aqueous phase was extracted with EtOAc (50 mL x 3) and the combined organic extracts were washed with water (50 mL x 2) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 26-2 (700 mg, 90% yield) as a yellow solid. LC-MS (ESI): m/z 458.1 [M+H]+.
[0379] Step 3. To a solution of compound 26-2 (685 mg, 1.5 mmol) in EtOH (20 mL) was added NaBH4 (1 14 mg, 3 mmol) in portions at 0 °C. After stirring at 0 °C for 2 hrs, the reaction was quenched by adding several drops of acetone. The mixture was concentrated and the residue was partitioned between EtOAc (25 mL) and water (25 mL). The aqueous phase was extracted with EtOAc (25 mL x 3) and the combined organic extracts were washed with brined (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give compound 26-3 (640 mg, 93% yield) as a colorless oil. LC-MS (ESI): m/z 460.1 [M+H]+.
[[0380] Step 4. To a solution of compound 26-3 (640 mg, 1.4 mmol) and DMAP (10 mg, 0.075 mmol) in DCM (50 mL) was added Et3N (0.83 mL, 6 mmol) at 0 °C, followed by MsCl (0.5 mL, 3 mmol). After stirring at 0 °C for 2 hrs, the reaction mixture was diluted with DCM (50 mL). The mixture was washed with sat. aq. NH4C1 (25 mL) and brine (25 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 2/1 (v/v)) to give compound 26-4 (450 mg, 95% yield) as a yellow solid. LC-MS (ESI): m/z 538.1 [M+H]+.
[0381] Step 5. To a solution of NaN3 (390 mg, 6 mmol) in DMF (5 mL) at 65 °C was added compound 26-4 (322 mg, 0.6 mmol). After stimng at 65 °C for 24 hrs, the reaction mixture was concentrated. The residue was partitioned between EtOAc (25 mLO and water (25 mL). The aqueous phase was extracted with EtOAc (25 mL x 3) and the combined organic extracts were washed with brine (50 mL) and dried with anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 2/1 (v/v)) to give compound 26-5 (121 mg, 41 % yield) as a yellow solid. LC- MS (ESI): m/z 485.1 [M+H]+.
[0382] Synthesis of compound 26-7. Following the same procedure as described in the synthesis of compound 25-9 from 25-7, compound 26-7 was obtained as a white solid in 43% yield (two steps from compound 26-5). LC-MS: (ESI) m/z 470.1 [M+H]+; *H NMR(500 MHz, CDC13): 6 7.99 (s, 1H), 7.87 - 7.90 (m, 2H), 7.70 (s, 1H),7.51 (s, 1H), 7.22 (t, / = 7.5 Hz, 2H), 6.21 (m, 1H), 5.85 (br, 1H), 4.97 and 5.17 (AB, JAB = 16.0 Hz, 2H), 3.20 (s, 3H), 3.01 (d, J = 4.5 Hz, 3H), 2.14 (d, J = 6.5 Hz, 3H) ppm.
Scheme 26a
Figure imgf000183_0001
[0383] Step 1. Refer to Scheme 26a. To a solution of compound 8-4 (4.6 g, 11 mmol) in a mixed solvent of DCM (20 mL) and EtOH (60 mL) at 0 °C was added NaBH4 (756 mg, 20 mmol) in small portions. After stirring at 0 °C for 2 hrs, the reaction mixture was slowly added H20 (20 mL) and then concentrated. The residue was extracted with DCM (100 mL x 3) and the combined organic extracts were washed with water (50 mL x 3) and brine (50 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 2/1 (v/v)) to give compound 26a-l (4.3 g, 92% yield) as a yellow solid. LC-MS (ESI); m/z 404.1 [M-H20+H]+.
[0384] Step 2. To a solution of compound 26a-l (4.3 g, 10 mmol) in toluene (120 mL) were added DPPA (4.3 mL, 20 mmol) and DBU (3 mL, 20 mmol). The reaction mixture was stirred at 50 °C for 4 hrs. Subsequently, the mixture was concentrated and the residue was purified by silica gel column chromatography (PE/EtOAc = 2/1 (v/v)) to give compound 26a- 2 (4.0 g, 85% yield) as a yellow solid. LC-MS (ESI): m/z, 447.1 [M+H]+.
[0385] Step 3. To a solution of compound 26a-2 (3.95 g, 8.8 mmol) in DMF (50 mL) was added K2CO3 (1.38 g, 10 mmol) and the mixture was stirred at rt for 30 min. Next, a solution of compound 26-1 (2.52 g, 12 mmol) in 20 mL DMF was added. After stirring at rt overnight, the reaction mixture was poured into H20 (150 mL). The mixture was extracted with EtOAc (100 mL x 3) and the combined organic extracts were washed with water (100 mL x 3) and brine (50 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 2/1 (v/v)) to give compound 26a-3 (3.3 g, 78% yield) as a yellow solid. LC-MS (ESI): m z 485.1 [M+H]+.
[0386] Step 4. To a solution of compound 26a-3 (3 g, 6.2 mmol) in DMSO/H20 (60 mL/20 mL) were added Sodium Ascorbate (2.32 g, 9.3 mmol) and CuS04«5H20 (1.55 g, 6.2 mmol). After stirring at rt overnight, the reaction mixture was poured into H20 (100 mL). The resulting mixture was extracted with EtOAc (100 mL x 3) and the combined organic extracts were washed with water (50 mL x 3) and brine (50 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (DCM MeOH = 40/1 (v/v)) to give compound 26-5 (2.1 g, 66% yield) as a yellow solid. LC- MS (ESI): m/z 485.1 [M+H]+.
[0387] Step 5. Following the same procedure as that for the preparation of 1-16 described in Scheme 1 and replacing compound 1-14 with 26-5, compound 26-7 (1.3 g, 67% yield) was obtained as a white solid. LC-MS (ESI): m/z 470.1 [M+H]+; !H NMR (500 MHz, -DMSO):
5 8.53 (q, / = 4.8 Hz, 1H), 8.04 (s, 1H), 7.97 - 7.99 (m, 2H), 7.96 (s, 1H), 7.60 (s, 1H), 7.42
(t, / = 8.5 Hz, 2H), 6.34 (q, J = 7.0 Hz, 1H), 5.39 and 4.72 (AB, JAB = 17.5 Hz, 2H), 3.56 (s,
1H), 2.86 (d, / = 4.5 Hz, 3H), 1.89 (d, / = 7.5 Hz, 3H) ppm. Compound 26-7 was separated into a pair of enantiomers: enantiomer 26-7_A (tR = 8.596 min) and enantiomer 26-7JB (tR = 1 1.887 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm χ 5 μιη ChiralPak AS column (column temperature: 40 °C; eluent: n-Hexane/EtOH/DEA = 70/30/0.1 (v/v/v); flow rate: l .O mL/min).
Scheme 26b
Figure imgf000185_0001
[0388] Step 1. Refer to Scheme 26b. Following the same procedure as that for the synthesis of compound 26-7 described in Scheme 26 and replacing compound 26-5 with 8-4,
compound 26b-l was obtained. LC-MS (ESI): m/z 405.1 [M+H]+.
[0389] Step 2. Following the same procedure as that for the synthesis of compound 26a-l described in Scheme 26a and replacing compound 8-4 with 26b-l, compound 26b-2 was obtained. LC-MS (ESI): m/z 407.1 [M+H]+.
[0390] Step 3. Following the same procedure as that for the synthesis of compound 26a-2 described in Scheme 26a and replacing compound 26a-l with 26b-2, compound 26b-3 was obtained as a yellow solid. LC-MS (ESI): m/z 390.1 [M-N3+H]+.
[0391] Step 4. To a solution of compound 26b-3 (43 mg, 0.1 mmol) in DMF (2 mL) was added K2C03 (28 mg, 0.2 mmol) and the resulting mixture was stirred at rt for 30 min. Next, a solution of 2-bromoacetonitrile (24 mg, 0.2 mmol) in 1 mL DMF was added. After stining at rt for 4 hrs, the mixture was poured into H20 (20 mL). The mixture was extracted with EtOAc (20 mL x 3) and the combined organic extracts were washed with water (15 mL x 3) and brine (10 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 2/1 (v/v)) to give compound 26b-4 (42 mg, 89% yield) as a yellow solid. LC-MS (ESI): m/z 429.1 [M-N3+H]+.
[0392] Step 5. To a solution of compound 26b-4 (24 mg, 0.05 mmol) in DMF (2 mL) was added NH4C1 (26, 0.5 mmol). After being heated at 150 °C in a microwave reactor for 8 hrs, the reaction mixture was cooled to rt and poured into H20 (30 mL). The suspension was extracted with EtOAc (20 mL x 3) and the combined organic extracts were washed with water (15 mL x 3) and brine (10 mL x 1 ) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by preparative HPLC to give compound 26b-5 (15 mg, 63% yield) as a yellow solid. LC-MS (ESI): m/z 471.1 [M+H]+; Ή NMR (500 MHz, CD3OD): δ 7.95 - 7.97 (m, 2H), 7.93 (s, 1H), 7.90 (s, 1H), 7.27 (t, 9 Hz, 2H), 6.34 (q, J = 7 Hz, 1H), 5.48 (m, 1H), 5.07 (m, 1H), 3.50 (s, 3H), 2.97 (s, 3H), 2.08 (br s, 3H) ppm.
Scheme 26c
Figure imgf000186_0001
[0393] Step 1. Refer to Scheme 26c. To a solution of compound 8-2 (5.0 g, 13.5 mmol) in EtOH (150 mL) was added NaBH4 (921 mg, 24.3 mmol) at rt. After stirring at rt for 4 hrs, the reaction mixture was added several drops of acetone and concentrated. The residue was diluted with water (20 mL) and EtOAc (100 mL). The organic layer was washed with water (25 mL x 2) and brine (25 mL), dried over anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography (PE/EtOAc = 2/1 (v/v)) to give compound 26c-l (4.3 g, 85% yield) as a yellow solid. LC-MS (ESI): m/z 356.2 [M-H20+H]+.
[0394] Step 2. To a solution of compound 26c-l (1.0 g, 2.7 mmol) in DMF (20 mL) at 0 °C was added dropwise a solution of PBr3 (0.78 mL, 8.1 mmol) in DMF (3 mL). After stirring at 0 °C for 10 min, the reaction mixture was added water (20 mL). The mixture was extracted with EtOAc (20 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography (PE EtOAc = 10/1 (v/v)) to give compound 26c-2 (500 mg, 43% yield) as a yellow solid. LC-MS (ESI): m/z 356.1 [M-Br+H]+.
[0395] Step 3. To a solution of compound 26c-2 (1.0 g, 2.7 mmol) and lH-imidazole-2- carbaldehyde (220 mg, 2.3 mmol) in DMF (5 mL) was added Na2C03 (366 mg, 3.45 mmol). After stirring at 80 °C for 2 hrs, the reaction mixture was diluted with water (20 mL). The resulting mixture was extracted with EtOAc (20 mL x 3). The combined organic extracts were washed with water (20 mL x 2) and brine (20 mL), dried over anhydrous Na2S0 , and concentrated. The residue was purified by silica gel column chromatography (PE/EtOAc = 10/1 (v/v)) to give compound 26c-3 (300 mg, 58% yield) as a yellow solid. LC-MS (ESI): mlz 452.1 [M+H] +.
[0396] Step 4. To a solution of compound 26c-3 (300 mg, 0.67 mmol) in EtOAc (10 mL) was added 10% Pd/C(150 mg), and the resulting mixture was stirred at rt for 12 hrs under an atmosphere of ¾. at the completion of the reaction, the reaction mixture was filtered through Celite®545 and the filtered cake was washed with EtOAc (20 mL x 2). The filtrate was concentrated and the residue was purified by silica gel column chromatography
(DCM/MeOH = 50/1 (v/v)) to give compound 26c-4 (150 mg, 56% yield) as a yellow solid. LC-MS (ESI): mlz 406.1 [M+H]+.
[0397] Step 5. To a solution of compound 26c-4 (150 mg, 0.37 mmol) in DCM (3 mL) was added Et3N (0.1 mL, 0.74 mmol), followed by MsCl (43 μί, 0.56 mmol). After stirring at rt for 2 hrs, the reaction mixture was diluted with DCM (35 mL) and washed with water (15 mL x 2) and brine (15 mL), dried over anhydrous Na2S04, and evaporated. The residue was purified by silica gel column chromatography (DCM/MeOH = 50/1 (v/v)) to give compound 26c-5 (60 mg, 34% yield) as a yellow solid. LC-MS (ESI): mlz 484.1 [M+H]+.
[0398] Step 6. Following the same procedure as that used for the preparation of 1-16 described in Scheme 1 and replacing compound 1-14 with 26c-5, compound 26c-6 was obtained as a white solid. LC-MS (ESI): mlz 469.1 [M+H]+; *H NMR (500 MHz, CDC13): δ 7.92 (s, 1H), 7.83 - 7.86 (m, 2H), 7.64 (s, 1H), 7.21 (t, J = 8 Hz, 2H), 6.96 (d, J - 1 1.5 Hz, 2H), 5.82 (d, J = 4.5 Hz, 1H), 5.67 - 5.68 (m, lH), 5.05 (s, 2H), 3.21 (s, 3H), 2.98 (d, J = 5.5 Hz, 3H), 2.05 (d, J = 7.5 Hz, 3H) ppm.
Scheme 27
Figure imgf000187_0001
[0399] Step 1. Refer to Scheme 27. To a stirred solution of compound 15-11 (1.0 g, 2.0 mmol) in DMF (25 mL) was added 2C03 (1.1 g, 8.0 mmol) at rt, followed by 3-bromo-2- methylpropene (324 mg, 2.4 mmol). After stirring at 80 °C for 2 hrs, the reaction mixture was cooled to rt and partitioned between water (60 mL) and EtOAc (50 mL). The aqueous layer was extracted with EtOAc (40 mL x 3). The combined organic extracts were washed with water (60 mL x 3) and brine (60 x 2 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 10/1 (v/v)) to give compound 27-la (760 mg, 67% yield) as a yellow solid. LC-MS (ESI): m/z 588.1 [M+Na]+.
[0400] Step 2. To a stirred solution of compound 27-la (375 mg, 0.66 mmol) in a mixed solvent of THF (6 mL) and MeOH (6 mL) was added NaBH4 (75.5 mg, 2.0 mmol) in portions at 0 °C. After stirring at 0 °C for 2 hrs, the reaction was quenched by adding several drops of acetone and the resulting mixture was concentrated. The residue was partitioned with water (20 mL) and EtOAc (20 mL) and the aqueous layer was extracted with EtOAc (30 mL x 3). Subsequently, the combined organic extracts were washed with water (30 mL x 3) and brine (10 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE EtOAc = 3/1 (v/v)) to give compound 27- la (369 mg, 98% yield) as a yellow solid. LC-MS (ESI): m/z 590.2 [M+Na]+.
[0401] Step 3. To a stirred solution of compound 27-2a (320 mg, 0.56 mmol) in DCM (20 mL) were added phenylselenophtalimide (255 mg, 0.85 mmol) and (±)-camphorsulfonic acid (26 mg, 0.11 mmol) at 0 °C. After stirring at rt overnight, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (PE/EtOAc = 3/1 (v/v)) to give compound 27-3a (290 mg, 71 % yield) as a white solid. LC-MS (ESI): m/z 746.1 [M+Na]+.
[0402] Step 4. To a stirred solution of compound 27-3a (320 mg, 0.44 mmol) in a mixed solvent of CH2C12 (30 mL) and EtOH (50 mL) was added Raney nickel (160 mg). After refluxing for 2 hrs, the reaction mixture was filtered through a pad of Celite® 545 and the filtrate was concentrated. The residue was purified by silica gel column chromatography (PE/EtOAc = 4/1 (v/v)) to give compound 27-4a (120 mg, 48% yield) as a yellow solid. LC- MS (ESI): m/z 590.2 [M+Na]+.
[0403] Step 5. Following the same procedure as that for the preparation of compound 1-16 described in Scheme 1 and replacing compound 1-14 with 27-4a, compound 27-5a was obtained as a white solid. LC-MS (ESI): m/z 553.2 [M+H]+; Ή NMR (500 MHz, CDC13): δ
7.82 - 7.87 (m, 4H), 7.04 - 7.11 (m, 6H), 5.80 - 5.85 (m, 1H), 5.15 (q, 7 = 6.4 Hz, 1H), 4.14
(d, / = 14.0 Hz, 1H), 3.11 (s, 3H), 2.99 (d, 7 = 5.0 Hz, 3H), 2.98 (d, 7 = 14.0 Hz, 1H), 1.67 (d,
7 = 7.0 Hz, 3H), 1.53 (s, 3H), 1.14 (s, 3H) ppm. Compound 27-5a was separated into a pair of enantiomers: enantiomer 27-5a_A (t¾ = 3.93 min) and enantiomer 27-5a_B (tR = 4.66 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm χ 5 μιη ChiralPak® IA column (column temperature: 40.2 °C; eluent: MeOH (0.1% DEA)/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; back pressure: 152 bar).
[0404] Synthesis of compound 27-5b. Follwoing the same procedure as that for the synthesis of compound 27-5a described in Scheme 27 and replacing compound 15-11 with 8- 4, compound 27-5b was obatined as a white solid. LC-MS (ESI): mlz 461 .1 [M+H]+; lH NMR (500 MHz, CDC13): δ 7.91 (dd, J, = 3.5 Hz, J2 = 6.2 Hz, 2H), 7.89 (s, 1H), 7.86 (s, 1 H), 7.19 (t, J = 8.5 Hz, 2H), 5.80 (m, 1H), 5.15 (q, J = 6.5 Hz, 1H), 4.14 (d, J = 14.5 Hz, 1H), 3.12 (s, 3H), 3.00 (d, J = 5.5 Hz, 3H), 2.89 (d, J = 14.5 Hz, 1H), 1.66 (d, J = 6.5 Hz, 3H), 1.54 (s, 3H), 1.15 (s, 3H) ppm. Compound 27-5b was separated into a pair of enantiomers: enantiomer 27-5b_A (tR = 2.31 min) and enantiomer 27-5b_B (tR = 3.38 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm, 5 μπι ChiralPak® AD-H column (column temperature: 39.6 °C; eluent: MeOH/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; back pressure: 151 bar).
Scheme 28
1. NaBH4, THF/MeOH; 2. allybromide, K2CO:
Figure imgf000190_0001
[0405] Synthesis of compound 28-3a. Refer to Scheme 28. Following the same procedure as that for the praparation of compound 27-3a from 15-11 described in Scheme 27 and replacing 3-bromo-2-methylpropene with allyl bromide, compound 28-3a was obtained as a white solid. LC-MS (ESI): mJz 732.1 [M+Naf.
[0406] Synthesis of compound 28-5a. Following the same procedure as that for the praparation of compound 27-5a from 27-3a described in Scheme 27 and replacing compound 27-3a with 28-3a, compound 28-5a was obtained as a white solid. LC-MS (ESI): mlz 539.2 [M+H]+; !H NMR (500 MHz, CDC13): δ 7.89 and 7.78 (s, s, 1H), 7.83 (dd, J, = 6.5 Hz, J2 = 8.5 Hz, 2H), 7.61 and 7.58 (br s, s, 1H), 7.04 - 7.12 (m, 6H), 5.83 (d, J = 4.0 Hz, 1H), 5.18 and 4.98 (dd, dd, J, = 13.5 Hz, J2 = 6.5 Hz, 1H), 4.13 - 4.16 and 3.78 - 3.81 (m, m, 2H), 3.15 and 3.12 (s, s, 3H), 3.12 and 2.85 (m, m, 1H), 3.00 (d, J = 5.0 Hz, 3H), 1.73 (t, J = 6.5 Hz, 3H), 1.23 and 1.17 (d, d, / = 6.5 Hz, 3H) ppm. Alternatively, compound 28-5a can be obtained using compound 28-7a as the starting material described in Scheme 28. [0407] Synthesis of compound 28-5b. Following the same procedure as that for the praparation of compound 28-5a described in Scheme 27 and replacing compound 27-3a with 28-3b, compound 28-5b was obtained as a white solid. LC-MS (ESI): m/z 447.1 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.89 - 7.92 (m, 2H), 7.87 (s, 1H), 7.59 (s, 1 H), 7.20 (t, J = 8.5 Hz, 2H), 5.78 (m, 1H), 4.98 (m, 1H), 4.14 (m, 2H), 3.15 and 3.12 (s, s, 3H), 3.01 (d, = 4.5 Hz, 3H), 2.83 (m, 1H), 1.73 and 1.71 (d, d, / = 7.0 Hz, 3H), 1.23 and 1.18 (d, d, 7 = 6.5 Hz, 3H) ppm. Alternatively, compound 28-5b can be obtained using compound 28-7b as the starting material described in Scheme 28.
[0408] Synthesis of compound 28-6a. To a solution of compound 28-3a (2.1 g, 3.0 mmol) in DCM (200 mL) was added m-CPBA (563 mg, 3.3 mmol) at 0 °C. After stirring at 0 °C for 30 min, the reaction mixture was washed with saturated aq. NaHC03 solution and water. The organic layer was dried over anhydrous Na2S04 and concentrated to dryness to give crude compound 28-6a as a red solid, which was used in the next step without further purification. LC-MS (ESI): m/z, 748.1 [M+Na]+.
[0409] Synthesis of compound 28-7a. Compound 28-6a (375 mg, 0.52 mmol) was dissolved in dry toluene (300 mL) and the resulting solution was added DBU (4.2 mL, 28.1 mmol) at 0 °C. After stirring at 100 °C for 45 min under an atmosphere of N2, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (PE/EtOAc = 5/1 to 3/1 (v/v)) to give compound 28-7a (248 mg, 87% yield) as an off white solid. LC-MS (ESI): m/z 552.1 [M+H]+; ]H NMR (500 MHz, -DMSO): δ 8.05 (d, / = 9.0 Hz, 2H), 8.00 (s, 1H), 7.79 (s, 1H), 7.31 (m, 2H), 7.21 - 7.23 (m, 2H), 7.12 (d, / = 9.0 Hz, 2H), 5.46 (q, J = 6.0 Hz, 1H), 4.67 (d, / = 14.0 Hz, 1H), 4.46 (s, 1H), 4.40 (s, 1 H), 4.36 (q, / = 7.0 Hz, 2H), 4.20 (d, = 14.0 Hz, 1H), 3.24 (s, 3H), 1.72 (d, J = 6.0 Hz, 3H), 1 .36 (t, / = 7.0 Hz, 3H) ppm.
[0410] Synthesis of compound 28-8a. Under an atmosphere of N2, ZnEt? (1 M in hexane, 7.40 mL, 7.40 mmol) was added to dry DCM (20 mL) at -78 °C, followed by CH2I2 (1.2 mL, 14.8 mmol) over 10 min. The resulting mixture was stirred at -78 °C for 30 min and then at -10 °C for 30 min. The mixture was cooled to -78 °C and a solution of TFA (137 uL, 1.9 mmol) in DCM (1 mL) was added dropwise. After stirring at -78 °C for 30 min, the mixture was added dropwise a solution of compound 28-7a (340 mg, 0.62 mmol) in DCM (2 mL) at -78 °C. The resulting mixture was stirred at -78 °C for 10 min, 0 °C for 1 hr, and 25 °C for 4 hrs. Subsequently, saturated aq. NH4C1 solution (10 mL) was added and the mixture was concentrated. The residue was extracted with DCM (20 mL x 3). The combined organic extracts were washed with saturated aq. NaHC03 solution and water and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 10/1 to 4/1 (v/v)) to give compound 28-8a (230 mg, 66% yield) as a white solid. LC-MS (ESI): m/z 566.2 [M+H]+; Ή NMR (500 MHz, 6- DMSO): δ 8.06 - 8.08 (m, 2H), 8.01 (s, IH), 7.88 (s, IH), 7.30 - 7.34 (m, 2H), 7.21 - 7.24 (m, 2H), 7.12 - 7.14 (m, 2H), 5.09 (q, J = 6.0 Hz, IH), 4.36 (q, / = 7.5 Hz, 2H), 3.69 (d, J = 15.0 Hz, IH), 3.57 (d, J = 15.0 Hz, IH), 3.32 (s, 3H), 1.57 (d, / = 6.0 Hz, 3H), 1.35 (t, / = 7.5 Hz, 3H), 0.71 - 0.96 (m, 4H) ppm.
[0411] Synthesis of compound 28-9a. Following the same procedure as that for the praparation of 1-16 described in Scheme 1 and replacing compound 1-14 with 28-8a, compound 28-9a was obtained as a white solid. LC-MS (ESI): m/z 551.2 [M+H]+; Ή NMR (500 MHz, -DMSO): δ 8.50 (d, J = 4.5 Hz, I H), 7.92 (d, J = 9 Hz, 2H), 7.83 (s, IH), 7.56 (s, IH), 7.28 - 7.32 (m, 2H), 7.17 - 7.20 (m, 2H), 7.12 (d, J = 8.5 Hz, 2H), 5.06 (dd, Ji = 12.5 Hz, J2 = 6.5 Hz, I H), 3.67 (d, / = 15.5 Hz, IH), 3.56 (d, = 14.5 Hz, IH), 3.31 (s, 3H), 2.84 (d, J = 4.5 Hz, 3H), 1.54 (d, / = 6 Hz, 3H), 0.70 - 0.93 (m, 4H) ppm. Compound 28-9a was separated into a pair of enantiomers: enantiomer 28-9a_A (tR = 4.13 min) and enantiomer 28- 9a_B (tR = 5.05 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μιη Regis (i?,/?)-Whelk-ol column (column temperature: 39.3 °C; eluent: MeOH/liquid C02 = 50/50 (v/v); C02 flow rate: 1.5 g/min and co-solvent flow rate: 1.5 g/min; front pressure: 218 bar and back pressure: 152 bar).
[0412] Synthesis of compound 28-9b. Following the same procedure as that for the praparation of compound 28-9a described in Scheme 28 and replacing compound 15-11 with 8-4, compound 28-9b was obtained as a white solid. LC-MS (ESI): m/z 459.1 [M+H]+; !H NMR (500 MHz, ^-DMSO): δ 8.53 (m, IH), 7.97 (dd, J, = 5.5 Hz, J2 = 8.7 Hz, 2H), 7.85 (s, IH), 7.58 (s, IH), 7.41 (t, J = 8.5 Hz, 2H), 5.06 (q, / = 6.5 Hz, IH), 3.68 (d, / = 14.5 Hz, I H), 3.57 (d, J = 14.5 Hz, IH), 3.32 (s, 3H), 2.84 (d, J = 4.5 Hz, 3H), 1.54 (d, / = 6.5 Hz, 3H), 0.93 (m, IH), 0.84 - 0.86 (m, 2H), 0.70 (m, IH) ppm. Compound 28-9b was separated into a pair of enantiomers: enantiomer 28-9b_A (tR = 4.36 min) and enantiomer 28-9b_B (tR = 6.09 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm 5 μηι ChiralPak® AD-H column (column temperature: 39.8 °C; eluent: MeOH/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; back pressure: 150 bar).
[0413] Synthesis of compound 28-10a. To a solution of compound 28-7a (680 mg, 1.2 mmol) in THF (10 mL) was added BH3 THF (7.4 mL, 7.4 mmol) at 0 °C. After stirring at rt for 3 hrs, the reaction mixture was added 3 N aq. NaOH (7 mL) at 0 °C, followed by 30% aq. H202 (7 mL). The reaction mixture was stirred at rt overnight and the added iced water (30 mL). The mixture was extracted with EtOAc (25 mL x 2). The combined organic extracts were washed with water (20 mL x 2), dried over anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography (DCM/ Acetone = 50/1 (v/v)) to give compound 28-10a (560 mg, 80% yield) as a white solid. LC-MS (ESI): mlz 592.2
[M+Na]+.
[0414] Synthesis of compound 28-10b. Following the same procedure as that for the praparation of compound 28-10a and replacing compound 28-7a with 28-7b, compound 28- 10b was obtained as a white solid. LC-MS (ESI): mlz 500.1 [M+Naf.
[0415] Synthesis of compound 28-lla. Following the same procedure as that for the praparation of compound 1-16 described in Scheme 1 and replacing compound 1-14 with 28- 10a, compound 28-lla was obtained as a white solid. LC-MS (ESI): mlz 555.2 [M+Hf; 'H NMR (500 MHz,
Figure imgf000193_0001
δ 8.42 - 8.50 (m, IH), 7.90 - 7.93 (m, 2H), 7.82 and 7.77 (s, s, IH), 7.56 and 7.54 (s, s, IH), 7.27 - 7.31 (m, 2H), 7.17 -7.19 (m, 2H), 7.11 (d, / = 8.5 Hz, 2H), 5.17 and 4.88 (m, m, IH), 4.78 (m, IH), 4.18 and 3.99 (m, m, IH), 3.93 (m, IH), 3.45 (m, IH), 3.47 (m, IH), 3.38 and 3.36 (s, s, 3H), 2.84 (d, / = 4.5 Hz, 3H), 2.83 (m, IH), 1.62 and 1.60 (d, d, J = 6.5 Hz, 3H) ppm.
[0416] Synthesis of compound 28-llb. Following the same procedure as that for the praparation of compound 28-lla described in Scheme 28 and replacing compound 28-10a with 28-10b, compound 28-llb was obtained as a white solid. LC-MS (ESI): mlz 463.1 [M+H]+; *H NMR (500 MHz, -DMSO): 5 8.52 (m, IH), 7.95 - 7.98 (m, 2H), 7.83 and 7.79 (s, s, 1 H), 7.58 and 7.57 (s, s, IH), 7.40 (t, / = 9.0 Hz, 2H), 4.88 (q, / = 6.5 Hz, IH), 4.78 (t, = 5.5 Hz, IH), 4.19 (d, i = 15 Hz, IH), 3.92 (m, IH), 3.43 - 3.48 (m, IH), 3.39 (s, 3H), 3.26 - 3.31 (m, IH), 2.84 (d, .7 = 4.5 Hz, 3H), 2.83 (m, IH), 1.62 and 1.60 (d, d, 7 = 6.0 Hz, 3H) ppm.
[0417] Synthesis of compound 28-12a. To a solution of compound 28-10a (200 mg, 0.35 mmol), DMAP (21 mg, 0.18 mmol) and Et3N (0.15 mL, 1.1 mmol) in CH2C12 (5 mL) was added TsCl (100 mg, 0.53 mmol) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added ice water (10 mL) and DCM (25 mL). The organic layer was washed with saturated aq. NaHC03 (10 mL x 2), water (10 mL x 2) and brine (10 mL), dried over anhydrous Na2SC>4, and concentrated. The residue was purified by silica gel column chromatography (PE/EtOAc = 6/1 to 2/1 (v/v)) to give the tosylate as a white solid (230 mg,
91% yield). LC-MS (ESI): mlz 746.2 [M+Na] +. Subsequently, a mixture of the tosylate (140 mg, 0.19 mmol), MeS02Na (59 mg, 0.58 mmol) and KI (964 mg, 0.581 mmol) in DMF (2 mL) was stirred at 120 °C for 2 hrs. The mixture was then poured into water (15 mL). The resulting precipitate was filtered and the white was washed with water (15 mL x 3) and dried in vacuo to give compound 28-12a (100 mg, 82% yield). LC-MS (ESI): mlz 654.1 [M+Na]+.
[0418] Synthesis of compound 28-12b. Following the same procedure as that for the praparation of compound 28-12a described in Scheme 28 and replacing compound 28-10a with 28-10b, compound 28-12b was obtained as a white solid. LC-MS (ESI): m/z 562.1
[M+H]+.
[0419] Synthesis of compound 28-13a. Following the same procedure as that for the praparation of compound 1-16 described in Scheme 1 and replacing compound 1-14 with 28- 12a, compound 28-13a was obtained as a white solid. LC-MS (ESI): m/z 617.1 [M+H]+; XH NMR (500 MHz, CDC13): δ 7.94 (s, 1 H), 7.81 (dd, 7/ = 2.5 Hz, J2 = 8.5 Hz, 2H), 7.61 (s, 1H), 7.05 - 7.13 (m, 6H), 5.82 (m, 1H), 5.09 (q, 7 = 8.5 Hz, 1H), 4.59 (t, 7 = 11.5 Hz, 1H), 4.24 (d, 7 = 18.5 Hz, 1H), 3.16 (s, 3H), 3.05 - 3.13 (m, 3H), 3.07 (s, 3H), 2.98 (d, 7 = 6.0 Hz, 3H), 1 .78 (d, 7 = 8.5 Hz, 3H) ppm. Alternatively, compound 28-13a can be obtained using compound 28-lla as the starting material as described in Scheme 28.
[0420] Synthesis of compound 28-13b. Following the same procedure as that for the praparation of compound 28-13a described in Scheme 28 and replacing compound 28-12a with 28-12b, compound 28-13b was obtained as a white solid. LC-MS (ESI): m/z 525.1
[M+H]+; !H NMR (500 MHz, -DMSO): δ 8.52 (m, 1H), 7.95 - 7.99 (m, 2H), 7.87 (s, 1H), 7.61 (s, 1H), 7.40 (t, 7 = 8.5 Hz, 2H), 4.98 (q, 7 = 6.0 Hz, 1H), 4.39 (t, 7 = 9.0 Hz, 1H), 4.20 (d, 7 = 14.0 Hz, 1H), 3.37 (s, 3H), 3.29 - 3.32 (m, 2H), 3.04 (s, 3H), 2.89 (m, 1H), 2.85 (d, 7 =4.5 Hz, 3H), 1.66 (d, 7 = 6.5 Hz, 3H) ppm. Alternatively, compound 28-13b can be obtained using compound 28-llb as the starting material as described in Scheme 28.
Figure imgf000194_0001
[0421] Step 1. Refer to Scheme 29. To a solution of compound 4-2 (9.0 g, 18.9 mmol) in DME (200 mL) and H20 (400 mL) were added K2C03 (7.8 g, 56.6 mmol), Pd(dppf)Cl2 (1.5 g, 1 .9 mmol) and 4,4,5,5-tetramethyl-2-vinyl-l ,3,2-dioxaborolane (4.4 g, 28.3 mmol). After stirring at 60 °C for 2 hrs under an atmosphere of Ar, the reaction mixture was concentrated and the residue was partitioned between water (150 mL) and EtOAc (150 mL). The aqueous phase was extracted with EtOAc ( 100 mL x 3) and the combined organic extracts were washed with water (100 mL x 3) and brine (100 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by silica gel column chromatography (PE/EtOAc = 15/1 (v/v)) to give compound 29-1 (5.0 g, 75% yield) as a yellow solid. LCMS (ESI): m/z 356.1 [M+H]+.
[0422] Step 2. To a solution of compound 29-1 (1.2 g, 3.4 mmol) in THF (50 mL), EtOH (20 mL) and HO Ac (40 mL) was slowly added Zn (1.3 g, 20.1 mmol) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was filtered and the filtrate was concentrated. The residue was partitioned between water (80 mL) and EtOAc (80 mL) and the organic layer was extracted with EtOAc (60 mL x 3). The organic extracts were combined and washed with water (80 mL x 2), sat. aq. NaHC03 (80 mL) and brine (80 mL) and dried over anhydrous Na2S04. The solvent was concentrated and the residue was dried in vacuo to give crude compound 29-2 (1.0 g, 91 % yield) as a yellow solid. LC-MS (ESI): m/z 326.1 [M+H]+.
[0423] Step 3. To a solution of compound 29-2 (1.0 g, 3.1 mmol) in anhydrous pyridine (5 mL) was treated with DMAP (20 mg), followed by a solution of MsCl (1.1 g, 9.2 mmol) in DCM (3 mL) at 0 °C. After stirring at rt for 3 hrs, the reaction mixture was concentrated and the residue was partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with DCM (30 mL x 3) and the combined organic extracts were washed with water (60 mL x 2) and brine (60 mL) and dried over anhydrous Na2S04. The solvent was removed and the residue was dried in vacuo to give crude compound 29-3 (1.1 g, 88% yield) as a yellow solid. LC-MS (ESI): m/z 404.1 [M+H]+.
[0424] Step 4. To a solution of compound 29-3 (700 mg, 1.7 mmol) in DMF (30 mL) were added K2C03 (719 mg, 5.2 mmol) and KI (144 mg, 0.87 mmol), followed by 2-bromobenzyl chloride (534 mg, 2.6 mmol). After stirring at 70 °C for 3 hrs, the reaction mixture was concentrated and the residue was partitioned between water (50 mL) and EtOAc (50 mL). The aqueous layer was extracted with EtOAc (3 x 40 mL) and the combined organic extracts were washed with water (80 mL x 3) and brine (50 mL) and dried over anhydrous Na S04. The solvent was removed and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 15/1 (v/v)) to give compound 29-4 (800 mg, 87% yield) as a yellow solid. LC-MS (ESI): m/z 574.0 [M+H]+.
[0425] Step 5. To a solution of compound 29-4 (770 mg, 1.34 mmol) in CH3CN (25 ml) were added Et3N (4.6 mL), and Pd(PPh3)4 (1.55 g, 1.34 mmol). After stirring at 80 °C for several hours under an atmosphere of Ar, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 10/1 (v/v)) to give compound 29-5 (260 mg, 40% yield) as a yellow solid. LC-MS (ESI): mlz 492.1 [M+H]+.
[0426] Step 6. To a solution of compound 29-5 ( 150 mg, 0.31 mmol) in EtOH (30 mL) was added 5% Pd/C (w/w, 200 mg). After stirring at 50 °C for several hours under an atmosphere of H2, the reaction mixture was filtered through a pad of Celite®545. The filtered cake was washed with EtOH (15 mL x 2). The filtrate was concentrated and the residue was dried in vacuo to give crude compound 29-6 (149 mg, 99% yield) as a yellow solid. LC-MS (ESI): mlz 494.1 [M+H]+.
[0427] Step 7. Following the same procedure as that for for the praparation of compound 1- 16 described in Scheme 1 and replacing compound 1-14 with 29-6, compound 29-7 was obtained (130 mg, 90% yield) as a pale brown solid. LC-MS (ESI): mlz 479.1 [M+H]+; Ή NMR (500 MHz, CDC13): δ 7.85 - 7.88 (m, 2H), 7.78 (s, 1H), 7.71 (s, 1H), 7.30 (d, 2H), 7.15 - 7.24 (m, 5H), 5.76 (brs, 2H), 5.12 (d, /= 16 Hz, 2H), 4.95 (d, 7 = 16 Hz, 5H), 4.57 - 4.62 (dd, J2 = 15 Hz, J2 = 7 Hz, 1 H), 2.72 (d, J = 5 Hz, 3H), 2.73 (s, 3H), 1.80 (d, 7 = 8 Hz, 3H) ppm. Compound 29-7 was separated into a pair of enantiomers: enantiomer 29-7_A (tR = 4.16 min) and enantiomer 29-7_B (tR = 6.05 min) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm 5 μιη ChiralPak® OD-H column (column temperature: 40.4 °C; eluent:
MeOH/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; front pressure: 205 bar and back pressure: 148 bar).
Scheme 30
Figure imgf000196_0001
30-1a R = F 30-2a R = F
30-1 b R = 4-F-PhO- 30-2b R = 4-F-PhO-
[0428] Chiral separation of compound 8-5. Compound 8-5 (3.8 g) was separated into a pair of enantiomers: (R)-8-5 (tR = 2.61 min, 1.6 g, 84% yield) and (5)-8-5 (tR = 3.14 min, 1.6 g, 84% yield) detected by UV absorption at 214 nm on a 4.6 mm x 250 mm x 5 μπι
ChiralPak® AD-H column (column temperature: 40.2 °C; eluent: MeOH (0.1 % DEA)/liquid C02 = 30/70 (v/v); C02 flow rate: 2.1 g/min and co-solvent flow rate: 0.9 g/min; front pressure: 206 bar and back pressure: 149 bar).
[0429] Chiral separation of compound 15-12. Using the same prep-chiral HPLC condition as that used for separating compound 8-5, Compound 15-12 (5.6 g) was separated into a pair of enantiomers: (/?)-15-12 (tR = 5.71 min, 1.1 g, 39% yield) and (S)- 15-12 (tR = 6.58 min, 1.0 g, 36% yield).
Figure imgf000197_0001
7.08 30-1a
[0430] Synthesis of compound 30-la. To a solution of the enantiomer came out first from the chiral separation of compound 8-5 (tR = 2.61 min) (30 mg, 0.07 mmol) and (i?)-MaNP (18.4 mg, 0.08 mmol) in CH2C12 (2 mL) was added DCC (72.1 mg, 0.35 mmol), followed by DMAP (17.1 mg, 0.14 mmol). After stirring at rt for 20 hrs, the reaction mixture was concentrated and the residue was diluted with EtOAc (45 mL). The solution was washed with water (20 mL) and brine (20 mL), dried with anhydrous Na2S04, and concentrated. The residue was purified by prep-HPLC to give compound 30-la (15 mg) as a white powder. LC- MS: (ESI) mlz = 656.2 [M+Na]+; Ή NMR (500 MHz, CDC13): δ 8.1 1 - 8.13 (m, 2H), 7.74 - 7.77 (m, 2H), 7.60 (d, / = 7.0 Hz, 2H), 7.47 (t, / = 8.0 Hz, 1H), 7.45 (s, 1H), 7.22 (t, = 9.0 Hz, 2H ), 7.08 (s, 1H), 7.00 (t, J = 7.0 Hz, 1H), 6.76 (t, / = 8.0 Hz, 1H), 6.07 (q, J = 7.0 Hz, 1H), 4.23 - 4.36 (m, 2H), 3.05 (s, 3H), 2.98 (s, 3H), 2.03 (s, 3H), 1.49 (d, J = 7.0 Hz, 3H), 1.27 (t, / = 7.0 Hz, 3H) ppm.
Figure imgf000197_0002
[0431] Synthesis of compound 30-2a. Following the same procedure as that used for preparing compound 30-la and replacing (R)-MaNP with (S)-MaNP, compound 30-2a was obtained. LC-MS: (ESI) mlz = 656.2 [M+Na]+; Ή NMR (500 MHz, CDC13): δ 8.06 - 8.09 (m, 2H), 7.95 (d, .7 = 8.5 Hz, 1 H), 7.87 (s, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.73 (s, 1H), 7.67 (s, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.28 (t, / = 7.5 Hz, 1 H), 7.20 (t, J = 7.5 Hz, 2H), 7.06 (t, / = 7.5 Hz, 1H), 6.12 (q, / = 6.5 Hz, 1H), 4.35 - 4.41 (m, 2H), 3.12 (s, 3H), 3.00 (s, 3H), 2.00 (s, 3H), 1.48 (d, / = 6.5 Hz, 3H), 1.27 (t, J = 7.0 Hz, 3H) ppm.
Figure imgf000198_0001
[0432] Synthesis of compound 30-lb. Following the same procedure as that used for preparing compound 30-la and using the enantiomer came out first from the chiral separation of compound 15-12 (tR = 5.71 min), compound 30-lb was obtained. LC-MS: (ESI) mlz = 748.2 [M+Na]+; !H NMR (500 MHz, CD3C1): 5 8.08 - 8.10 (m, 2H), 7.06 - 7.11 (m, 7H), 6.99 (t, / = 7.0 Hz, 1H), 6.75 (dt, /, = 1.0 Hz, J2 = 8.0 Hz, 1 H), 6.06 (q, J = 7.0 Hz, 1H), 4.24 - 4.35 (m, 2H), 3.05 (s, 3H), 2.98 (s, 3H), 2.03 (s, 3H), 1.49 (d, J = 7.0 Hz, 3H), 1.27 (t, / = 7.0 Hz, 3H) ppm.
Figure imgf000198_0002
[0433] Synthesis of compound 30-2b. Following the same procedure as that used for preparing compound 30-lb and replacing (R)-MaNP with (S)-MaNP, compound 30-2b was obtained. LC-MS: (ESI) mlz = 748.2 [M+Naf; Ή NMR (500 MHz, CD3C1): 5 8.06 (d, 7 = 7.0 Hz, 2H), 7.93 (d, J = 8.5 Hz, 1H), 7.85 (s, 1H), 7.83 (d, / = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.69 (s, 1 H), 7.63 - 7.66 (m, 2H), 7.46 (t, / = 8.0 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.04 - 7.10 (m, 7H), 6.10 (q, J = 7.0 Hz, 1H), 4.36 - 4.39 (m, 2H), 3.13 (s, 3H), 2.99 (s, 3H), 1.91 (s, 3H), 1.48 (d, J = 7.0 Hz, 3H), 1.36 (t, / = 7.0 Hz, 3H) ppm.
Figure imgf000199_0001
TetrahedronA- symmetry 2000, 11, 1249
Chirality 2002, 14, 81
[0434] Determination of chirality. Refer to Scheme 31. Based on the general rule of chemical shfits of a pair of diastereomeric esters derived from an alcohol with (7?)-ΜαΝΡ and (5)-Ma P, the chirality of the benzylic carbon in the enantiomer came out first (tR = 2.61 min) from the chiral separation of compound 8-5 was determined as R. Accordingly, the chirality of the benzylic carbon in the enantiomer came out first (tR = 5.71 min) from the chiral separation of compound 15-12 was determined as R.
Figure imgf000199_0002
(S)-8-S R = F
(S)-15-12 R = 4-F-PhO-
[0435] Synthesis of compound (R)-8-5. Refer to scheme 32. A 25 mL flask was charged with triethylamine (76 mg, 0.75 mmol, 7 eq.) in an ice bath, followed by adding formic acid (35 mg, 0.75 mmol, 7 eq.) dropwise. After stirring at rt for 20 min, a solution of compound 8- 4 (45 mg, 0.107 mmol, 1 equiv.) in DMF (6 mL) and RuCl[(R,«)-Tsdpen](p-cymene) (1.6 mg, 0.0029 mmol 0.024 equiv.) were added. The resulting dark red reaction mixture was stirred at 40 °C overnight and then concentrated. The residue was purified by silica column
chromatography (EtOAc/PE = 1 : 1 (v/v)) to give compound (/?)-8-5 (30 mg, 66% yield, 95.5%ee) as a white solid. The absolute configuration of the sample (tR = 2.59 min) was determined as R by taking chiral HPLC along with compound 8-5 following chiral HPLC the condition in Scheme 30. [0436] Synthesis of compound (5)-8-5. Following the same procedure as described for the preparation of compound (R)-8-5 and replacing RuCl[(i?,R)-Tsdpen](p-cymene) with RuCl[(S,S)-Tsdpen] ?-cymene), compound (S)-8-5 (28 mg, 66% yield, 94.0%ee, tR = 3.12 min, 5 configuration) was obtained from compound 8-4 (42 mg, 0.1 mmol).
[0437] Synthesis of compound ( ?)-15-12. Following the same procedure as described for the preparation of compound (R)-8-5 and replacing compound 8-4 with compound 15-11 (50 mg, 0.1 mmol), compound (S)-8-12 (38 mg, 75% yield, 95.9%e<?, tR = 5.76 min, R
configuration).
[0438] Synthesis of compound (S)-15-12. Following the same procedure as described for the preparation of compound (/f)-15-12 and replacing RuCl[(i?,i?)-Tsdpen](p-cymene) with RuCl[(S,5)-Tsdpen](/?-cymene), compound (S)-15-12 (70 mg, 70% yield, 96.6% ee, tR = 6.70 min, S configuration) was obtained from compound 15-11 (100 mg, 0.2 mmol).
[0439] Synthesis of compound (R)-8-9. Using compound (R)-8-5 as the starting material and following the same procedure for the preparation of compound 8-9 described in Scheme 8, compound (R)-8-9 was obtained. Chiral HPLC analysis determined that compound (R)-8-9 and enantiomer 8-9_A obtained from chiral separation of compound 8-9 are identical.
[0440] Synthesis of compound (/?)-15-15. Using compound (R)-15-12 as the starting material and following the same procedure for the preparation of compound 15-15 described in Scheme 15, compound (i?)-15-15 was obtained. Chiral HPLC analysis determined that compound (/?)-15-15 and enantiomer 15-15_A obtained from chiral separation of compound 15-15 are identical.
[0441] Syntheses of diastereomers of compounds 28-lla and -13a. Using either compounds (/?)-15-12 or (5)-15-12 as the starting material and following the procedure for the preparation of compounds 28-lla and -13a described in Scheme 28, those diastereomers of compounds 28-lla and -13a were obtained, respectively. The absolute configurations of those diastereomers were determined by 2D-COSY and NOESY spectra.
[0442] Syntheses of diastereomers of compounds 28-llb and -13b. Using either compounds (if )-8-5 or (S)-8-5 as the starting material and following the procedure for the preparation of compounds 28-llb and -13b described in Scheme 28, those diastereomers of compounds 28-llb and -13b were obtained, respectively. The absolute configurations of those diastereomers were determined by 2D-COSY and NOESY spectra.
Figure imgf000201_0001
[0443] Step 1. Refer to Scheme 33. A mixture of compound 8-5 (500 mg, 1.2 mmol), 2- chloro-l-(4-fluorophenyl)ethanone (266 mg, 1.5 mmol) and K2C03 (492 mg, 3.6 mmol) in DMF (4 mL) was stirred at 50 °C for 2 hrs. Subsequently, the reaction mixture was poured into water (100 mL) and the suspention was filtered. The solid obtained was purified by silica gel column chromatography (PE/EtOAc = 4/1 (v/v)) to give compound 33-1 (500 mg, 76 % yield) as a yellow solid. LC-MS (ESI): m/z 461.1 [M-H20-Ms+H]+.
[0444] Step 2. To a solution of compound 33-1 (300 mg, 0.54 mmol) in THF/EtOH (5 mL/5 mL) was added NaBH4 (102 mg, 2.7 mmol) at 0 °C. After stirring at rt for 2 hrs, the reaction mixture was added several drops of acetone and the concentrated. The residue was diluted with water (25 mL) and extracted with DCM (25 mL x 3). The combined extracts were washed with water (25 mL) and brine (25 mL), dried over anhydrous Na2S04, and concentrated. The residue was dried in vacuo to give compound 33-2 (300 mg, 99% yield) as a yellow solid. LC-MS (ESI): m/z 463.2 [M-H20-Ms+H]+.
[0445] Step 3. To a solution of compound 33-2 (180 mg, 0.322 mmol) in CH2C12 (2 mL) was added TMSOTf (143 mg, 0.64 mmol) at 0 °C. After stirring at 0 °C for 10 min, the reaction mixture was added saturated aq. NaHC03 (25 mL) and the resulting mixture was extracted with DCM (25 mL x 2). The combined organic extracts were washed with water (25 mL) and brine (25 mL), dried over anhydrous Na2S04, and concentrated. The residue was dried in vacuo to give compound 33-3 (160 mg, 92% yield) as a yellow solid. LC-MS (ESI): m/z 564.0 [M+Na]+.
[0446] Step 4. Following the same procedure as that for the praparation of compound 1-16 described in Scheme 1 and replacing compound 1-14 with 33-3, compound 33-4 was obtained (100 mg, 65% yield) as a white solid. LC-MS (ESI): m/z 527.1 [M+H]+; Ή NMR (500 MHz, -DMSO): 8 8.50 - 8.56 (m, 1H), 7.95 - 7.99 (m, 2H), 7.89 and 7.84 (s, s, 1 H), 7.66 (m, 1H), 7.32 - 7.42 (m, 4H), 7.16 - 7.21 (m, 2H), 5.35 and 5.08 (q, q, J = 6.5 Hz, 1H), 5.01 (d, 7 = 10 Hz, 0.5 H), 4.20 (d, J = 14 Hz, 0.5 Hz), 4.06 and 3,45 (m, m, 1H), 3.46 and 3.44 (s, s, 3H), 3.28 and 2.99 (m, m, 1H), 2.85 - 2.87 (m, 3H), 1.67 - 1.70 (m, 3H) ppm.
Scheme 34
Figure imgf000202_0001
(S, S)-34-2a R = F (S, R)-34-2a R = F
(S, S)-34-2b R = 4-F-PhO- (S, R)-34-2b R = 4-F-PhO-
[0447] Step 1. Refer to Scheme 34. To a solution of (S)-15-12 (5.13 g, 10 mmol) in DMF (40 mL) was added K2C03 (2.07 g, 15 mmol), the resulting mixture was stirred at rt for 30 min. Subsequently, a solution of racemic 2-(bromomethyl)oxirane (1.23 mL, 15 mmol) in DMF (10 mL) was dropwise added to the mixture. After stirring at 60 °C overnight, the reaction mixture was concentrated. The residue was diluted with H20 (100 mL) and EtOAc (150 mL). The aqueous layer was extracted with EtOAc (150 mL x 2). The combined organic extracts were combined, washed with ¾0 (100 mL x 2) and brine (100 mL), dried over anhydrous Na2S04, filtrated and concentrated. The residue was purified by silica gel column
chromatography (Petroleum ether/EtOAc = 1/1 (v/v)) to give 34-lb (4.8 g, 84% yield) as a white solid. LC-MS (ESI): m/z 570.1 [M+H]+ .
[0448] Step 2. To a solution of TsOH (38 mg, 0.2 mmol) in toluene (4 mL) at 100 °C was added 34-lb (57 mg, 0.1 mmol). After stirring at 100 °C for 4 hr, the reaction micture was concentrated and the residue was dissolved in DCM (25 mL). The mixture was washed with sat. aq. NaHC03 (25 mL x 2) abd Brine (25 mL), dried over anhydrous Na2S04, filtered, and concentrated. The residue was purified by silica gel column chromatography (Petroleum ether/EtOAc = 1/1 (v/v)) to give a mixture of (S, 5)-34-2b and (5, R)-34-2b (40 mg, 70% yield) as white solid with a ratio of 7.5/1 determined by the integration of the benzylic carbon at 5.08 ppm for (S, S)-34-2b and 5.20 ppm for (5, R)-34-2b, respectively. LC-MS (ESI): m/z 570.1 [M+H]+. (S, 5)-34-2b Ή NMR (500 MHz, CDC13): δ 8.14 (s, 1H), 8.04 (m, 2H), 7.58 (s, 1H), 7.03-7.11 (m, 6H), 5.08 (q, / = 6.5 Hz, 1H), 4.42 (q, J = 7.0 Hz, 2H), 4.13 - 4.19 (m, 2H), 3.73 (dd, J} = 3.5 Hz, J2 = 1 1.5 Hz, 1H), 3.53 (dd, Jj = 6.0 Hz, J2 = 11.8 Hz, 1H), 3.18 (s, 1H), 3.12 (m, 1H), 1.92 (bs, 1H), 1.77 (d, / = 7.0 Hz, 3H), 1.44 (t, / = 6.5 Hz, 3H) ppm. (S,?)-34-2b Ή NMR (500 MHz, CDC13): δ 7.94 - 7.97 (m, 3H), 7.52 (s, 1H), 6.96 - 7.03 (m, 6H), 5.20 (q, / = 6.5 Hz, 1H), 4.35 (q, J = 7.0 Hz, 2H), 3.94 (bm, 1H), 3.71 (dd, J, = 4.5 Hz, 72 = 11.8 Hz, 1H), 3.58 - 3.66 (m, 4H), 3.08 (s, 3H), 1.92 (bs, 1H), 1.67 (d, / = 7.0 Hz, 3H), 1.36 (t, / = 7.0 Hz, 3H) ppm.
[0449] Comparison of the stereo-selectivity of the acid catalyzed epoxide-opening-ring- formation step
Temperature and
Starting material Acid Solvent (5, S)-34-2/(S, R)-34-2 ratio reaction time
34-la TsOH (0.3 eq.) DCM 0 °C, overnight 1.0/3.0
34-la TsOH (2.0 eq.) DCM rt, overnight 1.0/1.0
34-la TsOH (2.0 eq.) DCE 60 °C, 4 hr 4.0/1.0
34-lb TsOH (0.3 eq.) DCM 0 °C, overnight 1.0/3.0
34-lb TsOH (2.0 eq.) DCM rt, overnight 1.0/1.0
34-lb TsOH (2.0 eq.) DCE 60 °C, 4 hr 6.5/1.0
34-lb TsOH (2.0 eq.) Toluene 100 °C, 4 hr 7.5/1.0
34-lb TsOH (2.0 eq.) DMF 150 °C, 2 hr 3.0/2.0
Figure imgf000203_0001
[0450] Synthesis of (S, S)-35-lb. Refer to Scheme 35. To a solution of (S, 5)-34-2b (120 mg, 0.22 mmol) and DMAP (159 mg, 1.3 mmol) in DCM (2 mL) was added diphenyl
phosphorochloridate (291 mg, 1.08 mmol) at 0 °C under an atmosphere of Ar. After stirring rt overnight, the reaction mixture was added ice water (10 mL) and DCM (10 mL). The organic layer was washed with saturated aq. NaHC03 (10 mL x 3) and water (10 mL x 3), dried over anhydrous Na2S04, filtered and concentrated. The residue was dried in vacuo to give crude (5, 5)-35-lb (120 mg, 71 % yield) as a white solid. LC-MS (ESI): mlz 787.2
[M+H]+.
[0451] Synthesis of (5, 5)-35-2b. To a solution of (S, 5)-35-lb (120 mg, 0.15 mmol) in THF (5 mL) was added Pt02 (50 mg). The resulting mixture was flushed with H2 and stirred at rt overnight. Subsequently, the mixture was diluted with THF (25 mL) and filtered through Celite 545. The filtrate was concentrated and the residue was diluted with water (25 mL). The suspension was filtered; the solid was washed with water (10 mL) and CH3CN (10 mL) and dried in vacuo to give (S, 5)-35-2b (50 mg, 52% yield) as a white solid. LC-MS (ESI): mlz 635.2 [M+H]+. Ή NMR (500 MHz, -DMSO): δ 8.50 (d, J = 4.5 Hz, 1H), 7.91 (d, 7 = 8.5 Hz, 2H),7.81 (s, 1H), 7.56 (s, 1H), 7.29 (d, 7 = 8.5 Hz, 2H), 7.15 - 7.18 (m, 2H), 7.10 (d, 7 = 8.5 Hz, 2H), 4.89 (d, 7 = 5.5 Hz, 1H), 4.10 - 4.16 (m, 1H), 4.03 (br, 1H), 3.77 (br, 1H), 3.58 - 3.60 (m, 1H), 3.47 (br, 2H), 3.36 (s, 3H), 2.89 (br, 1H), 2.83 (d, 7 = 4.5 Hz, 3H), 1.60 (d, 7 =5.5 Hz, 3H) ppm.
[0452] Synthesis of (S, S)-35-3b. To a solution of N, N-dimethylglycine (45 mg, 0.43 mmol), DCC (149 mg, 0.72 mmol) and (5, S)-34-2b (80 mg, 0.14 mmol) in CH2C12 (2 mL) was added DMAP (89 mg, 0.72 mmol) at rt. After stirring at rt overnight, the reaction mixture was filtered and the filtrated was concentrated. The residue was purified by preparative HPLC and product was converted to its HC1 salt to give (S, S)-35-3b (50 mg, 54% yield) as white solid. LC-MS (ESI): mlz 640.2 [M+H] +. !H NMR (500 MHz, -DMSO): δ 10.32 (br, 1H), 8.51 (d, 7 = 5.0 Hz, 1H), 7.91 (d, 7 = 9.0 Hz, 2H),7.86 (s, 1 H), 7.57 (s, 1H), 7.30 (t, 7 = 8.5 Hz, 2H), 7.17 - 7.20 (m, 2H), 7.12 (d, 7 = 9.0 Hz, 2H), 4.92 (q, 7 = 6.5 Hz, 1H), 4.19 - 4.26 (m, 6H), 3.04 (s, 1H), 3.00 (br, 1H), 2.83 (s, 9H), 1.64 (d, 7 = 6.0 Hz, 3H) ppm.
[0453] Synthesis of (S, 5)-35-4c. To a solution of N-Boc-L- Alanine (68 mg, 0.36 mmol), DCC (149 mg, 0.72 mmol) and (S, S)-35-lb (100 mg, 0.18 mmol) in CH2C12 (2 mL) was added DMAP (89 mg, 0.72 mmol) at rt. After stirring at rt overnight, the reaction mixture was filtered; the filtrate was concentrated and the residue was dried in vacuo to give crude (S, S)-35-4c (105 mg, 80% yield) as a white solid. LC-MS (ESI): mlz 626 A [M-Boc+2H]+.
[0454] Synthesis of (S, S)-35-5e. A mixture of (S, 5)-35-3c (100 mg, 0.14 mmol) and HC1 4- dioxane (4.0 M, 3 mL) was stirred at rt for 2 hr. The solvent was removed and the residue was purified by prep-HPLC to give (S, S)-35-5c (50 mg, 58% yield) as a white solid. LC-MS (ESI): mlz 62 A [M+H] +. !H NMR (500 MHz, -DMSO): δ 8.48 - 8.51 (m, 1H), 8.40 (s, 2H), 7.90 (d, 7 = 8.5 Hz, 2H), 7.81 (s, 1H), 7.56 (s, 1H), 7.31 (t, 7 = 8.5 Hz, 2H), 7.16 - 7.20 (m, 2H), 7.12 (d, 7 = 9.0 Hz, 2H), 4.91 (q, 7 = 6.5 Hz, 1H), 4.09 - 4.26 (m, 5H), 4.00 (s, 3H), 2.95 (br, 1H), 2.83 (d, 7 = 6.5 Hz, 1H), 1.61 (d, 7 = 4.5 Hz, 3H), 1.40 (d, 7 =7.0 Hz, 3H) ppm.
[0455] Synthesis of (S, 5)-35-5d. Following the same procedure as that used for preparing (S, 5)-35-4c and replacing N-Boc-L- Alanine with N-Boc-L-Valine, (S, S)-35-5d was obtained as a white solid in 69% yield. LC-MS (ESI): mlz 654.2 [M+H]+. lH NMR (500 MHz, cf- DMSO): δ 8.49 - 8.51(m, 1H), 8.08 (br, 2H), 7.91 (d, 7 = 9.0 Hz, 2H), 7.86 (s, 1H), 7.57 (s, 1H), 7.30 (t, 7 = 9.0 Hz, 2H), 7.17 - 7.20 (m, 2H), 7.12 (d, 7 = 9.0 Hz, 2H), 4.93 (d, 7 = 6.5 Hz, 1H), 4.15 - 4.20 (m, 4H), 3.87 (s, 1H), 3.36 (s, 3H), 2.95 (br, 1H), 2.84 (d, 7 = 4.0 Hz, 3H), 2.13 - 2.16 (m, 1H), 2.16 (d, J = 6.5 Hz, 3H), 1.00 (d, / = 6.5 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H) ppm.
Biological Activity
[0447] Biological activity of the compounds of the invention was determined using an HCV replicon assay. The 1 b_Huh-Luc/Neo-ET cell line persistently expressing a bicistronic genotype lb replicon in Huh 7 cells was obtained from ReBLikon GMBH. This cell line was used to test compound inhibition using luciferase enzyme activity readout as a measurement of compound inhibition of replicon levels.
[0448] On Day 1 (the day after plating), each compound is added in triplicate to the cells. Plates incubated for 72 please use consistent terminology prior to running the luciferase assay. Enzyme activity was measured using a Bright-Glo Kit (cat. number E2620) manufactured by Promega Corporation. The following equation was used to generate a percent control value for each compound.
% Control = (Average Compound Value/ Average Control)* 100
[0449] The EC 0 value was determined using GraphPad Prism and the following equation:
Y = Bottom + (Top-Bottom)/ (1+10Λ ((LogIC50-X)*HillSlope))
[0450] EC50 values of compounds are repeated several times in the replicon assay.
[0451] Compounds of the invention can inhibit multiple genotypes of HCV selected but not limited to l a, lb, 2a, 3a, and 4a. The EC50S are measured in the corresponding replicon assays that are similar to HCV lb replicon assay as described above.
[0452] Exemplary compounds of the disclosed invention are illustrated in the Tables attached as Appendix A and Appendix B. Apendix A shows inhibitory activity of the compound with respect to HCV lb, la, or 2a and HCV NS5B C316Y or S365A mutant as indicated. The biological activity against HCV lb, la, or 2a is indicated as being *, **, ***, or ****, which corresponds to EC50 ranges of EC50 >1000 nM, 100 nM < EC50 < 1000 nM, 10 nM < EC50 < 100 nM, or EC50 < 10 nM, respectively. The biological activity against HCV NS5B C316Y or S365A mutant is indicated as being†,††, or†††, which corresponds to EC50 ranges of EC50 >1000 nM, 200 nM < EC50 < 1000 nM, 200 nM < EC50, respectively.
[0453] Appendix A shows structures of 242 compounds of the invention identified by ID NOD B1-B242, and EC50 values determined for 242 of the compounds. Of these, the 151 compounds with the highest measured activity can be divided into two groups. Group 1 compound are those having a measured EC50 value, as determined by the concentration of the compound effective to produce a half -maximal inhibition of HCV lb replication (EC50) in a lb_Huh-Luc/Neo-ET cell line, in accordance with the method above, of 10 nM or less. This group includes the compounds identified in Appendix A by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B 121, B 127, B 128, B 130, B 131 , B 132, B138, B 139, B 145, B 148, B158, B 163, B 168, B 169, B 171 , B187, B190, B191, B192, B196, B197, B 198, B201 , B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240. Group 2 includes those compounds that have a measured EC50 of between 10 and 100 nM, and includes compounds identified in Appendix A by ID NOS: B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71, B84, B93, B100, B101, B106, B108, B109, Bi l l, B112, B113, B115, B116, B119, B123, B124, B134, B136, B137, B142, B144, B146, B147, B150, B151, B153, B154, B155, B156, B157, B159, B160, B161, B162, B164, B165, B166, B167, B170, B 172, B173, B174, B175, B176, B178, B179, B180, B181, B183, B184, B186, B188, B189, B193, B195, B199, B200, B202, B203, B204, B205, B210, B215, B216, B217, B219, B220, B222, B223, B224, B225, B227, B228, B229, B230, B231, B234, B235, and B241.
Pharmaceutical Compositions
[0454] An eleventh aspect of the invention provides a pharmaceutical composition comprising compounds of the invention. The compounds described herein can be used as pharmaceutical compositions comprising the compounds, optionally together with one or more pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic and/or prophylactic ingredients. Such excipients are known to those of skill in the art.
Pharmaceutically acceptable salts can be used in the compositions of the present invention and include, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates and the like. A thorough discussion of pharmaceutically acceptable excipients and salts is available in Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990), and in Handbook of
Pharmaceutical Excipients, 6th Edition, Ed. R. C. Rowe, P. J. Sheskey, and M. E. Quinn (American Pharmacists Association, 2009).
[0455] Depending on the intended mode of administration, the pharmaceutical
compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, creams, ointments, lotions or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, may include other pharmaceutical agents, adjuvants, diluents, buffers, etc. [0456] The invention includes a pharmaceutical composition comprising a compound of the present invention including isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof together with one or more
pharmaceutically acceptable carriers and optionally other therapeutic and/or prophylactic ingredients.
[0457] For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like.
[0458] For oral administration, the composition will generally take the form of a tablet, capsule, a softgel capsule nonaqueous solution, suspension or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent may be combined with emulsifying and suspending agents. If desired, flavoring, coloring and/or sweetening agents may be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents and the like.
[0459] A twelfth aspect of the invention provides use of the compounds of the invention in the manufacture of a medicament.
[0460] In a first embodiment of the twelfth aspect, the medicament is for the treatment of hepatitis C.
[0461] A thirteenth aspect of the invention provides a method of treating hepatitis C comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, optionally in a pharmaceutical composition. A pharmaceutically or therapeutically effective amount of the composition will be delivered to the subject. The precise effective amount will vary from subject to subject and will depend upon the species, age, the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. Thus, the effective amount for a given situation can be determined by routine experimentation. The subject may be administered as many doses as is required to reduce and/or alleviate the signs, symptoms or causes of the disorder in question, or bring about any other desired alteration of a biological system. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of this invention for a given disease. CombinationTherapy
[0462] The compounds of the present invention and their isomeric forms and
pharmaceutically acceptable salts thereof are useful in treating and preventing HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the HCV life cycle. Classes of compounds useful in the invention may include, without limitation, all classes of HCV antivirals, both direct-acting and indirect- acting Ocell-targeted' inhibitors of HCV replication). For combination therapies, mechanistic classes of agents that may be useful when combined with the compounds of the present invention include, for example, nucleoside and non-nucleoside inhibitors of the HCV protease inhibitors, helicase inhibitors, NS5A inhibitors, NS4B inhibitors and medicinal agents that functionally inhibit the internal ribosomal entry site (IRES), other NS5B inhibitors and other medicaments that inhibit HCV cell attachment or virus entry, HCV RNA translation, HCV RNA transcription, replication or HCV maturation, assembly or virus release.
[0463] Specific compounds in these classes and useful in the invention include, but are not limited to, linear, macrocyclic, and heterocyclic HCV protease inhibitors such as telaprevir (VX-950), boceprevir (SCH-503034), narlaprevir (SCH-900518), ITMN-191 (R-7227), TMC-435350 (a.k.a. TMC-435), MK-7009, MK-5172, BI-201335, , BMS-650032, ACH- 1625, ACH-2784, ACH-1095 (HCV NS4A protease co-factor inhibitor), AVL-181, AVL- 192, VX-813, PHX-1766, PHX-2054, IDX-136, IDX-316, IDX-320, GS-9256, GS-9265, GS- 9451 , ABT-450, EP-013420 (and congeners) and VB Y-376; the nucleosidic HCV
polymerase (replicase) inhibitors useful in the invention include, but are not limited to, R7128, PSI-7851, PSI-7977, PSI-938, PSI-879, PSI-6130, IDX-184, IDX-102, INX- 189, R1479, R1626, UNX-08189, and various other nucleoside and nucleotide analogs and HCV inhibitors including, but not limited to, those derived from 2'-C-methyl modified
nucleos(t)ides, 4'-aza modified nucleos(t)ides, and 7'-deaza modified nucleos(t)ides. NS5A inhibitors useful in the invention, include, but are not limited to, PPI-461 , BMS-790052, BMS-824393, GS-5885, EDP-239, ACH-2928, AZD-7295, IDX-719, IDX-380, ABT-267, GSK-2336805, CF-102, A-831 and INTM-9916. Non-nucleosidic HCV polymerase
(replicase) inhibitors useful in the invention, include, but are not limited to, VCH-759, VCH- 916, VCH-222, ANA-598, MK-3281 , ABT-333, ABT-072, PF-00868554 (filibuvir), BI- 207127, GS-9190, A-837093, GS -625433, JKT-109, GL-59728 and GL-60667. HCV NS5A inhibitors useful in the present invention include, but are not limited to, PPI-461, EDP- 239, BMS 790052 and BMS 824393, AZD7295, ACH-2928 and GS5885. HCV P7 inhibitors useful in the present invention include BIT-225 and other P7 inhibitors, as well as HCV NS4B inhibitors including but not limited to histamine agents that antagonize HCV NS4B function.
[0464] In addition, NS5B inhibitors of the present invention may be used in combination with cyclophyllin and immunophyllin antagonists (eg, without limitation, DEBIO
compounds, NM-811, SCY-635, EP-CyP282, as well as cyclosporine and its derivatives), kinase inhibitors, inhibitors of heat shock proteins (e.g., HSP90 and HSP70), other immunomodulatory agents that may include, without limitation, interferons (-alpha, -beta, - omega, -gamma, -lambda or synthetic) such as Intron A™, Roferon-A™, Canferon-A300™, Advaferon™, Infergen™, Humoferon™, Sumiferon MP™, Alfaferone™, IFN-β™, Feron™ and the like; polyethylene glycol derivatized (pegylated) interferon compounds, such as PEG interferon-a-2a (Pegasys™), PEG interferon-a-2b (PEGIntron™), pegylated IFN-a-conl and the like; long acting formulations and derivatizations of interferon compounds such as the albumin-fused interferon, Albuferon™, Locteron™ and the like; interferons with various types of controlled delivery systems (e.g. ITCA-638, omega-interferon delivered by the DUROS™ subcutaneous delivery system); compounds that stimulate the synthesis of interferon in cells, such as resiquimod and the like; interleukins; compounds that enhance the development of type 1 helper T cell response, such as SCV-07 and the like; TOLL-like receptor agonists such as CpG-10101 (actilon), isotorabine, ANA773, SD-101, IMO-2125, and the like; thymosin a -1 ; ANA-245 and ANA-246; histamine dihydrochloride;
propagermanium; tetrachlorodecaoxide; ampligen; IMP-321 ; KRN-7000; antibodies, such as civacir, XTL-6865 and the like and prophylactic and therapeutic vaccines such as GI-5005, TG-4040, InnoVac C, HCV E1E2/MF59 and the like. In addition, any of the above- described methods involving administering an NS5B inhibitor, a Type I interferon receptor agonist (e.g., an IFN-a) and a Type II interferon receptor agonist (e.g., an IFN-γ) can be augmented by administration of an effective amount of a TNF-cc antagonist. Exemplary, non- limiting TNF-a antagonists that are suitable for use in such combination therapies include ENBREL™, REMICADE™ and HUMIRA™
[0465] NS5B inhibitors of the present invention may also be used with alternative forms of interferons and pegylated interferons, ribavirin or its analogs (e.g., tarabavarin, levoviron), microRNA, small interfering RNA compounds (e.g., SIRPLEX- 140-N and the like) and microRNA agents (such as micro-RNA-122), nucleotide or nucleoside analogs,
multifunction inhibitors such as nitazoxanide, immunoglobulins, hepatoprotectants, antiinflammatory agents and other direct and indirect inhibitors of HCV replication. Inhibitors of other targets in the HCV life cycle include NS3 helicase inhibitors; NS4A co-factor inhibitors; antisense oligonucleotide inhibitors, such as ISIS-14803, ISIS-11, AVI-4065 and the like; vector-encoded short hairpin RNA (shRNA); HCV specific ribozymes such as heptazyme, RPI, 13919 and the like; entry inhibitors such as HepeX-C, HuMax-HepC and the like; alpha glucosidase inhibitors such as celgosivir, UT-231B and the like; KPE-02003002 and BIVN 401 and EVIPDH inhibitors.
[0466] Other illustrative HCV inhibitor compounds include those disclosed in the following publications: U.S. Pat. No. 5,807,876; U.S. Pat. No. 6,498, 178; U.S. Pat. No. 6,344,465; U.S. Pat. No. 6,054,472; U.S. Pat. No. 7,759,495; U.S. Pat. No. 7,704,992; U.S. Pat. No. 7,741, 347; WO 02/04425; WO 03/007945; WO 03/010141 ; WO 03/000254; WO 03/037895; WO 02/100851 ; WO 02/100846; EP 1256628; WO 02/18369; WO 05/073216; WO 05/073195; WO 08/021927; US 20080050336; US 20080044379; US 2009004716; US 20090043107; US 20090202478; US 20090068140; WO 10/096302; US 20100068176; WO 10/094977; WO 07/138242; WO 10/096462; US 2010091413; WO 10/075380; WO 10/062821 ; WO 10/09677; WO 10/065681 and WO 10/065668.
[0467] Additionally, combinations of, for example, ribavirin a NS3 protease inhibitor, a replicase inhibitor and interferon, may be administered as multiple combination therapy with at least one of the compounds of the present invention. The present invention is not limited to the aforementioned classes or compounds and contemplates known and new compounds and combinations of biologically active agents {see, for example, Klebl et al. "Host cell targets in HCV therapy: novel strategy or proven practice, etc etc, each of which is incorporate by reference in their entirety herein). It is intended that combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the anti-viral activity of the compound of this inventive group or the anti-viral activity of the pharmaceutical composition itself.
[0468] Combination therapy can be sequential, that is treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be treatment with both agents at the same time (concurrently). Sequential therapy can include a reasonable time after the completion of the first therapy before beginning the second therapy. Treatment with both agents at the same time can be in the same daily dose or in separate doses. The dosages for both concurrent and sequential combination therapy will depend on absorption, distribution, metabolism and excretion rates of the components of the combination therapy as well as other factors known to one of skill in the art. Dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules may be adjusted over time according to the individual's need.
[0469] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
[0470] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the invention as defined in the appended claims.
A endix A
Figure imgf000212_0001
Appendix A Page 1 Appendix A
Figure imgf000213_0001
Appendix A Page 2 Appendix A
Figure imgf000214_0001
Appendix A Page 3 Appendix A
Figure imgf000215_0001
Appendix A Page 4 A endix A
Figure imgf000216_0001
Appendix A Page 5 Appendix A
Figure imgf000217_0001
Appendix A Page 6 Appendix A
Figure imgf000218_0001
Appendix A Page 7 A endix A
Figure imgf000219_0001
Appendix A Page 8 Appendix A
Figure imgf000220_0001
Appendix A Page 9 A endix A
Figure imgf000221_0001
Appendix A Page 10 Appendix A
Figure imgf000222_0001
Appendix A Page 11 Appendix A
Figure imgf000223_0001
Appendix A Page 12 A endix A
Figure imgf000224_0001
Appendix A Page 13 A endix A
Figure imgf000225_0001
Appendix A Page 14 Appendix A
Figure imgf000226_0001
Appendix A Page 15 Appendix A
Figure imgf000227_0001
Appendix A Page 16 Appendix A
Figure imgf000228_0001
Appendix A Page 17 Appendix A
Figure imgf000229_0001
a pair of syn- isomers
Appendix A Page 18 Appendix A
Figure imgf000230_0001
Appendix A Page 19 Appendix A
Figure imgf000231_0001
Appendix A Page 20 A endix B
Figure imgf000232_0001
Appendix B Page 1 A endix B
Figure imgf000233_0001
Appendix B Page 2 A endix B
Figure imgf000234_0001
Appendix B Page 3 A endix B
Figure imgf000235_0001
Appendix B Page 4 A endix B
Figure imgf000236_0001
Appendix B Page 5 A endix B
Figure imgf000237_0001
Appendix B Page 6 A endix B
Figure imgf000238_0001
Appendix B Page 7 A endix B
Figure imgf000239_0001
Appendix B Page 8 A endix B
Figure imgf000240_0001
Appendix B Page 9

Claims

IT IS CLAIMED:
1. A compound having the
Figure imgf000241_0001
wherein,
1 2 3
L , L and L together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 0-4 heteroatoms of N, O, S, P and/or Si; and
L1, L2, or L3 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, -NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2;
U or V is independently CH, N, CF, CC1, or CCN;
W, X, or Z is independently C or N;
Y is NRN, N, O, S, Se, or -CRaRb;
RN is hydrogen, C alkyl, C3-6 cycloalkyl, C4_5 heterocycle, aryl, heteroaryl, amide, sulfonamide, or carbamate;
Ra, R is independently hydrogen, methyl, or together to form a C3-6 cycloalkyl bearing 0-1 heteroatom of O or NR3;
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C (=NOMe)NH 7, C(=NOH)NHR7, -C(CF3)NHR8, -C(CN)NHR9, -
S(0)2NHR' , -C(=NCN)NHR ,
Figure imgf000241_0002
;
R2 is a substituted or unsubstituted aryl or heteroaryl;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R and R are independently methyl, ethyl, or cyclopropyl;
R6 is hydrogen, allyl, Ci_4 alkyl, cyclopropyl, or benzyl;
R7 is hydrogen, Q.4 alkyl, cyclopropyl, Ci_4 alkoxy, cyclopropoxy, alkylsulfonyl, or cycloalkyl sulf onyl ;
R8, R9, R10, or R11 is independently hydrogen, C1-4 alkyls, cyclopropyl, C1-4 alkoxys, or cyclopropoxy; and
R13, R16 is independently hydrogen, hydroxyl, azide, C2.4 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4
21 1 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S.
2. The compound of claim 1, having an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half -maximal inhibition of HCVlb replication (EC50) in a lb_Huh-Luc/Neo-ET cell line in culture, of 1 mM or less.
3. The compound of claim 1 , wherein
Figure imgf000242_0001
, together with the attached carbons of the aromatic ring is a seven- or eigh
4. The compound of claim
Figure imgf000242_0002
, together with the attached carbons of the aromatic ring to form a 5-9 member ring, L1 is -C(R!5R16)-, and L3 is -N(S02Me)- or -0-, where
R15, R16 is independently hydrogen, hydroxyl, azide, C2 alkenyl, C2-4 alkynyl, C1-4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci„4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S.
5. The compound of claim 1, having the structure:
Figure imgf000242_0003
wherein,
L1, L2 and-N(S02Me)- together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
Llor L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, - NR3-, -S(0)„-, -P(0 , -Si(R4R5)-, -C(0)0, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2; and
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NOMe)NHR7, C(=NOH)NHR7, -C(CF3)NHR8, -C(CN)NHR9, -
-K N"" - Ν3"" - N'N NT SN
S(0)2NHR10, -C(=NCN)NHRn, H , H , H , or H
R2 is an aryl or heteroaryl having one or more R17 substituents;
212 R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R13, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2-4 alkynyl, Q-4 alkyl, cyclopropyl, C1-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Q.4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NR and/or S; and
17 is H, F, CI or CN.
sting
Figure imgf000243_0001
213 R
Figure imgf000244_0001
1 is selected from the group consisting of ;
Figure imgf000244_0002
7. The compound of claim 6, selected from the group consisting of compounds identified by ID NOS: B89, B96, B97, B 125, B 126, and B 129.
8. The compound of claim 5, wherein R
Figure imgf000244_0003
is ¾ H .
9. The compound of claim 5, wherein R2 is phenyl substituted with one or more R17 substituents.
10. The compound of claim 5, where R2 is 4-phenoxyphenyl and the phenoxy group is substituted with one or more R17 substituents. pound of claim 5, wherein R is selected from ^— " and
Figure imgf000244_0004
12. The compound of claim 1, having the structure IV
214
Figure imgf000245_0001
wherein,
-y
L , L and-N(S02Me)- together with the attached carbons of the aromatic ring to form a 5- member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L*or L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, -
NR3-, -S(0)n-, -P(O)-, -Si(R R5)-, -C(O)-, -C(0)O, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2; and
R2 is an aryl or heteroaryl having one or more R17 substituents;
R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2_4 alkynyl, Ci_4 alkyl, cyclopropyl, C]_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Ci_4 alkenylidene or R13 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is F, CI or CN
13. The compound of claim 1, having the structure II
Figure imgf000245_0002
wherein,
L1, L2 and -N(S02Me)- together with the attached carbons of the aromatic ring to form a 5-
12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L*or L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, -
NR3-, -S(0)n-, -P(O)-, -Si(R R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
R2 is an aryl or het teerrooaarryyll hhaavviinngg oonnee oorr mmooire R17 substituents; R3 is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2A alkenyl, C2-4 alkynyl, C]„4 alkyl, cyclopropyl, Ci-4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
14. The compound of claim 1, having the structure:
Figure imgf000246_0001
L1, L2 and-N(S02R12)- together with the attached carbons of the aromatic ring to form a 5-12 member ring, containing 1 -4 heteroatoms of N, O, S, P and/or Si;
L!or L2 is independently selected from the group consisting of a bond, -0-, -C(RI5R16)-, -
NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaryl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2; and
R1 is selected from hydrogen, halide, -CF3, -CN, -C(0)H, -C(0)OR6-, -C(0)NHR7, - C(0)N(OH)R7, -C(=NOMe)NHR7, C(=NOH)NHR7, -C(CF3)NHR8, -C(CN)NHR9, -
Figure imgf000246_0002
R2 is an aryl or heteroaryl having one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R12 is independently C1-3 alkyl, cyclopropyl, -OMe, or -NHMe;
R15, R16 is independently hydrogen, hydroxyl, azide, C2_4 alkenyl, C2-4 lkynyl, Q.4 alkyl, cyclopropyl, C] -4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or Q_4 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S; and
R17 is F, Cl or CN.
216
15. The compound of claim 14, having an inhibitory activity with respect to HCV, as measured by the concentration of the compound effective to produce a half-maximal inhibition of HCVlb replication (EC50) in a lb_Huh-Luc/Neo-ET cell line in culture, of 100
Figure imgf000247_0001
217
Figure imgf000248_0001
218
Figure imgf000249_0001
219
Figure imgf000250_0001
17. The compound of claim 16, selected from the group consisting of compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, Bl 18, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, B240, B2, B3, B4, B6, B7, B9, B16, B18, B19, B22, B29, B31, B32, B34, B36, B47, B48, B54, B55, B57, B60, B63, B71, B84, B93, B100, B101, B106, B108, B109, Bill, Bl 12, Bl 13, Bl 15, Bl 16, Bl 19, B123, B124, B134, B136, B137, B142, B144, B146, B147, B150, B151, B153, B154, B155, B156, B157, B159, B160, B161, B162, B164, B165, B166, B167, B170, B172, B173, B174, B175, B176, B178, B179, B180, B181, B183, B184, B186, B188, B189, B193, B195, B199, B200, B202, B203, B204, B205, B210, B215, B216, B217, B219, B220, B222, B223, B224, B225, B227, B228, B229, B230, B231, B234, B235, andB241.
Figure imgf000250_0002
220
Figure imgf000251_0001
19. The compound of 18, selected from the group consisting of compounds identified by ID NOS: B5, B15, B20, B33, B35, B45, B67, B85, B92, B94, B107, B118, B120, B121, B127, B128, B130, B131, B132, B138, B139, B145, B148, B158, B163, B168, B169, B171, B187, B190, B191, B192, B196, B197, B198, B201, B207, B208, B212, B214, B218, B221, B226, B232, B233, B236, B237, B238, B239, and B240.
20. The compound of claim 14, wherein R is
Figure imgf000251_0002
221 21. The compound of claim 14, wherein
Figure imgf000252_0001
, together with the attached carbons of the aromatic ring is a seven- or eight-member ring.
22. The compound of claim 14, wherein R2 is phenyl substituted with one or more R17 substituents.
23. The compound of claim 14, where R2 is 4-phenoxyphenyl and the phenoxy group is substituted with one or more R17 substituents. pound of claim 14, wherein R is selected from "— " and
Figure imgf000252_0002
25. The compound of clai VIII
Figure imgf000252_0003
wherein,
L1, L2 and-N(S02Me)- together with the attached carbons of the aromatic ring to form a 5- 12 member ring, containing 1-4 heteroatoms of N, O, S, P and/or Si;
L!or L2 is independently selected from the group consisting of a bond, -0-, -C(R15R16)-, -
NR3-, -S(0)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(0)0-, and substituted alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkoxy, heterocycle, aryl, heteroaiyl, amide, carbamate, urea, and sulfonamide;
n is 0, 1, or 2; and
R2 is an aryl or heteroaryl having one or more R17 substituents;
R is selected from the group of hydrogen, alkylcarbonyl, cycloalkylcarbonyl,
alkoxylcarbonyl, cycloalkoxycarbonyl, alkylsulfonyl and cycloalkylsulfonyl;
R4 and R5 are independently methyl, ethyl, or cyclopropyl;
R15, R16 is independently hydrogen, hydroxyl, azide, C2-4 alkenyl, C2.4 alkynyl, C]_4 alkyl, cyclopropyl, Ci_4 alkoxy, or cyclopropoxy or R15 and R16 together are a carbonyl or C]_4
222 alkenylidene or R15 and R16 joined together with the attached carbon are 3-6 member ring optionally containing 0-3 heteroatoms of O, NRN and/or S;
R17 is H, F, CI or CN; and
V is CH, N, CF, CC1, or CCN.
26. A pharmaceutical composition containing the compound of claim 1 together with one or more pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic and/or prophylactic ingredients.
27. The composition of claim 26, containing the compound of claims 7 or 17.
28. The composition of claim 26, containing the compound of claim 19.
29. The composition of claim 26, formulated for oral delivery.
30. The composition of claim 26, which further includes a second anti-HCV agent selected from the group consisting of interferon-alpha, ribavirin, NS3 protease inhibitors, replicase inhibitors and/or NS5A inhibors.
31. A method of treating HCV infection in a subject comprising
administering to the subject, a pharmaceutically acceptable dose of the compound of claim 1 , and
continuing said administering until a selected reduction of in the subject's HCV titer is achieved.
32. The method of claim 31 , wherein the compound administered is the compound of claims 7 or 17.
33. The method of claim 31, wherein the compound administered is the compound of claim 19.
34. The method of claim 31, which further includes administering to the subject, either in a single or separate administrations, a second anti-HCV agent selected from the group consisting of interferon-alpha, ribavirin, or both.
35. The method of claim 31, wherein said administering is by oral administration.
36. The compound of claim 1, for use in the treatment of HCV infection in an infected subject.
37. The compound of claims 7 or 17 for use in the treatment of HCV infection in an infected subject.
38. The compound of claim 19, for use in the treatment of HCV infection in an infected subject.
39. The use of the compound of claim 1 in the preparation of a medicament for the treatment of HCV in an HCV-infected subject.
223
40. The use of the compound of claims 7 or 17 in the preparation of a mediment for the treatment of HCV in an HCV-infected subject.
41. The use of the compound of claim 19 in the preparation of a mediment for the treatment of HCV in an HCV-infected subject.
224
PCT/US2011/057398 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus WO2012058125A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
JP2013536688A JP5731004B2 (en) 2010-10-26 2011-10-21 Hepatitis C virus inhibitor
MX2013004655A MX2013004655A (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus.
NZ609564A NZ609564A (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
EA201390433A EA025151B1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
UAA201306405A UA108671C2 (en) 2010-10-26 2011-10-21 HEPATITIS VIRUS INHIBITORS C.
US13/882,138 US20130302282A1 (en) 2010-10-26 2011-10-21 Inhibitors of Hepatitis C Virus
KR1020137013396A KR101594166B1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
CA2815537A CA2815537A1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
BR112013009789A BR112013009789A2 (en) 2010-10-26 2011-10-21 hepatitis c virus inhibitors
SG2013031141A SG189985A1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
EP11836903.2A EP2632261B1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
CN201180061899.2A CN103269586B (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus
AU2011320696A AU2011320696B2 (en) 2010-10-26 2011-10-21 Inhibitors of Hepatitis C Virus
US13/456,181 US9085587B2 (en) 2010-10-26 2012-04-25 Inhibitors of hepatitis C virus
US13/544,261 US8614207B2 (en) 2010-10-26 2012-07-09 Inhibitors of hepatitis C virus
IL225853A IL225853A0 (en) 2010-10-26 2013-04-21 Inhibitors of hepatitis c virus
ZA2013/03752A ZA201303752B (en) 2010-10-26 2013-05-23 Inhibitors of hepatitis c virus
US14/083,429 US9309260B2 (en) 2010-10-26 2013-11-18 Inhibitors of hepatitis C virus
HK13113396.8A HK1185763A1 (en) 2010-10-26 2013-12-02 Inhibitors of hepatitis c virus

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40697210P 2010-10-26 2010-10-26
US61/406,972 2010-10-26
US201161438429P 2011-02-01 2011-02-01
US61/438,429 2011-02-01
US201161524220P 2011-08-16 2011-08-16
US61/524,220 2011-08-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/456,181 Continuation-In-Part US9085587B2 (en) 2010-10-26 2012-04-25 Inhibitors of hepatitis C virus
US13/544,261 Continuation US8614207B2 (en) 2010-10-26 2012-07-09 Inhibitors of hepatitis C virus

Publications (1)

Publication Number Publication Date
WO2012058125A1 true WO2012058125A1 (en) 2012-05-03

Family

ID=45994336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057398 WO2012058125A1 (en) 2010-10-26 2011-10-21 Inhibitors of hepatitis c virus

Country Status (21)

Country Link
US (4) US20130302282A1 (en)
EP (1) EP2632261B1 (en)
JP (1) JP5731004B2 (en)
KR (1) KR101594166B1 (en)
CN (1) CN103269586B (en)
AR (1) AR083565A1 (en)
AU (1) AU2011320696B2 (en)
BR (1) BR112013009789A2 (en)
CA (1) CA2815537A1 (en)
CL (1) CL2013001141A1 (en)
CO (1) CO6700883A2 (en)
EA (1) EA025151B1 (en)
HK (1) HK1185763A1 (en)
IL (1) IL225853A0 (en)
MX (1) MX2013004655A (en)
NZ (1) NZ609564A (en)
PE (1) PE20140109A1 (en)
SG (1) SG189985A1 (en)
TW (1) TWI486348B (en)
WO (1) WO2012058125A1 (en)
ZA (1) ZA201303752B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528922A1 (en) * 2010-01-27 2012-12-05 AB Pharma Ltd Polyheterocyclic compounds highly potent as hcv inhibitors
US8765731B2 (en) 2009-07-16 2014-07-01 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
US8779156B2 (en) 2010-03-24 2014-07-15 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2014110066A1 (en) 2013-01-10 2014-07-17 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
US9085587B2 (en) 2010-10-26 2015-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
WO2015143257A1 (en) 2014-03-21 2015-09-24 Bristol-Myers Squibb Company 6h-furo[2,3-e]indole compounds for the treatment of hepatitis c
WO2015179392A1 (en) 2014-05-21 2015-11-26 Bristol-Myers Squibb Company 2-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c
WO2015191653A1 (en) 2014-06-11 2015-12-17 Bristol-Myers Squibb Company Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c
US9249152B2 (en) 2014-03-21 2016-02-02 Bristol-Myers Squibb Company Cyano containing azabenzofuran compounds for the treatment of hepatitis C
WO2016022513A1 (en) 2014-08-05 2016-02-11 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
WO2016054299A1 (en) 2014-10-02 2016-04-07 Bristol-Myers Squibb Company Macrocyclic benzofuran compounds for the treatment of hepatitis c
WO2016133961A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors
WO2016133963A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as hcv inhibitors
WO2016133970A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as hcv inhibitors
WO2016133948A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
WO2016133972A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis c

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2506085A (en) * 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
EP3119769A1 (en) * 2014-03-21 2017-01-25 Bristol-Myers Squibb Pharma Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
US11831699B2 (en) * 2016-09-08 2023-11-28 Harmonic, Inc. Using web-based protocols to assist graphic presentations when providing digital video

Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US347A (en) 1837-08-08 dixon
US7741A (en) 1850-10-29 Cak-cottpling
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO2002004425A2 (en) 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002018369A2 (en) 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
EP1256628A2 (en) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US6498178B2 (en) 1999-03-19 2002-12-24 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
WO2003000254A1 (en) 2001-06-26 2003-01-03 Japan Tobacco Inc. Fused cyclic compounds and medicinal use thereof
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003010141A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with a heterobicyclic structure
WO2003037895A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
WO2004099241A1 (en) * 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Hepatitis c virus ns5b polymerase inhibitor binding pocket
WO2005073216A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
WO2007059421A2 (en) 2005-11-10 2007-05-24 Wyeth Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
WO2007138242A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2008012587A2 (en) 2006-07-27 2008-01-31 Artemis Intelligent Power Ltd A digital hydraulic pump/motor torque modulation system and apparatus
US20080044379A1 (en) 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2008021927A2 (en) 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20090004716A1 (en) 2007-05-23 2009-01-01 Vgx Pharmaceuticlas, Inc. Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US20090043107A1 (en) 2007-08-08 2009-02-12 Bristol-Myers Squibb Company Process for Synthesizing Compounds Useful for Treating Hepatitis C
US20090068140A1 (en) 2006-08-11 2009-03-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2009051306A1 (en) 2007-10-16 2009-04-23 Dasan Rnd Co., Ltd. Treadmill with automatic speed control, control module of the same and control method of the same
US20090202478A1 (en) 2008-02-13 2009-08-13 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090208449A1 (en) 2008-02-14 2009-08-20 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2010009677A1 (en) 2008-07-25 2010-01-28 华为技术有限公司 Method, system for reserving path and path computation client, path computation element
US20100068176A1 (en) 2008-08-07 2010-03-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20100091413A1 (en) 2008-10-09 2010-04-15 Isao Nunokawa Magnetic Recording Head, Method of Manufacturing the Same, and Magnetic Recording/Reproducing Device
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010096302A1 (en) 2009-02-17 2010-08-26 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010099166A1 (en) 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024804A2 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
KR20050065661A (en) 2002-11-01 2005-06-29 비로파마 인코포레이티드 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2005112640A2 (en) 2004-05-13 2005-12-01 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8076365B2 (en) * 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008082725A1 (en) 2006-12-29 2008-07-10 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
US20090047246A1 (en) 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
GB0707000D0 (en) * 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
EA201000201A1 (en) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи NITROGEN-CONTAINING BICYCLIC CHEMICALS FOR THE TREATMENT OF VIRAL INFECTIONS
AR068106A1 (en) 2007-08-29 2009-11-04 Schering Corp DERIVATIVES OF INDOL 2-CARBOXI SUBSTITUTED AND A PHARMACEUTICAL COMPOSITION
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102448548A (en) 2009-05-20 2012-05-09 弗·哈夫曼-拉罗切有限公司 Heterocyclic antiviral compounds
JP2013515068A (en) * 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション Fused tricyclic compounds for the treatment of viral diseases and methods of use thereof
AR080185A1 (en) 2010-02-19 2012-03-21 Glaxo Group Ltd DERIVATIVES OF BORONIC AND BENZOFURAN ACID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME IN THE TREATMENT AND / OR PREVENTION OF VIRAL INFECTIONS, IN PARTICULAR BY HEPATITIS C (HCV) VIRUSES.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
BR112012022125A2 (en) * 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp compound, dihydrochloride salt, pharmaceutical composition, use of the compound, and method for treating a patient
CN102906089A (en) 2010-03-10 2013-01-30 百时美施贵宝公司 Compounds for the treatment of hepatitis C
WO2011112191A1 (en) 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8324239B2 (en) * 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
AU2011320696B2 (en) 2010-10-26 2016-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741A (en) 1850-10-29 Cak-cottpling
US347A (en) 1837-08-08 dixon
US6344465B1 (en) 1996-04-23 2002-02-05 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6498178B2 (en) 1999-03-19 2002-12-24 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
WO2002004425A2 (en) 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002018369A2 (en) 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
EP1256628A2 (en) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2003000254A1 (en) 2001-06-26 2003-01-03 Japan Tobacco Inc. Fused cyclic compounds and medicinal use thereof
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003010141A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with a heterobicyclic structure
WO2003037895A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
WO2004099241A1 (en) * 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Hepatitis c virus ns5b polymerase inhibitor binding pocket
WO2005073216A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
WO2007059421A2 (en) 2005-11-10 2007-05-24 Wyeth Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
WO2007138242A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2008012587A2 (en) 2006-07-27 2008-01-31 Artemis Intelligent Power Ltd A digital hydraulic pump/motor torque modulation system and apparatus
WO2008021927A2 (en) 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20080050336A1 (en) 2006-08-11 2008-02-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090068140A1 (en) 2006-08-11 2009-03-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20080044379A1 (en) 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090004716A1 (en) 2007-05-23 2009-01-01 Vgx Pharmaceuticlas, Inc. Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US20090043107A1 (en) 2007-08-08 2009-02-12 Bristol-Myers Squibb Company Process for Synthesizing Compounds Useful for Treating Hepatitis C
WO2009051306A1 (en) 2007-10-16 2009-04-23 Dasan Rnd Co., Ltd. Treadmill with automatic speed control, control module of the same and control method of the same
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090202478A1 (en) 2008-02-13 2009-08-13 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090208449A1 (en) 2008-02-14 2009-08-20 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2010009677A1 (en) 2008-07-25 2010-01-28 华为技术有限公司 Method, system for reserving path and path computation client, path computation element
US20100068176A1 (en) 2008-08-07 2010-03-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20100091413A1 (en) 2008-10-09 2010-04-15 Isao Nunokawa Magnetic Recording Head, Method of Manufacturing the Same, and Magnetic Recording/Reproducing Device
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010065681A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010096302A1 (en) 2009-02-17 2010-08-26 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010099166A1 (en) 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations", 1999, WILEY-RCH
"Handbook of Pharmaceutical Excipients", 2009, AMERICAN PHARMACISTS ASSOCIATION
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
B.D. LINDENBACH; C.M. RICE, NATURE, vol. 436, 2005, pages 933 - 938
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
J.A. JOULE; K. MILLS: "Heterocyclic Chemistry", 2010, J WILEY AND SONS
See also references of EP2632261A4
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, J WILLEY AND SONS

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765731B2 (en) 2009-07-16 2014-07-01 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2528922A1 (en) * 2010-01-27 2012-12-05 AB Pharma Ltd Polyheterocyclic compounds highly potent as hcv inhibitors
EP2528922A4 (en) * 2010-01-27 2013-10-16 Pharma Ltd Ab Polyheterocyclic compounds highly potent as hcv inhibitors
US8779156B2 (en) 2010-03-24 2014-07-15 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9085587B2 (en) 2010-10-26 2015-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
US9309260B2 (en) 2010-10-26 2016-04-12 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
WO2014110066A1 (en) 2013-01-10 2014-07-17 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
US9434738B2 (en) 2013-01-10 2016-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C
WO2015143257A1 (en) 2014-03-21 2015-09-24 Bristol-Myers Squibb Company 6h-furo[2,3-e]indole compounds for the treatment of hepatitis c
US9249152B2 (en) 2014-03-21 2016-02-02 Bristol-Myers Squibb Company Cyano containing azabenzofuran compounds for the treatment of hepatitis C
US9914739B2 (en) 2014-03-21 2018-03-13 Bristol-Myers Squibb Company 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C
WO2015179392A1 (en) 2014-05-21 2015-11-26 Bristol-Myers Squibb Company 2-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c
WO2015191653A1 (en) 2014-06-11 2015-12-17 Bristol-Myers Squibb Company Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c
WO2016022513A1 (en) 2014-08-05 2016-02-11 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
WO2016054299A1 (en) 2014-10-02 2016-04-07 Bristol-Myers Squibb Company Macrocyclic benzofuran compounds for the treatment of hepatitis c
WO2016133963A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as hcv inhibitors
WO2016133970A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as hcv inhibitors
WO2016133948A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
WO2016133972A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis c
WO2016133961A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors

Also Published As

Publication number Publication date
TW201245195A (en) 2012-11-16
CN103269586A (en) 2013-08-28
MX2013004655A (en) 2013-08-27
HK1185763A1 (en) 2014-02-28
CA2815537A1 (en) 2012-05-03
CL2013001141A1 (en) 2013-10-04
US9309260B2 (en) 2016-04-12
US9085587B2 (en) 2015-07-21
US20140286899A1 (en) 2014-09-25
JP2014500861A (en) 2014-01-16
EA025151B1 (en) 2016-11-30
SG189985A1 (en) 2013-06-28
PE20140109A1 (en) 2014-02-23
ZA201303752B (en) 2014-04-30
CO6700883A2 (en) 2013-06-28
IL225853A0 (en) 2013-06-27
EP2632261A1 (en) 2013-09-04
EP2632261A4 (en) 2013-11-27
AU2011320696A1 (en) 2013-05-23
US20120251497A1 (en) 2012-10-04
JP5731004B2 (en) 2015-06-10
KR20130121111A (en) 2013-11-05
CN103269586B (en) 2015-07-15
KR101594166B1 (en) 2016-02-15
US8614207B2 (en) 2013-12-24
US20130302282A1 (en) 2013-11-14
EP2632261B1 (en) 2016-07-13
AU2011320696B2 (en) 2016-07-21
US20120276051A1 (en) 2012-11-01
TWI486348B (en) 2015-06-01
NZ609564A (en) 2015-06-26
AR083565A1 (en) 2013-03-06
EA201390433A1 (en) 2013-10-30
BR112013009789A2 (en) 2016-07-19

Similar Documents

Publication Publication Date Title
AU2011320696B2 (en) Inhibitors of Hepatitis C Virus
ES2659216T5 (en) Methods for treating HCV
RU2534613C2 (en) Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them
EP2575475A1 (en) Inhibitors of hcv ns5a
WO2010065668A1 (en) Inhibitors of hcv ns5a
MX2014007023A (en) 2&#39;,4&#39;-difluoro-2&#39;-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication.
CN105307662A (en) 4&#39;-fluor0-2&#39;-methyl substituted nucleoside derivatives
EP2953462B1 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
EP3013834A1 (en) Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
AU2012360910A1 (en) Quinazolinone derivatives as HCV inhibitors
WO2013163466A1 (en) Inhibitors of hepatitis c virus
EP3271371A1 (en) Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c
US20160318912A1 (en) A Novel Compound for the Treatment of Hepatitis C

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11836903

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013536688

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12013500770

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 225853

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 201390433

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2815537

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2013001141

Country of ref document: CL

Ref document number: 000909-2013

Country of ref document: PE

Ref document number: MX/A/2013/004655

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011836903

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011836903

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011320696

Country of ref document: AU

Date of ref document: 20111021

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201306405

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20137013396

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13128218

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 13882138

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009789

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013009789

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130422